AD_____

Award Number: W81XWH-11-1-0278

TITLE: Blast Concussion mTBI, Hypopituitarism, and Psychological Health in OIF/OEF Veterans

PRINCIPAL INVESTIGATOR: Charles W. Wilkinson, Ph.D.

CONTRACTING ORGANIZATION: Seattle Institute for Biomedical and Clinical Research
Seattle, WA 98108 US

REPORT DATE: June 2014

TYPE OF REPORT: Final Report

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. **PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.**

1. REPORT DATE	2. REPORT TYPE	3. DATES COVERED
June 2014	Final	15 March 2011 - 14 April 2014

4. TITLE AND SUBTITLE

Blast Concussion mTBI, Hypopituitarism, and Psychological Health in OIF/OEF Veterans

5a. CONTRACT NUMBER

5b. GRANT NUMBER
W81XWH-11-1-0278

5c. PROGRAM ELEMENT NUMBER

6. AUTHOR(S)

Charles W. Wilkinson, Ph.D.

E-Mail: wilkinso@uw.edu

5d. PROJECT NUMBER

5e. TASK NUMBER

5f. WORK UNIT NUMBER

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
VA Puget Sound Health Care System
Seattle, Washington 98108

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES)
U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

10. SPONSOR/MONITOR'S ACRONYM(S)

11. SPONSOR/MONITOR'S REPORT NUMBER(S)

12. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for Public Release; Distribution Unlimited

13. SUPPLEMENTARY NOTES

14. ABSTRACT
Chronic hypopituitarism (deficient production of one or more pituitary hormones) occurs in 25-50% of cases of civilian traumatic brain injury. Although repetitive blast concussion is the signature injury of combat in Iraq and Afghanistan, the prevalence of hypopituitarism after blast-induced concussion or mild traumatic brain injury (mTBI) is undetermined. Pituitary dysfunction is associated with symptoms including fatigue, mood disturbances, anxiety and depression, irritability, insomnia, memory loss, social isolation, and decreased quality of life, as well as muscular weakness, erectile dysfunction, infertility, and diminished cardiovascular function. Concentrations of 12 hormones in blood samples from Veterans of deployment to Iraq and Afghanistan who had sustained at least one blast concussion were compared with those from Veterans of deployment without blast exposure. Veterans with blast mTBI were found to have a prevalence of pituitary dysfunction of 42.9% compared to 6.7% in those not exposed. The prevalence of hypopituitarism in the general population has been estimated at 0.03%. Based on this estimation, the frequency of hypopituitarism after blast concussion is 1,430 times greater than that of the general population. The most frequent hormone deficiency disorders were growth hormone deficiency and hypogonadism, which may result in significant changes in mood, energy, body composition, muscular strength, sexual function and quality of life.

15. SUBJECT TERMS
blast, concussion, mild traumatic brain injury, pituitary, hormones, hypopituitarism, hypogonadism, growth hormone deficiency

16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
					USAMRMC
a. REPORT	b. ABSTRACT	c. THIS PAGE			19b. TELEPHONE NUMBER *(include area code)*
U	U	U	UU	75	

Table of Contents

Introduction..... 4

Body..... 4

Key Research Accomplishments.....12

Reportable Outcomes.....13

Conclusion..... 17

References.....17

Appendices.....20

- **Appendix 1 - Statement of Work..... 20**
- **Appendix 2 - Peer-reviewed Publication.....23**
- **Appendix 3 - Abstracts and Posters.....35**
- **Appendix 4 - Curriculum Vitae.....50**
- **Appendix 5 - Reportage of the Study in Media.....73**

INTRODUCTION

Chronic hypopituitarism (deficient production of one or more anterior pituitary hormones) occurs in 25-50% of cases of civilian traumatic brain injury. However, the prevalence of posttraumatic hypopituitarism (PTHP) after blast-induced concussion or mild traumatic brain injury (mTBI) has not been determined despite the fact that repetitive blast concussion is the signature injury of combat in Iraq and Afghanistan. PTHP is associated with symptoms that overlap considerably with those of PTSD including fatigue, mood disturbances, anxiety and depression, irritability, insomnia, memory loss, social isolation, and decreased quality of life. Muscular weakness, erectile dysfunction, infertility, and diminished cardiovascular function are also frequent consequences. These symptoms, if appropriately diagnosed as consequences of neuroendocrine disorders, can generally be treated successfully with hormone replacement. The objectives of this study are to measure basal hormone concentrations in blood from Veterans who sustained at least one blast-induced mTBI during deployment to Iraq or Afghanistan. The values will be compared to hormone levels in combat-zone Veterans without blast exposure to determine the frequency and nature of pituitary dysfunction resulting from blast concussions. Methods for screening for PTHP will be developed and refined. Accurate, routine diagnosis of PTHP has the potential of markedly improving the psychological health and facilitating the recovery of blast mTBI victims.

BODY

During Year 1 of the project, plasma and serum samples used for measurement of hormone concentrations were acquired from a sample repository (University of Washington Alzheimer's Disease Center Participant Registry and Sample Repository). Blood samples from healthy male civilians were culled from the repository to provide a reference sample to use in determining normal reference ranges for each hormone. Blood samples from Veterans who had sustained a blast concussion during deployment to Iraq or Afghanistan and samples from deployed Veterans without blast exposure were also withdrawn from the repository. These samples had been added to the repository as a component of another, larger study of blast concussion.

Initially, samples from 59 healthy community control participants were used to establish normal reference ranges for each of the 12 hormones and to determine criteria for classifying levels of each of the hormones in Veterans' samples as normal or abnormal. During Year 1, samples from 26 Veterans with blast mTBI and 7 deployed-control Veterans were acquired from the repository and Milestones 1-5 in the Statement of Work were completed for these samples ***(Appendix 1)***. Preliminary results based on the hormonal analysis of these samples were published (Wilkinson *et al.*, 2012). Details of inclusion/exclusion criteria and sample acquisition are described fully on p. 2 of the

article, and demographic characteristics and blast exposure assessment data are described in Table 4, p. 7. ***(Appendix 2)***

Six anterior pituitary hormones (follicle-stimulating hormone [FSH], luteinizing hormone [LH], growth hormone [GH], adrenocorticotropin [ACTH], thyroid-stimulating hormone [TSH] and prolactin [PRL]) were measured. In addition, concentrations of two posterior pituitary hormones (oxytocin [OT] and vasopressin [AVP], and four target-organ hormones (testosterone, insulin-like growth factor-I [IGF-I], cortisol, and thyroxine) were determined for each participant. Methods for hormone measurements and the sources of the materials used are described in Table 1, p. 3 of Wilkinson *et al.*, 2012.

Hypopituitarism was defined as a dysfunction in at least one of seven hormonal axes. (Table 2, p. 2; Wilkinson *et al.*, 2012). The specific criteria for dysfunction of each axis were derived from age-adjusted percentiles based on the lognormal distribution of concentrations for each hormone in the samples from the 59 community control participants. These criteria were modeled after those used in published studies of hypopituitarism after civilian TBI from all causes.

This initial analysis was made with a limited number of samples in relation to the target goals of the study. At the time of publication, data were available from 59 of the targeted sample of 100 healthy community control participants, 26 of the target number of 40 of Veterans with TBI and 7 of the target number of 20 deployed Veterans without blast exposure.

Eleven of the 26 Veterans with TBI were found to have one or more hormonal abnormalities consistent with hypopituitarism, whereas none of the deployment control Veterans was found to have any hormonal deficiencies (Table 1). As has been found in the majority of civilian studies of hypopituitarism after TBI, the most prevalent deficiencies in anterior pituitary function were in the GH-IGF-I axis and the gonadotropin (LH and FSH)-testosterone axis. None of the participants in either of the Veteran groups was found to have deficiencies in the pituitary-adrenal or pituitary-thyroid axis.

Single measures of GH during the daytime are of very limited utility in assessing growth hormone deficiency (GHD) because GH is secreted almost entirely during nighttime hours. For this reason, measurement of IGF-I, which is produced by the liver in response to GH, is frequently used as a surrogate for GH in diagnosing GHD. Markedly low levels IGF-I are strongly indicative of GHD. Five members of the TBI group were found with sufficiently low levels of IGF-I to meet criteria for GHD. See Table 1 below and Fig. 1, p. 4 in Wilkinson *et al.*, 2012.

The long-term sequelae of GHD in adults for health, quality of life (QoL), and morbidity are multifaceted and complex. Low GH secretion has been associated with behavioral symptoms and deficits in several cognitive domains (Popovic *et al.*, 2004; Falleti *et al.*,

2006). GHD also has significant deleterious effects on body composition and cardiovascular function. Adult GHD is associated with lipidemia, reduced lean body mass, and increased adiposity (Colao *et al.*, 2006; Colao, 2008). Poor QoL is also a prominent feature of adult GHD, especially in the areas of energy and vitality (Kelly *et al.*, 2006; Bushnik *et al.*, 2007; Svensson *et al.*, 2004). Adult GHD is also associated with reductions in muscle volume and strength, decreased physical mobility, fatigue, sleep impairment, social isolation, depression, lowered metabolic rate, low sexual drive, and reduced aerobic capacity (Rosén *et al.*, 1994; Mossberg *et al.*, 2008). However, many of the symptoms of GHD can be successfully ameliorated or reversed by growth hormone replacement therapy (Svensson *et al.*, 2004; Colao *et al.*, 2006; Falleti *et al.*, 2006; Kreitschmann-Andermahr *et al.*, 2008; Götherström *et al.*, 2009; High *et al.*, 2010; Reimunde *et al.*, 2011).

The criteria for dysfunction of the male pituitary-gonadal axis, or hypogonadism, are testosterone levels below the 5th percentile of the reference sample together with an LH or FSH level below the 10th percentile of the reference distributions as shown in Fig. p. 5 (Wilkinson *et al.*, 2012). Three of the Veterans with blast mTBI met the combined low testosterone and low LH criteria for hypogonadism. None of the deployed, non-blast-exposed Veterans were found with hormone levels indicative of pituitary-gonadal axis dysfunction.

Hypogonadism has significant deleterious consequences in addition to its adverse effects on fertility, psychosexual function, and general wellbeing. Testosterone deficiency in males is associated with decreased energy and motivation, muscle weakness, reduced lean body mass, and impaired exercise tolerance (Agha and Thompson, 2005). In addition, a recent large epidemiological study has shown that untreated hypogonadism is associated with premature mortality secondary to cardiovascular disease (Tomlinson *et al.*, 2001).

In addition, abnormalities in three other pituitary hormone levels were found among the Veterans who had sustained blast mTBI. The abnormalities were prolactin excess or deficiency (Fig. 1), vasopressin excess or deficiency (Fig. 2), and oxytocin deficiency (Fig. 3). Graphic representations of the concentrations of these hormones were not included in the published manuscript, and the data are shown and interpreted in greater detail below. None of the deployment control group was found with abnormal levels of any of these three hormones.



Figure 1. Data from the deployment control (DC) group are indicated on the left by purple triangles, and mTBI group data are shown by yellow circles on the right. Both hypoprolactinemia and hyperprolactinemia are associated with sexual and reproductive dysfunction including erectile dysfunction and infertility. Serum prolactin levels above the 95th percentile of the distribution of prolactin concentrations in our community control reference group were considered to be aberrant and indicative of hyperprolactinemia. Similarly, values below the 5th percentile of the distribution of prolactin concentrations in our reference sample were considered to be markers of hypoprolactinemia. None of the Veterans in the DC group were found with abnormal prolactin levels. However, one participant in the mTBI group had a prolactin value considered to abnormally low and one had an excessively high prolactin level. Data from these two Veterans are indicated by the green circles. The same two participants were also found to have probable hypogonadism as determined by our criteria based upon LH and testosterone concentration (Table 1).



Figure 2. Similarly to the case with prolactin, both abnormally low and abnormally high levels of plasma vasopressin (antidiuretic hormone) are associated with serious medical conditions. Low levels (diabetes insipidus, DI) result in excessive thirst, excretion of large amounts of severely diluted urine, and potential dehydration. Abnormally high concentrations (syndrome of inappropriate antidiuretic hormone hypersecretion, SIADH) result in water retention and excess excretion of sodium. Elevated AVP concentrations in animals and humans have been linked to anxiety, depression, and aggression, and high plasma and/or CSF levels have been associated with personality disorder, depression, obsessive-compulsive disorder, schizophrenia, and PTSD. Data for each of the two subject groups are presented as in Figure 1. Our criterion for excessive AVP concentration was a level above the 95th percentile of our reference sample. Functional vasopressin deficiency was defined as an AVP concentration below the 5th percentile together with very dilute urine (urine specific gravity less than 1.003). Two of the mTBI group met our criterion for excessive AVP secretion, and two of the same group, indicated by the green circles, met both criteria for functional vasopressin deficiency. None of the deployment control group was found to have abnormal plasma prolactin levels.



Figure 3. Oxytocin has been shown to play a role in multiple aspects of maternal, social, and romantic bonding and to have significant anxiolytic and anti-stress effects on social approach behavior and in socially challenging situations. It has also been linked to promotion of social recognition and interpretation of social signals. Extremely low concentrations of OT have been linked to mental disorders characterized by severe social disturbances such as autism. None of the Veterans in the deployment control group, but four members of the mTBI group met our sub-5th-percentile criterion for OT deficiency. The two participants whose data are marked by green circles were those who were also found to have a functional vasopressin deficiency. The occurrence of deficiencies of both of these posterior pituitary hormones in the same individuals suggest the possibility of disruption of the axons that carry these hormones through the pituitary stalk prior to release into the circulation.

In this analysis of the initial sample of 26 Veterans who had sustained blast concussions during deployment to Iraq or Afghanistan, five participants were found to have IGF-I concentrations consistent with GHD (Table 1). Three of the mTBI group had LH and testosterone levels indicative of hypogonadism. Of these three, two had extremely low IGF-I levels, two had aberrant prolactin concentrations, and one had an OT level below the sensitivity of the assay. In light of the fact that none of the deployment control participants (at this point, a small group of 7) were found with abnormal levels of any of the hormones measured, we feel that our data strongly suggest that blast-induced mTBI carries a high risk for chronic pituitary dysfunction.

Subj.	LH	FSH	tTest	PRL	IGF-I	AVP	OT
	mIU/ml	U/L	ng/dl	ng/ml	ng/ml	pg/ml	pg/ml
T-2	2.03	---	669	9.6	185	12.3	181
T-4	2.03	2.06	252	54.9	110	8.0	88
T-8	2.72	4.02	401	11.9	141	0.2	44
T-10	1.97	2.43	520	12.3	230	0.2	22
T-12	7.27	5.70	715	13.0	198	12.0	55
T-13	1.92	1.18	253	6.3	187	6.4	50
T-14	2.66	2.51	390	12.0	151	0.5	19
T-16	2.64	4.01	380	21.5	126	0.9	190
T-21	4.00	4.48	588	12.8	227	0.0	21
T-23	2.24	4.34	463	7.2	146	2.1	25
T-26	2.11	2.64	264	15.3	86	8.4	0

Table 1. The table shows the hormone concentrations of the 11 of 26 Veterans with blast-induced mTBI who were found to have aberrant levels (highlighted in yellow) of one or more hormones.

During Year 2, repository samples were acquired for nine additional Veterans with mTBI and eight new deployment control Veterans. Hormonal analysis of these samples revealed two additional individuals with blast mTBI who exhibited IGF-I levels suggestive of GHD and two more with LH and testosterone concentrations indicative of hypogonadism. These results confirm our early results in that 4 of 9 (44.4%) of the TBI group had abnormal hormone levels, and the most frequent anterior pituitary hormone abnormalities were again those associated with GHD and hypogonadism. In this sample, one of the eight (12.5%) members of the deployment control group was found to have serum hormone levels meeting the criteria for both hypogonadism and GHD. Overall, at the end of Year 2, 15 of 35 (42.9%) Veterans with mTBI and 1 of 15 (6.7%) deployed non-blast exposed Veterans displayed hormonal abnormalities.

Because of the study's focus on *blast* concussion in particular and in order to take a conservative approach to analysis, Veterans with *non-blast* mTBI were not excluded

from the deployment control group. It is possible that the individual in the deployment control group who exhibited hormonal abnormalities had experienced an impact-related concussion that precipitated hypopituitarism. Also, it is generally considered the nature of military culture results in marked under-reporting of concussions.

The overall percentage of participants meeting criteria for GHD or hypogonadism in each of the two subject groups for all samples measured thus far are shown in Figure 4. These results confirm and support our initial conclusion that Veterans who sustain blast mTBI during deployment are at significantly greater risk for pituitary dysfunction than deployed Veterans without blast exposure and that the most prevalent hormonal abnormalities are those indicative of probable GHD and hypogonadism.



Figure 4. Results for all samples analyzed to date show that 14.3% (5/35) of mTBI subjects and 6.7% (1/15) of deployment control subjects met criteria for hypogonadism. Criteria for GHD were met by 20.0% (7/35) of mTBI subjects and 6.7% (1/15) of deployment control subjects.

Problems in Accomplishing the Tasks

A single highly significant problem was encountered in performing the tasks described in the Statement of Work and completing the study. That problem was the continuing lack of availability of a sufficient number of appropriate blood samples in the repository from which our samples were drawn. This study was dependent on the repository for samples, demographic information, and screening data. The problem stemmed from a temporary cessation of subject recruitment for the large mTBI imaging study that generated the samples in the repository. The delay was caused by the necessity for major revision of the IRB application for that study. Even after approval was obtained from both the VA Puget Sound Health Care System IRB and the University of Washington IRB for that study, recruitment has progressed extremely slowly and has twice necessitated requests for no-cost extensions.

During the final extension of this project we have succeeded in closing in on our goals for acquisition of samples to meet targets for all three participant groups. Our final sample totals are: community controls = 100/100; Veterans with blast concussion = 39/40; deployment controls = 20/20. These goals have only been reached during the past month, and the final hormone assays for all hormones in samples from all subjects are currently being carried out. Final tabulation and analysis of the data will be followed by the writing of a thorough description, analysis, and interpretation of the completed study and submission to a peer-reviewed journal.

Personnel receiving pay from the research study

Elizabeth A. Colasurdo
Steven P. Millard
Yun Xiang

KEY RESEARCH ACCOMPLISHMENTS

- Determined reference ranges for 12 pituitary and target-organ hormones in blood samples from healthy male civilians
- Used distribution statistics from above to establish criteria for defining abnormal levels of each hormone in Veteran participant groups
- Determined that 42.9% of Veterans with blast concussions for whom assays have been completed had at least one hormonal abnormality
- Found that 6.7% of deployed Veterans without a blast concussion for whom assays have been completed had one or more hormonal abnormality
- Confirmed hypothesis that blast concussion is a serious risk factor for hypopituitarism
- Determined that the most common hormonal deficits after blast mTBI were consistent with growth hormone deficiency (20.0%) and hypogonadism (14.3%)

- Referred participants identified as having probable hypopituitarism for clinical evaluation when possible
- Completed sample acquisition for all three participant groups and are currently assaying all samples for all 12 hormones

REPORTABLE OUTCOMES

Oral and Poster Presentation and Abstracts

1. "Chronic hypopituitarism after blast concussion mild traumatic brain injury in Iraq/Afghanistan combat Veterans." Charles W Wilkinson, Elaine R Peskind, Elizabeth A Colasurdo, and Jane B Shofer. Oral Presentation: 93rd Annual Meeting & Expo of The Endocrine Society, Boston Convention & Exhibition Center, Boston, MA, June 4-7, 2011. Abstract published in *Endocrine Reviews* **32** (03_MeetingAbstracts): OR16-4, 2011. ***(Appendix 3, p.35)***
http://edrv.endojournals.org/cgi/content/meeting_abstract/32/03_MeetingAbstracts/OR16-4?sid=611ee69b-229e-4ea6-8d33-6f794557b3b7

2. "Pituitary dysfunction after traumatic brain injury (TBI): relevance for psychological health and rehabilitation." Charles W. Wilkinson. Oral Presentation, Case Conference: Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, June 10, 2011.

3. "Pituitary dysfunction in OIF/OEF Veterans with repetitive blast mild traumatic brain injury." Charles W. Wilkinson. Oral Presentation in Symposium: Structural and Functional Neuroimaging, Pituitary Dysfunction, and Animal Modeling in Blast Concussion Mild Traumatic Brain Injury. Elaine R. Peskind, Rajendra Morey, Charles W. Wilkinson, and David G. Cook. 3rd Federal Interagency Conference on Traumatic Brain Injury, Washington Hilton, Washington, DC, June 13-15, 2011. ***(Appendix 3, p.36-37)***

4. "Blast concussion mTBI, hypopituitarism, and psychological health in OIF/OEF Veterans." Charles W. Wilkinson. Oral Presentation: Military Operational Medicine Research Program (MOMRP)/Joint Program Committee for Military Operational Medicine (JPC5) In Progress Review (IPR), Hilton Garden Inn, Frederick, MD, July 27, 2011.

5. "Pituitary dysfunction after blast concussion: relevance for psychological health and rehabilitation." Charles W. Wilkinson. Oral Presentation: National Intrepid Center of Excellence (NICoE) Grand Rounds, NICoE, National Naval Medical Center, Bethesda, MD, July 28, 2011.

6. "Chronic pituitary dysfunction after blast-related mild traumatic brain injury." Charles W. Wilkinson, Elaine R. Peskind, Elizabeth A. Colasurdo, Kathleen F. Pagulayan, and

Jane B. Shofer. Poster Presentation: American College of Neuropsychopharmacology (ACNP) 50th Annual Meeting, Hilton Waikoloa Village, Waikoloa, HI, December 4-8, 2011. ***(Appendix 3, p. 38-40)***

Abstract published in *Neuropsychopharmacology* **36:**S407–S408, 2011
http://www.nature.com/npp/journal/v36/n1s/full/npp2011293a.html

7. "Chronic pituitary dysfunction associated with cognitive and neuropsychiatric deficits after blast-related concussion." Charles W. Wilkinson, Kathleen F. Pagulayan, Jane B. Shofer, and Elaine R. Peskind. Poster Presentation: 22nd Pacific Coast Brain Injury Conference, Sheraton Vancouver Wall Centre, Vancouver, BC, Canada, February 15-17, 2012. ***(Appendix 3, p. 41)***

8. "Prevalence and characteristics of chronic pituitary dysfunction after blast-related mild traumatic brain injury." Charles W. Wilkinson, Elaine R. Peskind, Elizabeth A. Colasurdo, Kathleen F. Pagulayan, and Jane B. Shofer. Oral Presentation: Ninth World Congress on Brain Injury, Edinburgh International Conference Centre, Edinburgh, Scotland, March 21-25, 2012. ***(Appendix 3, p. 42-43)***

Abstract published in *Brain Injury* **26**:732, 2012
http://informahealthcare.com/doi/pdf/10.3109/02699052.2012.660091

9. "Chronic pituitary hormone abnormalities after blast-induced mild traumatic brain injury in combat Veterans: a psychiatric concern?" Charles W. Wilkinson. Oral Presentation, Grand Rounds: University of Washington Department of Psychiatry and Behavioral Sciences, Harborview Medical Center, Seattle, WA, April 6, 2012.

10. "Hormonal abnormalities after blast concussion in Veterans: implications for quality of life." Charles W. Wilkinson. Oral Presentation in Symposium: Overview of VA/UW Blast-related Traumatic Brain Injury Research Program. Lance Stewart, Elaine R. Peskind, Charles W. Wilkinson, and David G. Cook. VA Puget Sound Health Care System, Seattle, WA, April 9, 2012.

11. "Hormonal abnormalities after blast concussion in Veterans: implications for quality of life." Charles W. Wilkinson. Oral Presentation, Research Seminar: Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, April 9, 2012.

12. "Blast concussion is associated with high frequency of pituitary dysfunction." C. Wilkinson, K. Pagulayan, E. Colasurdo, J. Shofer, and E. Peskind. Poster Presentation: ICE/ECE 2012: 15th International Congress of Endocrinology, Fortezza da Basso, Florence, Italy, May 5-9, 2012. ***(Appendix 3, p. 44-45)***

Abstract published in *Endocrine Abstracts* **29**:P1436
http://www.endocrine-abstracts.org/ea/0029/ea0029p1436.htm

13. "Pituitary Function After Blast Concussion: Why It Happens and Why It Matters." Charles W. Wilkinson. Oral Presentation, Neuroscience Research Seminar, VA Puget Sound Health Care System, Seattle, WA, March 1, 2013.

14. "Prevalence of chronic hypopituitarism after blast concussion." Charles W. Wilkinson, Elizabeth A. Colasurdo, Kathleen F. Pagulayan, Jane B. Shofer, and Elaine R. Peskind. Poster Presentation, Experimental Biology 2013, Boston Convention & Exhibition Center, Boston, MA, April 20-24, 2013. ***(Appendix 3, p. 46-47)***
Abstract published in *FASEB J* **27**:935.3, 2013
http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/935.3?sid=c78bc1bd-2e77-40db-b5d2-c95ae9e715ed

15. "TBI: Screening and Evaluation of Headache and Endocrine Disorders." Elaine R. Peskind and Charles W. Wilkinson. Cyber Seminar Presentation, VA HSR&D Center for Information Dissemination and Education Resources, April 25, 2013.

16. "Pituitary dysfunction after blast concussion: imaging and psychological correlates." Charles W. Wilkinson, Eric C. Petrie, Satoshi Minoshima, Donna J. Cross, Todd L. Richards, Kathleen F. Pagulayan, and Elaine R. Peskind. Poster Presentation, ENDO 2013: The Endocrine Society Annual Meeting & Expo, Moscone Center, San Francisco, CA, June 15-18, 2 013. ***(Appendix 3, p. 48)***
Abstract published in *Endocr Rev* 34: SUN-148, 2013
https://endo.confex.com/endo/2013endo/webprogram/Paper7712.html

17. "High Frequency of Pituitary Dysfunction and Associated Cognitive and Behavioral Deficits after Blast Concussion." Charles W. Wilkinson, Kathleen F. Pagulayan, Elizabeth A. Colasurdo, Jane B. Shofer, Madeleine L. Werhane, and Elaine R. Peskind. Abstract Accepted, Poster Presentation,1st PanAmerican Congress of Physiological Sciences (PanAm-2014): Physiology without borders, Rafain Palace Hotel & Convention Center, Iguassu Falls, Brazil, August 2-6, 2014. ***(Appendix 3, p. 49)***

Peer-reviewed Publication

"High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury." Charles W. Wilkinson, Kathleen F. Pagulayan, Eric C. Petrie, Cynthia L. Mayer, Elizabeth A. Colasurdo, Jane B. Shofer, Kim L. Hart, David Hoff, Matthew A. Tarabochia, and Elaine R. Peskind. *Front Neurol* **3**:11, 2012. Published online 2012 February 7. Prepublished online 2011 December 27. doi: 10.3389/fneur.2012.00011 PMCID: PMC3273706 (http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273706/?tool=pubmed)

Funding Applied for and Received Based on Work Supported by this Award

VA Rehabilitation Research & Development Merit Review Award.

Application Number: 1I01RX000509-01A1.
Principal Investigator: Charles W. Wilkinson, PhD
Project Title: Pituitary dysfunction, behavioral symptoms, and quality of life after blast mTBI.
Period: April 1, 2012- March 31, 2016.
Estimated Award Total: $932,347

Research Opportunities Received Based on Experience Supported by this Award

Contact was initiated with three investigators from the Naval Medical Research Center (NMRC) in San Diego (LCDR Andrew MacGregor, PhD, MPH; Mary Clouser, MD, MPH; and Michael Galarneau, MS) to collaborate to obtain selected serum samples from the Department of Defense Serum Repository (DoDSR) maintained by the Armed Forces Health Surveillance Center (AFHSC). The DoDSR receives and stores serial serum specimens related to operational deployments worldwide which are made available to qualified DoD researchers upon acceptance of an application proposal. The AFHSC retains demographic, occupational, and medical information linked to the serum samples in the repository. The NMRC maintains the Expeditionary Medical Encounter Database (EMED), which contains clinical records completed by providers at forward-deployed medical facilities and including those of combatants with serious injuries who are subsequently evacuated to higher levels of care, as well as those with mild injury who are returned to duty. The clinical records provide details about the injury incident, such as injury mechanism, as well as the number, type, and severity of injuries, including TBI. The collaboration with NMRC investigators will involve the selection of Marines who experienced mTBI in Iraq or Afghanistan as well as deployed non-blast-exposed Marines selected on the basis of the EMED records. Matching serum samples will be requested from the DoDSR.

The hypothesis of the proposed study is that serum hormone deficiencies characteristic of hypogonadism and growth hormone deficiency (GHD) are significantly more frequent in US Marines who have sustained blast-related mild traumatic brain injury (mTBI), i.e., concussion, while deployed in Iraq, Operation Iraqi Freedom (OIF) or Afghanistan, Operation Enduring Freedom (OEF) (mTBI group) than in similarly deployed Marines not exposed to blast trauma (Non Blast Exposed (NBE) group). This hypothesis will be tested by measuring luteinizing hormone (LH), testosterone, and insulin-like growth factor-I (IGF-I) in my laboratory in predeployment and postdeployment serum samples from Marines in each of the two groups. The study will also investigate potential associations of hormonal abnormalities after blast mTBI with particular constellations of demographic, medical history, injury mechanism, and injury-specific data to determine to what extent each of these factors or combinations of factors best predict the occurrence of chronic pituitary dysfunction after blast concussion.

A proposal submitted by the NMRC investigators and I has been approved by the AFHSC and the project will begin when the linkage between serum samples and data in the EMED is completed.

CONCLUSION

In data analyzed to date, 42.9% of participants with blast mTBI showed evidence of posttraumatic hypopituitarism as determined by basal hormone measurements. The prevalence of hypopituitarism from all causes in the general population has been estimated at 300 cases per million, or 0.03%. Based on this estimation, the prevalence of pituitary dysfunction in Veterans who sustained blast concussions while deployed in Iraq or Afghanistan is 1,430 times greater than that of the general population. These data suggest a problem of enormous significance for the health, recovery, and rehabilitation of service members and Veterans. The most frequently observed hormone deficiency disorders observed after concussion are GHD and hypogonadism. Both conditions result in significant changes in mood, energy, body composition, and QoL.

PTHP is associated with a constellation of symptoms that overlap considerably with those of PTSD, including fatigue, mood disturbances, anxiety and depression, irritability, insomnia, memory loss, social isolation, and decreased quality of life. Muscular weakness, erectile dysfunction, infertility, deleterious effects on body composition, and diminished cardiovascular function are also frequent consequences. These symptoms, if they result from PTSD, are often resistant to successful treatment. However, if some or all of the symptoms are indeed of neuroendocrine origin and are appropriately diagnosed as consequences of neuroendocrine disorders, they can be treated successfully with hormone replacement. Therefore, failure to consider the diagnosis of PTHP may result in inappropriate and ineffective treatment of these symptoms.

Therefore, routine screening for pituitary dysfunction after blast concussion shows promise for: (a) identifying those individuals whose symptoms are of neuroendocrine origin; (b) directing diagnostic and therapeutic strategies that might otherwise remain unconsidered; and (c) markedly facilitating recovery and rehabilitation after blast concussion.

REFERENCES

Agha, A., and Thompson, C. J. (2005). High risk of hypogonadism after traumatic brain injury: clinical implications. Pituitary 8, 245–249.

Bushnik, T., Englander, J., and Katznelson, L. (2007). Fatigue after TBI: association with neuroendocrine abnormalities. *Brain injury : [BI]* 21, 559-566.

Colao, A., Di Somma, C., Savanelli, M.C., De Leo, M., and Lombardi, G. (2006). Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. *Growth Horm IGF Res* 16 Suppl A, S41-48.

Colao, A. (2008). The GH-IGF-I axis and the cardiovascular system: clinical implications. *Clin Endocrinol (Oxf)* 69, 347-358.

Falleti, M.G., Maruff, P., Burman, P., and Harris, A. (2006). The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. *Psychoneuroendocrinology* 31, 681-691.

Götherström, G., Elbornsson, M., Stibrant-Sunnerhagen, K., Bengtsson, B.A., Johannsson, G., and Svensson, J. (2009). Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. *J Clin Endocrinol Metab* 94, 809-816.

High, W.M., Jr., Briones-Galang, M., Clark, J.A., Gilkison, C., Mossberg, K.A., Zgaljardic, D.J., Masel, B.E., and Urban, R.J. (2010). Effect of growth hormone replacement therapy on cognition after traumatic brain injury. *Journal of neurotrauma* 27, 1565-1575.

Kelly, D.F., Mcarthur, D.L., Levin, H., Swimmer, S., Dusick, J.R., Cohan, P., Wang, C., and Swerdloff, R. (2006). Neurobehavioral and quality of life changes associated with growth hormone insufficiency after complicated mild, moderate, or severe traumatic brain injury. *Journal of neurotrauma* 23, 928-942.

Kreitschmann-Andermahr, I., Poll, E.M., Reineke, A., Gilsbach, J.M., Brabant, G., Buchfelder, M., Fassbender, W., Faust, M., Kann, P.H., and Wallaschofski, H. (2008). Growth hormone deficient patients after traumatic brain injury--baseline characteristics and benefits after growth hormone replacement--an analysis of the German KIMS database. *Growth Horm IGF Res* 18, 472-478.

Mossberg, K.A., Masel, B.E., Gilkison, C.R., and Urban, R.J. (2008). Aerobic capacity and growth hormone deficiency after traumatic brain injury. *J Clin Endocrinol Metab* 93, 2581-2587.

Popovic, V., Pekic, S., Pavlovic, D., Maric, N., Jasovic-Gasic, M., Djurovic, B., Medic Stojanoska, M., Zivkovic, V., Stojanovic, M., Doknic, M., Milic, N., Djurovic, M., Dieguez, C., and Casanueva, F.F. (2004). Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. *J Endocrinol Invest* 27, 1048-1054.

Reimunde, P., Quintana, A., Castanon, B., Casteleiro, N., Vilarnovo, Z., Otero, A., Devesa, A., Otero-Cepeda, X.L., and Devesa, J. (2011). Effects of growth hormone (GH) replacement and cognitive rehabilitation in patients with cognitive disorders after traumatic brain injury. *Brain injury : [BI]* 25, 65-73.

Rosén, T., Wiren, L., Wilhelmsen, L., Wiklund, I., and Bengtsson, B.A. (1994). Decreased psychological well-being in adult patients with growth hormone deficiency. *Clin Endocrinol (Oxf)* 40, 111-116.

Svensson, J., Mattsson, A., Rosen, T., Wiren, L., Johannsson, G., Bengtsson, B.A., and Koltowska Haggstrom, M. (2004). Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. *Growth Horm IGF Res* 14, 207-215.

Tomlinson, J.W., Holden, N., Hills, R.K., Wheatley, K., Clayton, R.N., Bates, A.S., Sheppard, M.C., and Stewart, P.M. (2001). Association between premature mortalityand hypopituitarism. West Midlands Prospective Hypopituitary Study Group. *Lancet* 357, 425–431.

Wilkinson, C.W., Pagulayan, K.F., Petrie, E.C., Mayer, C.L., Colasurdo, E.A., Shofer, J.B., Hart, K.L., Hoff, D., Tarabochia, M.A., and Peskind, E.R. (2012). High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury. *Front Neurol* 3:11. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273706/

Blast Concussion mTBI, Hypopituitarism, and Psychological Health in OIF/OEF Veterans
PT090753 Principal Investigator: Charles W. Wilkinson, Ph.D.
Statement of Work (SOW)

Introduction and Rationale: Chronic hypopituitarism (deficient production of one or more anterior pituitary hormones) occurs in 30-70% of cases of civilian traumatic brain injury (TBI). Although repetitive blast concussion TBI (mTBI) is the signature injury sustained by combat troops deployed to Operation Iraqi Freedom (OIF) and/or Operation Enduring Freedom in Afghanistan (OEF), the incidence of hypopituitarism resulting from this type of mTBI has not been determined. Hypopituitarism is associated with symptoms easily mistaken for those of posttraumatic stress disorder (PTSD) including fatigue, mood disturbances, anxiety and depression, irritability, insomnia, memory loss, social isolation, and decreased quality of life. Muscular weakness, erectile dysfunction, infertility, and diminished cardiovascular function can also result. These symptoms, if diagnosed as consequences of hypopituitarism as opposed to being of purely neurological origin, can generally be relieved with hormone replacement. Provocative testing, often used in screening for hypopituitarism after TBI, is costly, time-consuming, and labor-intensive, but measurement of basal concentrations of pituitary hormones and their target hormones has been shown to have considerable diagnostic utility. This study is designed to establish normative values for each of 12 pituitary and target-organ hormones, to measure these hormones in banked blood samples from groups of Veterans of OIF/OEF with and without blast mTBI, to establish criteria for individual hormone deficiencies and the diagnosis of hypopituitarism, to refer Veterans provisionally identified with hypopituitarism for clinical evaluation and treatment, and to determine the frequency and specific pituitary deficits consequent to blast mTBI. Accurate, routine diagnosis of hypopituitarism has the potential of markedly improving the psychological health and facilitating the recovery of blast mTBI victims.

Specific Aim 1: Measurement of basal concentrations of anterior pituitary hormones and their target-organ hormones in serum or plasma from 100 male civilian control subjects in order to establish normative parameters for each hormone concentration.

Task 1: Obtainment of all regulatory approvals required in order to proceed with this aim: biohazard, radiation safety, local institutional review board (IRB), and Department of Defense (DOD) Human Research Protection Office (HRPO) human subjects approval. Submission of applications for biohazard, radiation safety and local IRB approval has already been completed. The IRB application is for expedited review, and approval is expected before the end of the first three months (quarter 1 [Q1]) of the study. HRPO submission will follow IRB approval immediately, and all approvals are expected to be received by the end of Q2.

Task 2: Measurement of the 12 hormones (adrenocorticotropin [ACTH], cortisol, thyroid-stimulating hormone [TSH], free thyroxine, growth hormone [GH], insulin-like growth factor I [IGF-I], luteinizing hormone [LH], follicle-stimulating hormone [FSH], total testosterone, prolactin [PRL], vasopressin, and oxytocin) in blood samples from 100 community control subjects will require:

a) selection of a commercially available hormone assay kit for each hormone and tests of the performance of the assays as carried out according to the manufacturers' protocols. Test assays will not be performed until biohazard and radiation safety approvals have been obtained. Cortisol, IGF-I, LH, and vasopressin will be measured by radioimmunoassay (RIA) techniques. All other hormones will be measured using enzyme-linked immunosorbent assay (ELISA) techniques. Performance of this sub-task will be completed during months four through six (Q2) of the study duration. This sub-task does not employ any human tissue or biological fluids or any other use of human subjects and does not require IRB approval. This is a test of assay performance only.

b) procurement of banked plasma and serum samples previously obtained from 100 selected male community control subjects between the ages of 21 and 50 with a body mass index (BMI) less than 34. All samples to be analyzed will be samples banked in a regulated repository; no direct sampling of biological fluids from human participants will be employed in this study. Banked samples will NOT be obtained prior to IRB and HRPO approvals. This subtask will require only a very short period of time and is expected to be completed by the end of the Q2.

Task 3: Performance of assays of all 12 hormones listed above on plasma or serum samples from the 100 selected male community control subjects, tabulation and statistical analysis of all assay results, and use of those analyses to determine ranges of normal concentrations of each hormone to establish diagnostic criteria for individual hormone deficiencies. ACTH, cortisol, TSH, vasopressin, and oxytocin will be measured in plasma samples. Free thyroxine, GH, IGF-I, LH,FSH, total testosterone, and PRL will be measured in serum samples. Identification of pituitary hormone deficiencies will be based upon measurement of hormone values below the normative ranges established

with assays of samples from community control subjects. Performance of this task will be completed during months 7-10 of the study (Q3).

All tasks addressing Specific Aim 1 are expected to be completed by the end of Q3.

Specific Aim 2: Measurement of basal concentrations of the 12 pituitary and target-organ hormones described above in banked plasma/serum samples from 40 male Veterans of OIF/OEF exposed to blast concussion mTBI – the mTBI group – and banked samples from a second group of 20 male OIF/OEF Veterans without blast concussion mTBI or PTSD – the deployment control (DC) group. Pituitary deficiencies and occurrence of hypopituitarism in individual subjects and for each of the two subject groups will be tabulated to describe the frequency and specific pituitary deficits consequent to blast mTBI.

Task 4: Performance of assays, as described above on banked samples from 100 community control subjects, of ACTH, cortisol, TSH, free thyroxine, GH, IGF-I, LH, FSH, total testosterone, PRL, vasopressin, and oxytocin in plasma/serum samples from 40 mTBI and 20 DC subjects followed by tabulation and analysis of the data. Task 4 will be completed by the end of Q4.

Task 5: Determine the individual hormone deficiencies and the probable incidence of hypopituitarism in each Veteran and in each of the two Veteran groups (mTBI and DC) by:

a) using criteria derived from community control normative data to identify individual hormone deficiencies in each of the 60 Veteran subjects (40 mTBI and 20 DC). For each of the 12 hormones, a measured value that falls in the lowest 5 percentile of the community control group will be defined as a hormone deficiency.

b) identify the existence of probable hypopituitarism in each subject. Hypopituitarism will be defined as deficiencies indicating dysfunction in any one of the following pituitary hormone/target hormone systems: ACTH/cortisol; TSH/thyroxine; GH/IGF-I; LH/FSH/testosterone; PRL; vasopressin; and oxytocin.

c) using the data from individual subjects, determine the incidence of each specific hormone deficiency in the mTBI group and in the DC group. Based on the definition of hypopituitarism above (in the description of Task 5b) determine the incidence of hypopituitarism in each of the Veteran groups. Statistically analyze the group data to identify possible significant differences in pituitary dysfunction between the two groups.

All tasks addressing Specific Aim 2 are expected to be completed by the end of Q5.

Specific Aim 3: Refer individuals provisionally identified with pituitary deficits for more extensive diagnostic tests and treatment, use those clinical data to further refine and validate the hormonal screening criteria, and determine predictive accuracy of the final screening method.

Task 6: Veteran subjects provisionally identified with pituitary dysfunction will be referred to physicians specializing in endocrinology for further clinical evaluation, diagnosis, and treatment, and results from clinical evaluations will be used to refine the cutoff criteria provided by the hormone assays. Based on the refined criteria, group data will be re-evaluated to determine specific differences related to blast mTBI, and receiver operating characteristic (ROC) analysis will be used to assess the predictive accuracy of the hormone screening method.

All tasks addressing Specific Aim 3 are expected to be completed by the end of Q6.

Consult timeline below for graphic presentation of the sequence of tasks and their expected time of completion.

Primary Outcomes:

1. Referral for clinical evaluation and treatment of Veteran subjects provisionally identified with hypopituitarism.

2. Determination of hypothesized increased incidence of specific hormone deficiencies and diagnosis of hypopituitarism in individuals exposed to blast concussion mTBI.

3. Dissemination of findings and their significance for Veterans' physical and psychological health by publication in an appropriate scientific journal.

The principal investigator Charles Wilkinson and co-investigator Elaine Peskind will participate in all tasks. All work will be performed at:

Department of Veterans Affairs Puget Sound Health Care System (VAPS)
1660 S. Columbian Way
Seattle, WA 98108

	Q1	Q2	Q3	Q4	Q5	Q6
Specific Aim 1 — Measure basal pituitary and target hormone concentrations in plasma/serum from 100 community control subjects						
Task 1: Obtain all necessary regulatory approvals for project						
1.a: Obtain biohazard and radiation safety approval	VAPS					
1.b: Obtain IRB approval to use banked blood samples	VAPS					
1.c: Obtain DOD HRPO approval for project	DOD	DOD				
Milestone 1: All regulatory approvals obtained		VAPS				
Task 2: Select and characterize samples from 100 community controls and test assay methods						
2.a: Test performance of assays for all hormones	VAPS	VAPS				
2.b: Obtain banked samples after protocols approved		VAPS				
2.c: Sort samples; select for age 21-50, BMI < 34		VAPS				
Milestone 2: Assays validated and 100 control samples identified		VAPS				
Task 3: Perform all hormone assays on samples from 100 community controls and analyze data						
3.a: Perform 12 hormone assays on 100 control samples			VAPS			
3.b: Analyze and tabulate data			VAPS			
3.c: Use data to identify normative hormone ranges			VAPS			
Milestone 3: Assays performed and normal ranges established			VAPS			
Specific Aim 2 — Measure basal pituitary and target hormone concentrations in plasma/serum from 40 OIF/OEF Veterans exposed to blast mTBI and 20 OIF/OEF Veterans without mTBI or PTSD						
Task 4: Assay and analyze all samples from 40 mTBI-exposed and 20 deployment-control Veterans						
4.a: Perform 12 hormone assays on 60 Veteran samples				VAPS		
4.b: Tabulate and analyze data				VAPS		
Milestone 4: mTBI and DC samples assayed and analyzed				VAPS		
Task 5: Use criteria derived from normative data to identify probable hypopituitarism in each Veteran group						
5.a: Use control data to set criteria for deficiencies				VAPS	VAPS	
5.b: Identify subjects with probable hypopituitarism				VAPS	VAPS	
5.c: Ascertain hormone deficit incidence in each group				VAPS	VAPS	
Milestone 5: Screening criteria established, applied and analyzed					VAPS	
Specific Aim 3 — Refer Veterans with probable hypopituitarism for clinical evaluation and treatment and use de-identified evaluations to validate and refine the diagnostic utility of the hormone assay screening procedure						
Task 6: Carry out clinical referrals and use clinical data to assess specificity and sensitivity of screening						
6.a: Refer for clinical evaluation and treatment				VAPS	VAPS	
6.b: Use clinical outcome data to refine screening criteria					VAPS	
6.c: Re-evaluate data for group hypopituitarism incidence					VAPS	
6.c: Find predictive accuracy of method by ROC analysis					VAPS	
6.d: Write manuscript and submit for publication						VAPS
Milestone 6: Publication of final results of study						VAPS

Q1 = Quarter 1 (months 1-3) / Q2 = Quarter 2 (months 4-6) / Q3 = Quarter 3 (months 7-9)
Q4 = Quarter 4 (months 10-12) / Q5 = Quarter 5 (months 13-15) / Q6 = Quarter 6 (months 16-18)

frontiers in NEUROLOGY

ORIGINAL RESEARCH ARTICLE
published: 07 February 2012
doi: 10.3389/fneur.2012.00011

High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury

Charles W. Wilkinson[1,2]*, Kathleen F. Pagulayan[2,3], Eric C. Petrie[2,3], Cynthia L. Mayer[2,3], Elizabeth A. Colasurdo[1], Jane B. Shofer[2], Kim L. Hart[3], David Hoff[3], Matthew A. Tarabochia[3] and Elaine R. Peskind[2,3]

[1] Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA
[2] Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
[3] VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, USA

Edited by:
Mattias Sköld, Uppsala University, Sweden

Reviewed by:
Ibolja Cernak, Johns Hopkins University Applied Physics Lab, USA
Stefan Plantman, Karolinska Institutet, Sweden

***Correspondence:**
Charles W. Wilkinson, Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, S-182 GRECC, 1660 South Columbian Way, Seattle, WA 98108, USA.
e-mail: wilkinso@uw.edu

Studies of traumatic brain injury from all causes have found evidence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones at least 1 year after injury, in 25–50% of cases. Most studies found the occurrence of posttraumatic hypopituitarism (PTHP) to be unrelated to injury severity. Growth hormone deficiency (GHD) and hypogonadism were reported most frequently. Hypopituitarism, and in particular adult GHD, is associated with symptoms that resemble those of PTSD, including fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, cognitive deficiencies, and decreased quality of life. However, the prevalence of PTHP after blast-related mild TBI (mTBI), an extremely common injury in modern military operations, has not been characterized. We measured concentrations of 12 pituitary and target-organ hormones in two groups of male US Veterans of combat in Iraq or Afghanistan. One group consisted of participants with blast-related mTBI whose last blast exposure was at least 1 year prior to the study. The other consisted of Veterans with similar military deployment histories but without blast exposure. Eleven of 26, or 42% of participants with blast concussions were found to have abnormal hormone levels in one or more pituitary axes, a prevalence similar to that found in other forms of TBI. Five members of the mTBI group were found with markedly low age-adjusted insulin-like growth factor-I (IGF-I) levels indicative of probable GHD, and three had testosterone and gonadotropin concentrations consistent with hypogonadism. If symptoms characteristic of both PTHP and PTSD can be linked to pituitary dysfunction, they may be amenable to treatment with hormone replacement. Routine screening for chronic hypopituitarism after blast concussion shows promise for appropriately directing diagnostic and therapeutic decisions that otherwise may remain unconsidered and for markedly facilitating recovery and rehabilitation.

Keywords: traumatic brain injury, hypopituitarism, blast, concussion, growth hormone, pituitary

INTRODUCTION

Recent studies investigating chronic pituitary dysfunction resulting from TBI have reported a prevalence of posttraumatic hypopituitarism (PTHP) ranging from 5 to 95% with a median of 35%, the variation being primarily due to differences in screening criteria (Bavisetty et al., 2008; Srinivasan et al., 2009; Berg et al., 2010; Englander et al., 2010; High et al., 2010; Kokshoorn et al., 2010, 2011; Krahulik et al., 2010; Park et al., 2010; Pavlovic et al., 2010; Reimunde et al., 2011; Schneider et al., 2011). Pituitary hormone disorders are frequently among the immediate consequences of TBI; some resolve during the following months while a smaller proportion of new dysfunctions emerge (Agha et al., 2005; Aimaretti et al., 2005; Schneider et al., 2006, 2011; Tanriverdi et al., 2006, 2008b; Klose et al., 2007; Krahulik et al., 2010). By ∼6 months subsequent to TBI, the pattern of pituitary deficits is considered to be relatively permanent.

The risk factors and the mechanisms, other than immediate trauma-induced tissue damage and subsequent edema, for chronic hypothalamo-pituitary dysfunction due to TBI are unclear. Roles for polymorphisms in apolipoprotein E genotype (*APOE*), inflammatory processes – both systemic and neural, and anti-hypothalamic (AHAs) and anti-pituitary antibodies (APAs) have been proposed, and each has empirical support.

There is evidence that the apolipoprotein E (*APOE*) ε3/ε3 genotype may be associated with a reduced risk of TBI-related hypopituitarism. *APOE* ε3 is the most common of the three alleles and is found in more than half of the general population. The ε2 and ε4 alleles have been associated with altered risks for Alzheimer's disease, hyperlipoproteinemia, and atherosclerosis. Pituitary dysfunction in patients with TBI has been found to be significantly less prevalent in individuals with the *APOE* ε3/ε3 genotype (17.7%)

than in patients with other genotypes (41.9%; $p = 0.01$; Tanriverdi et al., 2008a).

Evidence for the involvement of APAs and/or AHAs in the development of chronic PTHP comes from two studies. APAs were detected in 44.8% of patients who had completed a 3-year-follow-up after TBI and in none of the healthy control subjects, and the prevalence of hypopituitarism was significantly higher in APA-positive (46.2%) than APA-negative TBI patients (12.5%; $p = 0.04$; Tanriverdi et al., 2008b). In another study of active and retired boxers, AHAs were detected in 21.3% and APAs in 22.9% of boxers, whereas no evidence of APAs or AHAs was found in control subjects (Tanriverdi et al., 2010a).

It is well established that TBI results in the acute induction of both neural and systemic inflammatory responses and consequent anti-inflammatory counter-responses (Lu et al., 2009; Ziebell and Morganti-Kossmann, 2010). In addition, animal studies provide evidence of the development of a chronic inflammatory state after TBI. Three months after moderate focal brain injury in rats, persistent major histocompatibility complex (MHC)-II up-regulation, mononuclear phagocytosis, and elevated interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α) synthesis were observed in large areas of the ipsilateral hemisphere (Holmin and Mathiesen, 1999). In another study, 2 months after cortical contusion injury to the medial frontal cortex of rats, IL-1β was significantly increased in the cortex and hypothalamus compared with a sham–trauma group, and glial fibrillary acidic protein (GFAP) was elevated in the cortex, hypothalamus, and anterior pituitary of the TBI group (Kasturi and Stein, 2009).

In general, the frequency of occurrence of pituitary hormone abnormalities has not been found to be related to the severity of the trauma (Lieberman et al., 2001; Agha et al., 2004a; Aimaretti et al., 2004, 2005; Bondanelli et al., 2004; Schneider et al., 2006; Park et al., 2010; Kokshoorn et al., 2011), although there have been reports of a positive relationship (Kelly et al., 2000; Klose et al., 2007). Of the traumatic brain injuries sustained by ~1.7 million Americans annually (Faul et al., 2010), 75% are considered mild TBI (mTBI; National Center for Injury Prevention and Control, 2003).

Mild TBI is defined by the American Congress of Rehabilitation Medicine (ACRM) as a head trauma resulting in any one of the following: loss of consciousness (LOC) for 30 min or less, alteration of mental state for up to 24 h (being dazed, confused, disoriented, etc.), or loss of memory for events immediately before or after the trauma (American Congress of Rehabilitation Medicine, 1993). The terms mTBI and concussion are frequently used interchangeably (National Center for Injury Prevention and Control, 2003; Department of Veterans Affairs/Department of Defense, 2009).

Mild TBI-related chronic pituitary dysfunction has been reported in boxers and kick boxers subjected to repetitive head injuries. In a preliminary study, 45% of professional boxers were found with apparent growth hormone deficiency (GHD), but no other pituitary hormone deficiencies were observed (Kelestimur et al., 2004). In a larger study of active and retired boxers 18% had pituitary hormone deficiencies in one or more axes (Tanriverdi et al., 2008c). An investigation of pituitary dysfunction in amateur kick boxers revealed GH and/or adrenocorticotropin (ACTH) deficiencies in 27.3% of the athletes (Tanriverdi et al., 2007).

In 2010, the injuries in 80% of over 30,000 U.S. military service members medically diagnosed with TBI were classified as mTBI (Military Health System, 2011), and mTBI sustained from explosive blasts is one of the most common combat injuries resulting from deployment to Iraq or Afghanistan. About 10–20% of returnees report having experienced at least one blast concussion (Tanielian et al., 2008; Terrio et al., 2009).

The extensive documentation of the high prevalence of hypopituitarism after TBI from all causes and the absence of any published studies of the frequency of PTHP after blast-related mTBI provided the rationale for this investigation of hypopituitarism in U.S. Veterans of combat in Iraq and/or Afghanistan who have experienced at least one blast concussion.

MATERIALS AND METHODS

PARTICIPANTS AND SAMPLE ACQUISITION

The VA Puget Sound Health Care System (VAPSHCS) Institutional Review Board and the U.S. Army Medical Research and Materiel Command (USAMRMC) Office of Research Protections (ORP) Human Research Protection Office (HRPO) approved the subject protocol with a waiver of informed consent. All plasma and serum samples, demographic, and blast exposure data were obtained from an established biorepository entitled "Alzheimer's Disease Research Center (ADRC) Participant Registry and Sample Repository." All subjects whose samples were utilized had consented to have their samples and data used in future research of this type.

The mTBI Veteran participants (T group) whose samples were obtained from the repository were a convenience sample of 26 male Veterans recruited from VAPSHCS, all of whom had documented hazardous duty experience in Iraq and/or Afghanistan with the U.S. Armed Forces and had reported experiencing at least one blast exposure in the war zone that resulted in acute mTBI as defined by ACRM criteria (American Congress of Rehabilitation Medicine, 1993) except that Glasgow Coma Scale scores were not obtained in the combat setting. Samples from the repository were also collected from seven male Veterans who had been deployed to Iraq and/or Afghanistan but who had not been exposed to blast and had no history of TBI. These individuals made up the deployment control (DC) group.

Additional samples from the repository which were used to establish normal hormonal reference ranges had been collected from 59 cognitively normal male community volunteers recruited from the ADRC, all of whom were medically healthy and had Mini-Mental State Examination scores of 29.4 ± 1.0 (mean ± SEM; range 27–30); Clinical Dementia Rating scores of zero; no evidence or history of cognitive or functional decline; and no history of blast exposure or head injury. These samples were used only for the establishment of normative hormone concentrations with our assay methods. Resting blood samples had been collected from all participants between 9:00 and 10:00 a.m., at least 30 min after the insertion of an intravenous catheter in an antecubital vein.

None of the Veteran or community control participants had a history of blast exposure, head injury with LOC greater than 30 min; penetrating head wound; seizure disorder; insulin-dependent diabetes; current or past DSM-IV diagnoses of schizophrenia, other psychotic disorders, bipolar disorder, or dementia; or a DSM-IV diagnosis of alcohol or other substance abuse or dependence within the previous 3 months. Participants using medications likely to affect brain function, such as opioids,

benzodiazepines, or anti-depressants, were asked not to take those medications for 24 h prior to blood sampling.

BLAST EXPOSURE ASSESSMENT

Blast exposure and mTBI histories had been obtained from mTBI Veteran participants during a clinical interview in which specific inquiries were made regarding total number of blast exposures accompanied by acute symptoms of TBI and/or LOC in Iraq and/or Afghanistan and lifetime history of non-blast exposure head injuries accompanied by acute symptoms of TBI and/or LOC (e.g., sports or motor vehicle accident-related concussion).

NEUROLOGICAL ASSESSMENT

All subjects underwent a full neurological examination, including the Unified Parkinson's Disease Rating Scale (UPDRS) motor section (Martínez-Martín et al., 1994). Olfactory function was assessed using the Brief Smell Identification Test (B-SIT; Doty et al., 1996).

HORMONE MEASUREMENT

Blood samples for the measurement of plasma hormone concentrations were collected between 9:00 and 10:00 a.m. in chilled tubes containing ethylenediaminetetraacetic acid (EDTA), placed on ice, and centrifuged at 4°C prior to removal of the plasma fraction. Blood samples for measurement of serum hormones were collected in serum-separator tubes, allowed to clot at room temperature for 10 min, and centrifuged to isolate serum. Serum and plasma samples were aliquoted and stored at −70°C. Twelve pituitary or target-organ hormones were measured in these samples. The type, source, and performance characteristics of the assay kits used for the measurement of hormone concentrations in serum and plasma are shown in **Table 1**. ACTH, cortisol, thyroid-stimulating hormone (TSH), oxytocin, and vasopressin concentrations were determined in plasma; free thyroxine, luteinizing hormone (LH), follicle-stimulating hormone (FSH), total testosterone, insulin-like growth factor-I (IGF-I), growth hormone, and prolactin were measured in serum.

CLINICAL LAB DATA

Measurements of plasma and urine osmolality were not available but urine specific gravity was measured and used as a criterion to determine functional vasopressin insufficiency.

STATISTICAL ANALYSIS AND CRITERIA FOR PITUITARY DEFICIENCIES

The criteria for PTHP, derived using hormone measurements from the 59 community control participants are shown in **Table 2**. For each hormone, age-adjusted percentiles based on the lognormal distribution from community control participants were estimated and dysfunction in each of seven hormonal axes was defined (R Development Core Team, 2011). Hypopituitarism was defined as a dysfunction in at least one of these seven axes. These criteria were

Table 1 | Sources and characteristics of hormone assay kits.

Assay	Kit name	Manufacturer	Location
ACTH	ACTH Immunoradiometric (IRMA) Assay	Scantibodies Laboratory	Santee, CA, USA
Cortisol	GammaCoat™Cortisol ^{125}I RIA	Diasorin	Stillwater, MN, USA
FSH	DELPHIA hFSH	Perkin Elmer	Waltham, MA, USA
GH	hGH-ELISA, Ultra-Sensitive	DSL	Webster, TX, USA
IGF-I	IGF-I RIA	IBL America	Minneapolis, MN, USA
LH	ImmuChem™Coated Tube LH ^{125}I RIA	MP Biomedicals	Costa Mesa, CA, USA
Oxytocin	Oxytocin EIA Kit – Extraction-free	Peninsula Labs/Bachem	San Carlos, CA, USA
Prolactin	ImmuChem™Coated Tube Prolactin ^{125}I IRMA	MP Biomedicals	Costa Mesa, CA, USA
Testosterone	Total Testosterone	Siemens Diagnostics	Los Angeles, CA, USA
Thyroxine	Free Thyroxine (FT_4) Microplate EIA	MP Biomedicals	Costa Mesa, CA, USA
TSH	ImmuChem™Coated Tube TSH ^{125}I IRMA	MP Biomedicals	Costa Mesa, CA, USA
Vasopressin	Vasopressin Direct RIA	ALPCO	Salem, NH, USA

Hormones	Assay type	Sample type	Assay size	Sample size	Assay range	Sensitivity	Intra-assay CV	Inter-assay CV
ACTH	IRMA	Plasma	100 Tubes	200 μl	9–1693 pg/ml	<1.0 pg/ml	4.05	6.66
Cortisol	RIA	Plasma	100 Tubes	10 μl	1–60 μg/dl	0.21 μg/dl	7.03	9.20
FSH	Fluoroimmunoassay	Serum	96 Wells	25 μl	0.98–256 U/l	0.05 U/l	2.33	1.87
GH	EIA	Serum	96 Wells	100 μl	4.5–500 pg/ml	0.66 pg/ml	6.00	5.40
IGF-1	RIA	Serum	100 Tubes	100 μl	0.16–10.0 ng/ml	0.02 ng/ml	2.97	10.30
LH	RIA	Serum	100 Tubes	100 μl	2.5–200 mIU/ml	1.5 mIU/ml	5.90	7.90
Oxytocin	EIA	Plasma	96 Wells	50 μl	0–630 pg/ml	6.5 pg/ml	9.36	13.67
Prolactin	IRMA	Serum	100 Tubes	25 μl	2.5–100 ng/ml	2.5 ng/ml	5.13	8.08
Testosterone	Solid-phase RIA	Serum	100 Tubes	50 μl	20–1600 ng/dl	4 ng/dl	3.40	7.90
Thyroxine	EIA	Serum	96 Wells	50 μl	0.45–7.6 ng/dl	0.05 ng/dl	6.83	6.47
TSH	IRMA	Plasma	100 Tubes	200 μl	0.2–50 μIU/ml	0.04 μIU/ml	4.10	5.23
Vasopressin	RIA	Plasma	100 Tubes	400 μl	1.25–80 pg/ml	0.1 pg/ml	6.00	9.90

Table 2 | Screening criteria for identifying abnormal circulating hormone levels.

Axis	Criteria using lognormal distribution of community control reference sample
Adrenal insufficiency	Cortisol < 10th percentile (6.7 μg/dl), and ACTH < 10th percentile (18 pg/ml)
Thyroid deficiency	Free T-4 < 5th percentile (0.87 ng/dl), and TSH < 50th percentile (2.39 μIU/ml)
Hypogonadism	Total testosterone < 5th percentile (330 ng/dl) and either LH or FSH < 10th percentile (2.3 mIU/ml, 1.3 U/l, respectively) OR (total testosterone < 5th percentile and prolactin > 95th percentile (32 ng/ml)
Vasopressin abnormality	Vasopressin > 95th percentile (9.46 pg/ml) OR vasopressin < 5th percentile (0.27 pg/ml) and urine specific gravity < 1.003
Prolactin abnormality	Prolactin > 95th percentile (32.0 ng/ml) OR prolactin < 5th percentile (6.7 ng/ml)
GH deficiency	IGF-1 < age-adjusted 10th percentile (SDS < −1.4)
Oxytocin deficiency	Oxytocin < 5th percentile (22.7 pg/ml)
Hypopituitarism	Abnormalities in at least one of these 7 axes

modeled after those used in published studies of hypopituitarism after TBI from all causes.

RESULTS

PLASMA/SERUM HORMONE SCREENING EVALUATIONS

Eleven of 26 mTBI subjects (T), or 42%, were found to have abnormal hormone values in at least one axis. As reported in earlier studies of PTHP, deficiencies in the growth hormone-IGF-I and pituitary–gonadal axes were observed most frequently (Bavisetty et al., 2008; Dusick et al., 2008; Schneider et al., 2008; Englander et al., 2010; Kokshoorn et al., 2010; Krahulik et al., 2010; Park et al., 2010; Pavlovic et al., 2010; van der Eerden et al., 2010).

Markedly low IGF-I levels are strong indicators of adult GHD (Juul et al., 1997; Hartman et al., 2002; Hadjadj et al., 2007; Ho, 2007; Prodam et al., 2008; Tanriverdi et al., 2011; Zgaljardic et al., 2011). The red line in **Figure 1** represents the cutoff level used to define our criterion for subnormal IGF-I levels indicative of probable GHD. The cutoff level was defined to be an IGF-I concentration below the age-adjusted 10th percentile level [equivalent to an SD score (SDS) below −1.4] of the community control reference sample (**Figure 1**; **Table 2**). Five Veteran participants with mTBI (T-4, T-8, T-16, T-25, and T-28) were found to have serum IGF-I concentrations below this cutoff line. None of the Veteran participants in the DC group were found to have subnormal age-adjusted IGF-I levels (**Figure 1**).

Three participants with mTBI (T-4, T-13, and T-28) were found with abnormal hormonal profiles indicating probable hypogonadism. The criteria were a total testosterone concentration less than the 5th percentile of the reference sample together with an LH or FSH level below the 10th percentile reference level (**Figure 2**; **Table 2**). T-4 and T-28 also had the lowest two IGF-I levels among the participants (T-4: 126 ng/ml, SDS = −2.325; T-28: 86 ng/ml, SDS = −2.989). Elevated prolactin levels in conjunction with low testosterone are also indicative of hypogonadism. A serum prolactin concentration markedly higher than the 95th percentile of the reference sample was found in serum from participant T-4. A subnormal prolactin concentration (<5th percentile), also associated with sexual dysfunction, was measured in serum from T-13.

None of the Veterans in the DC group were found to have hormone levels indicative of hypogonadism. One participant in the DC group was found with a total testosterone concentration below the 5th percentile reference standard and another had an LH concentration below the 10th LH percentile, but neither exhibited the combined gonadotropin and testosterone deficiencies consistent with hypogonadism.



FIGURE 1 | IGF-I concentrations in serum from deployment control (DC) participants (triangles) and participants with mTBI (T, circles). The screening criterion for growth hormone deficiency was an IGF-I level below the age-adjusted 10th percentile of IGF-I concentration (diagonal red line) in the community control reference group. Serum IGF-I values of five Veterans with mTBI fell below this cutoff line. None of the DC group met this criterion.

None of the Veteran participants in either the T or DC group exhibited abnormalities in the hypothalamic-pituitary–adrenocortical or hypothalamic-pituitary–thyroid axis (**Table 3**). The corticotrophs and thyrotrophs are located in the protected median wedge of the anterior pituitary and are anatomically less vulnerable to injury than gonadotropin- and GH-secreting cells. This differential anatomical vulnerability correlates well with the frequency of chronic hormonal abnormalities observed after TBI (Bavisetty et al., 2008; Blair, 2010; Krahulik et al., 2010).

In addition to the findings of anterior pituitary hormone abnormalities in six Veteran participants with mTBI, eight instances of anomalous posterior pituitary hormone levels were



FIGURE 2 | Serum LH (left) and testosterone (right) in the deployment control (DC, triangles) and mTBI (T, circles) groups. Screening criteria for hypogonadism: LH (or FSH) levels below the 10th percentile of the control range together with testosterone below the 5th percentile (red lines). Green circles mark data from 3 T subjects falling below both cutoffs. No DC subjects met both criteria.

found in six Veterans in the mTBI group, one of whom, T-28, also had evidence of presumptive GHD and hypogonadism. The plasma oxytocin concentration was unmeasurably low in this individual (**Table 3**). None of the Veterans in the DC group were found to have abnormal posterior pituitary hormone values.

Three additional participants from the mTBI group (T-10, T-14, and T-22) also were found to have circulating oxytocin concentrations below the reference sample's 5th percentile level. Two of these participants, T-10 and T-22, also met our criteria for arginine vasopressin (AVP) deficiency: plasma vasopressin concentration below the 5th percentile of the reference level in combination with urine specific gravity less than 1.003. In addition, plasma vasopressin concentrations in participants T-2 and T-12 were abnormally elevated above the 95th percentile of the reference group.

DEMOGRAPHICS, DEPLOYMENT HISTORY, BLAST EXPOSURE, AND MEDICATION USE

After completion of hormone measurement and identification of Veterans with apparent hypopituitarism, participants in the T group were divided into two subgroups, based on the presence or absence of hormone abnormalities, for comparison of demographic, deployment history, blast exposure, and medication use data with each other and with the DC group. The three groups of Veteran participants did not differ in age, education, or body mass index at the time of enrollment, and the two mTBI subgroups did not differ significantly from one another on any of the measures of deployment history or blast exposure (**Table 4**).

CONCURRENT MEDICATIONS

Medications with potential neuroendocrine effects taken by mTBI subjects found to have indications of hypopituitarism were opiates (2/11), prazosin (2/11), selective serotonin reuptake inhibitors (SSRIs; 4/11), serotonin and norepinephrine reuptake inhibitors (SNRIs; 2/11), hypnotics (2/11), atypical antipsychotics (1/11), calcium channel blockers for migraine (1/11), benzodiazepines (1/11), and mirtazapine (1/11). Five subjects in this group were not taking any neuroactive medications. Medications with potential neuroendocrine effects taken by mTBI subjects found to have hormone levels within normal ranges were opiates (1/15), prazosin (4/15), SSRIs (3/15), SNRIs (2/15), mirtazapine (1/15), trazodone (1/15), benzodiazepines (1/15), and disulfiram (1/15). Nine subjects in this group were not taking any neuroactive medications. Medications with potential neuroendocrine effects taken by DC subjects were opiates (1/7), SSRIs (1/7), and SNRIs (1/7). Five subjects in this group were not taking any neuroactive medications.

DISCUSSION

Our findings in this preliminary study support the hypothesis that blast mTBI carries a risk of PTHP similar to that found in several previous studies of hypopituitarism in the general population after TBI from all causes. We have found that blood samples from 11 of 26, or 42% of Veterans of combat in Iraq or Afghanistan had abnormal circulating hormone concentrations consistent with PTHP. Five participants with blast mTBI exhibited evidence of anterior pituitary dysfunction, five additional subjects had anomalous posterior pituitary hormone levels, and the eleventh was found to have both anterior and posterior pituitary hormonal abnormalities. In contrast, none of the seven Veterans of deployment to Iraq and/or Afghanistan in the study who did not experience blast trauma – the DC group – were found to have evidence of pituitary dysfunction.

As Kokshoorn et al. (2010) pointed out in their review of 14 investigations of PTHP conducted between 2000 and 2009, these early studies used a broad variety of screening criteria that were sometimes described in general terms rather than with specifically

Table 3 | Plasma or serum hormone concentration for each participant.

Subject	Age	#BE	ACTH (pg/ml)	Cort (μg/dl)	LH (mIU/ml)	FSH (U/l)	tTest (ng/dl)	PRL (ng/ml)	TSH (μIU/ml)	fT-4 (ng/dl)	IGF-I (ng/ml)	GH (pg/ml)	AVP (pg/ml)	OT (pg/ml)
T-1	24	11	24	6.6	2.58	0.46	473	12.5	1.70	1.29	190	58	3.4	64
T-2	26	6	20	11.9	2.03	–	669	9.6	1.92	1.67	185	71	12.3	181
T-3	27	10	22	10.2	5.15	2.05	557	13.0	1.59	1.59	164	50	4.0	166
T-4	33	15	19	7.5	2.03	2.06	252	54.9	1.17	1.22	110	11	8.0	88
T-5	38	102	24	12.8	2.11	2.33	362	14.9	1.16	1.18	133	0	0.4	71
T-6	46	5	29	12.1	1.95	1.41	402	11.1	1.08	1.09	143	152	0.7	61
T-7	26	20	28	14.1	3.34	1.63	559	12.0	2.26	1.29	172	223	0.0	39
T-8	25	21	35	11.3	2.72	4.02	401	11.9	1.13	1.55	141	294	0.2	44
T-9	24	102	39	12.0	4.81	3.28	730	14.4	1.16	1.05	251	1288	8.0	52
T-10	26	20	30	9.6	1.97	2.43	520	12.3	2.41	1.39	230	68	0.2	22
T-11	28	9	31	10.2	1.64	2.38	382	9.2	1.30	1.22	182	0	1.1	36
T-12	27	15	27	9.9	7.27	5.70	715	13.0	1.57	1.38	198	60	12.0	55
T-13	31	7	40	7.8	1.92	1.18	253	6.3	2.24	1.14	187	0	6.4	50
T-14	30	6	36	8.8	2.66	2.51	390	12.0	3.75	1.13	151	310	0.5	19
T-15	27	11	16	7.4	2.27	3.56	377	10.1	1.40	1.14	168	42	4.4	85
T-16	28	66	25	11.7	2.64	4.01	380	21.5	0.65	1.52	126	0	0.9	190
T-17	25	18	26	11.2	9.32	3.00	465	17.1	1.26	1.25	197	0	4.8	151
T-18	24	7	30	14.2	3.65	2.21	556	12.2	1.27	1.30	179	60	4.3	32
T-19	30	1	32	18.6	5.44	3.01	457	11.7	1.55	1.13	190	66	0.0	46
T-20	28	3	17	25.0	6.65	3.91	309	10.4	0.79	1.31	210	1696	7.9	519
T-22	25	4	21	17.6	4.00	4.48	588	12.8	1.09	1.24	227	110	0.0	21
T-23	29	52	11	8.7	2.52	2.55	554	8.9	1.34	1.35	166	95	4.0	199
T-25	25	12	8	7.7	2.24	4.34	463	7.2	1.42	1.23	146	813	2.1	25
T-26	26	11	9	6.8	5.94	1.14	488	8.4	0.81	1.18	185	42	0.9	457
T-27	43	5	29	7.5	2.52	3.89	263	7.1	0.60	1.04	126	13	2.6	50
T-28	41	12	15	11.1	2.11	2.64	264	15.3	1.22	1.11	86	375	8.4	0

*Shaded values indicate hormone axis abnormalities as defined in **Table 2**. #BE, number of self-reported blast exposures meeting ACRM criteria for mTBI during military career; ACTH, adrenocorticotropin; Cort, cortisol; LH, luteinizing hormone; FSH, follicle-stimulating hormone; tTest, total testosterone; PRL, prolactin; TSH, thyroid-stimulating hormone; fT-4, free thyroxine; IGF-I, insulin-like growth factor-I; GH, growth hormone; AVP, vasopressin; OT, oxytocin.*

defined cutoffs. We attempted to use relatively conservative and explicitly defined criteria based on the distribution of specific hormone concentrations measured in a reference population. We did not employ provocative testing but used criteria based on measurement of both pituitary hormones and their target-organ hormones when possible, e.g., a combination of measurements of total testosterone, LH, FSH, and prolactin to screen for hypogonadism.

It should be cautioned that the determinations of basal hormone concentrations, such as those made in this study, are meant to be screening tools, and are not intended to be, nor should they be interpreted to be, diagnostic in the absence of clinical assessment. Measurement of basal circulating hormone concentrations is generally considered an appropriate screening tool for provisional identification of deficient thyroid function, hypogonadism, and prolactin and oxytocin deficiencies. Diagnosis of significant abnormalities of vasopressin secretion normally require confirmation by measures of plasma and/or urine osmolality, urine specific gravity (UGS), and/or the administration of a water deprivation test. Although provocative testing is generally considered necessary for diagnosis of sAI and GHD, measurement of basal cortisol and IGF-I concentrations remain valuable screening tools to identify individuals most likely to benefit from additional testing and clinical referral. Evaluation of clinical signs and symptoms are essential for definitive diagnoses in all cases.

Previous studies have found GHD to be the most prevalent chronic endocrine consequence of TBI, and it carries with it a potentially large range of symptoms. Provocative testing is considered to be a requisite for the reliable diagnosis of GHD because serum GH concentrations measured in the morning are not valid indicators of daily secretion or somatotroph function. GH secretion occurs predominantly during sleep, and morning levels are generally very low but punctuated unpredictably by short secretory bursts (Van Cauter et al., 1992). However, GH stimulates hepatic production of IGF-I that provides a useful index of somatotroph function. IGF-I concentrations have low diagnostic sensitivity for identifying GHD but are highly specific. The presence of normal IGF-I values cannot be used to exclude GDH because it is often diagnosed in individuals with normal or even elevated IGF-I levels. However, markedly low age-adjusted levels of IGF-I are strongly indicative of GHD (Juul et al., 1997; Hadjadj et al., 2007; Ho, 2007; Prodam et al., 2008; Tanriverdi et al., 2011; Zgaljardic et al., 2011). Circulating IGF-I concentrations decline markedly with increasing age, and this decline must be taken into account when interpreting them.

Table 4 | Mean ± SEM and (range) for demographic, deployment, and blast exposure data for each group of participants.

	DC ($n = 7$)	mTBI without PTHP($n = 15$)	mTBI with PTHP($n = 11$)
A. DEMOGRAPHICS			
Age (years)	31.1 ± 3.3 (23–47)	29.7 ± 1.8 (24–46)	28.8 ± 1.5 (25–41)
Education (years)	14.0 ± 0.7 (12–17)	13.3 ± 0.4 (11–16)	13.6 ± 0.5 (12–16)
Marital status	3/7 Married, 4/7 single	7/15 Married, 4/15 single, 2/15 divorced, 2/15 unknown	7/11 Married, 1/11 single, 1/11 separated, 2/11 unknown
Body mass index (BMI)	28.5 ± 2.1 ($n = 5$)[†]	27.9 ± 1.3 ($n = 14$)[†]	29.0 ± 1.3 ($n = 10$)[†]
B. DEPLOYMENT HISTORY			
Number of deployments	1.7 ± 0.4 (1–3)	1.9 ± 0.2 (1–4)	2.1 ± 0.3 (1–3)
Time between first and second deployments (months)	14.3 ± 7.0 (3.5–27.5) ($n = 3$)	15.9 ± 3.1 (4.0–39.5) ($n = 10$)	15.4 ± 2.4 (7.5–30.0) ($n = 8$)
Time between second and third deployments (months)	6.0 ± 1.0 (5.0–7.0) ($n = 2$)	8.0 ± 2.0 (6–12) ($n = 3$)	7.6 ± 2.0 (3.0–12.5) ($n = 4$)
Time between third and forth deployments (months)		8.0 ± 0.0 ($n = 1$)	
Total deployment time (months)	13.0 ± 1.8 (7–21)	18.7 ± 2.2 (7–37)	18.2 ± 1.7 (11–27)
C. BLAST EXPOSURE			
Deployment blast exposures meeting ACRM criteria for mTBI	0	11.1 ± 3.3 (1–52)	14.6 ± 5.4 (4–66)
Blast exposures meeting ACRM criteria during military career	0.3 ± 0.3 (0–2)	24.5 ± 8.7 (1–102)	16.7 ± 5.2 (4–66)
Blast exposures with LOC	0	1.3 ± 0.3 (0–4)	0.6 ± 0.2 (0–2)
Lifetime events with LOC	0.1 ± 0.1 (0–1)	3.1 ± 0.7 (0–11)	1.3 ± 0.4 (0–3)
Time since last blast exposure (months)		45.2 ± 4.2 (14–66)	47.4 ± 4.3 (20–67)

The Veterans with blast mTBI (T group) were divided into two subgroups based upon the presence or absence of abnormal hormonal profiles suggesting PTHP.[†] BMIs were not obtained for all participants.

Studies using receiver operating characteristic (ROC) analysis to compare the diagnostic accuracy of IGF-I relative to diagnosis of GHD based on provocative testing of GH secretion have reported a diagnostic specificity of 100% with IGF-I SDS cutoffs of −1.3 (Corneli et al., 2007) or −1.7 (Maghnie et al., 2005).

The individuals classified here as having a high probability of GHD all had values less than −1.4 SDs below the age-adjusted means of the reference sample. The high specificity of IGF-I measurements at this level assures a very low likelihood of false positives in diagnosing GHD. However, in light of the low sensitivity of IGF-I concentrations in predicting GHD, it is probable that some Veteran participants with normal IGF-I levels may be growth hormone deficient.

The long-term sequelae of GHD in adults for health, quality of life (QoL), and morbidity are multifaceted and complex. Low GH secretion has been associated with behavioral symptoms and deficits in several cognitive domains (Popovic et al., 2004; Falleti et al., 2006; Pavlovic et al., 2010). GHD also has significant deleterious effects on body composition and cardiovascular function. Adult GHD is associated with lipidemia, reduced lean body mass, and increased adiposity. Even partial GHD in adult patients is associated with adverse lipid profiles and early atherosclerosis (Colao et al., 2006a,b; Colao, 2008). Impairment in QoL is also a prominent feature of adult GHD, especially in the areas of energy and vitality (McGauley, 1989; Kelly et al., 2006; Bushnik et al., 2007; Svensson et al., 2007; Bavisetty et al., 2008). Adult GHD is also associated with reductions in muscle volume and strength, decreased physical mobility, fatigue, sleep impairment, social isolation, depression, lowered metabolic rate, low sexual drive, and reduced aerobic capacity (Rosén et al., 1994; Mossberg et al., 2008).

Many of the symptoms of GHD can be successfully ameliorated or reversed by growth hormone replacement therapy. Five retrospective studies have shown that the risk of premature death from cardiovascular disease is elevated in patients with GHD (Svensson et al., 2004a). The increased risk factors such as adverse lipid profiles, increased blood pressure, abnormal body composition, increased body weight, increased coagulability, and increased markers of inflammation have all been shown to improve with GH replacement (Svensson et al., 2004a, 2007; Götherström et al., 2007a; Verhelst and Abs, 2009). GH replacement has been found to be effective in reversing cognitive impairments in several domains including simple motor speed, information processing speed, episodic memory, mental flexibility, verbal memory, and executive functioning in patients after TBI (High et al., 2010; Reimunde et al., 2011). GH replacement also normalizes muscle strength and increases bone mineral density (Götherström et al., 2007b, 2009), improves psychiatric functioning by ameliorating depression, intensity of interpersonal sensitivity, hostility, paranoid ideation, and anxiety (Maric et al., 2010), and improves QoL (Svensson et al., 2004b, 2007; Kreitschmann-Andermahr et al., 2008).

Three of the Veteran participants in the T group met our criteria for hypogonadism: a total testosterone concentration less than the 5th percentile of the reference sample together with an LH or FSH level below the 10th percentile reference level. In our very small sample, the occurrence of hypogonadism was found to be next highest in frequency to that of GHD, as was the case in several of the studies of PTHP after TBI from all causes in the general population (Bavisetty et al., 2008; Dusick et al., 2008; Krahulik et al., 2010; Park et al., 2010; Tanriverdi et al., 2010b).

Hypogonadism has significant deleterious consequences in addition to its adverse effects on fertility, psychosexual function, and general well being. Testosterone deficiency in males is associated with decreased energy and motivation, muscle weakness, reduced lean body mass, and impaired exercise tolerance (Agha and Thompson, 2005). In addition, a recent large epidemiological study has shown that untreated hypogonadism is associated with premature mortality secondary to cardiovascular disease (Tomlinson et al., 2001).

One mTBI participant, T-4, was found to have a highly elevated concentration of prolactin, 2.5 times higher than the next highest concentration measured in the T group and more than four times higher than the highest value in the DC group. Hyperprolactinemia has been causally linked with hypogonadism, specifically by reducing LH and FSH secretion, blocking LH stimulation of testicular testosterone secretion, and producing oligospermia by reducing FSH levels, resulting in hypoactive sexual desire and erectile dysfunction.

Prolactin is the only anterior pituitary hormone that is under predominantly inhibitory control. Its secretion is suppressed by dopamine, and in the absence of this inhibition, prolactin is released at high levels. Hyperprolactinemia frequently results from the use of antipsychotic medications that act as antagonists at dopamine D2 receptors (Holt, 2008; Inder and Castle, 2011).

Participant T-4 had been taking quetiapine, an atypical antipsychotic with fast dissociation kinetics at the D2 receptor [released from D2 within 12–24 h (Seeman, 2010)] that results only in low and transient prolactin secretion (Carboni et al., 2011). It has not generally been associated with hyperprolactinemia in clinical use (Haddad and Wieck, 2004; Byerly et al., 2007; Bushe et al., 2010) although a prevalence of 22% was found in one study (Montgomery et al., 2004). It is often referred to as a dopamine-sparing antipsychotic, and although it is much less potent in elevating prolactin levels than several other antipsychotics (e.g., haloperidol and risperidone), it may have prolactin-elevating effects in some individuals, perhaps including participant T-4.

One of the Veterans with mTBI was found to have a subnormal (less than 5th percentile) prolactin concentration. Hypoprolactinemia is rare in the general population, but it too has been associated with sexual dysfunction, primarily arteriogenic erectile dysfunction and premature ejaculation (Corona et al., 2009).

We found no evidence of dysfunction in the thyroid or adrenal axes as a result of blast mTBI. Previous studies of pituitary deficiencies after TBI from all causes have generally reported a lower prevalence of TSH and adrenocorticotropin (ACTH) deficiencies than of GH or gonadotropin deficits (Bavisetty et al., 2008; Blair, 2010; Krahulik et al., 2010). This pattern may be due in part to the location of pituitary corticotrophs and thyrotrophs in the gland's protected median wedge and their blood supply via both the long hypophysial portal vessels and the inferior hypophysial artery. GH-secreting somatotrophs, on the other hand, are anatomically more vulnerable to damage because of their location in the pituitary's exposed lateral wings and their primary dependence on vascular input from the portal system alone. Gonadotrophs are distributed throughout the anterior pituitary, and the cells in the lateral wings are relatively vulnerable.

In addition to the six participants with hormonal levels consistent with hypogonadism and/or GHD, six of the Veterans with mTBI (including one with anterior pituitary hormonal abnormalities) exhibited abnormal plasma vasopressin and/or oxytocin concentrations. Oxytocin concentrations below the 5th percentile value of the community control group were observed in four of the mTBI participants. Two of the four also exhibited indications of vasopressin deficiency as defined by vasopressin levels below the 5th percentile of the community reference group together with urine specific gravity less than 1.003. The occurrence of deficits of both vasopressin and oxytocin in two participants suggests the possibility of disruption of the pituitary stalk or hypothalamic damage in these individuals. In addition, elevated plasma vasopressin concentrations above the reference 95th percentile were measured in two subjects.

In several studies, elevated cerebrospinal fluid (CSF) or peripheral vasopressin concentrations have been associated with PTSD, depression, schizophrenia, and other psychiatric disorders, but a causal relationship has not been established (Purba et al., 1996; van Londen et al., 1997; Coccaro et al., 1998; Merali et al., 2006; de Kloet et al., 2008; Goekoop et al., 2009; Heinrichs et al., 2009). In contrast, there is evidence from both animal and human studies for the positive association of oxytocin levels with social bonding, attenuation of stress responses in socially relevant challenges, mediation of social support, and positive social interactions (Heinrichs et al., 2009; Campbell, 2010).

Our finding of a high frequency of abnormal peripheral hormone levels after blast mTBI in this preliminary study is consistent with the investigations cited above, in which the prevalence of pituitary dysfunction fell in the 30–60% range in 11 of 22 reports. However, in general, those studies focused exclusively on anterior pituitary dysfunction. Although few studies have investigated the prevalence of chronic posterior pituitary hormonal abnormalities after TBI, most (Agha et al., 2004b, 2005; Krahulik et al., 2010), but not all (Bondanelli et al., 2004), found significant evidence of damage in that lobe as well. In this study we found significant anterior pituitary dysfunction in 23.1% of Veterans with mTBI and abnormal posterior pituitary hormone levels in 23.1% of this group as well. In contrast, the prevalence of hypopituitarism in the general adult population ranges between 290 and 455 cases per million (Regal et al., 2001).

The only other ongoing study of hypopituitarism after blast mTBI of which we are aware recently reported preliminary results based on two retrospective chart reviews. Of 147 Marines with blast-related mTBI screened approximately 1 year or more after injury, 25% were found to have abnormal levels of one or more anterior pituitary hormones (Stokes and Gallagher, 2011).

The Veteran groups in this study are highly similar in demographic characteristics and share the common experience of

deployment under highly stressful and dangerous conditions accentuated by extreme heat and the burden of heavy equipment even when not actively engaged in combat. Despite these commonalities, the experience of blast trauma and the combat situations in which these exposures occur have major long-term consequences well beyond those of deployment to Iraq or Afghanistan. The considerable overlap between the constellations of symptoms typical of chronic hypopituitarism and persistent post-concussive symptoms (PPCS), in addition to the similarities of both to PTSD, make accurate diagnosis of the etiology, progression, and identifiable differences between the conditions of critical importance for successful treatment, recovery, and rehabilitation (Masel, 2005).

The consequences of undiagnosed and untreated pituitary hormone deficiencies are manifold and significant and include diminished QoL, cognitive deficiencies, fatigue, sleep disturbance, sexual dysfunction, deleterious changes in metabolism and body composition, behavioral and psychiatric problems including anxiety, irritability, social isolation, depression, and increased cardiovascular mortality. PTHP, unlike PTSD and PPCS, is readily treatable if correctly diagnosed, and many of its symptoms can be reversed or ameliorated with appropriate hormone replacement therapy.

Several of the authors of previous studies of hypopituitarism after TBI have advocated routine endocrine evaluation after brain injury (Masel, 2004; Leal-Cerro et al., 2005; Schneider et al., 2005; Urban et al., 2005; Powner et al., 2006; Behan and Agha, 2007; Ho, 2007; Behan et al., 2008; Tanriverdi et al., 2008b, 2010b; Blair, 2010; Krahulik et al., 2010; Park et al., 2010). A recent review of the literature (Guerrero and Alfonso, 2010) stated that because "many of the symptoms of hypopituitarism are similar to those of TBI, it is important to make clinicians caring for combat veterans aware of its occurrence. . . All patients who had a TBI of any severity, should undergo baseline hormonal evaluation."

To our knowledge, this is the first published study of basal hormonal evaluation of combat Veterans with blast mTBI, and our preliminary findings of PTHP in 42% of study participants supports the advisability of routine screening for hypopituitarism after brain injury in both military and civilian populations. Routine provocative testing for sAI and for GHD, the most frequently observed chronic endocrine disorder resulting from TBI, is neither economically nor practically viable. However, measurement of basal concentrations of a panel of pituitary and target-organ hormones similar to those performed here may provide valuable preliminary indications of those individuals most likely to benefit from further clinical evaluation. Similar preliminary screening for pituitary dysfunction after blast concussion shows promise for appropriately directing diagnostic and therapeutic decisions that otherwise may remain unconsidered and for markedly facilitating recovery and rehabilitation.

ACKNOWLEDGMENTS

We gratefully acknowledge the skillful assistance of Carl Sikkema for laboratory work, Carol Xiang and Daniel Morelli for data management, Molly Chinn and Alka Goyal for administrative guidance, Natalia Czajkiewicz for graphic design, and Dr. Leanne Madre for significant contributions in shaping the manuscript into its final form. The work was supported by U.S. Department of Defense Congressionally Directed Medical Research Program Concept Award PT090753; the Geriatric Research, Education and Clinical Center, and the Research and Development Service of the VA Puget Sound Health Care System; the VA Northwest Network Mental Illness Research, Education and Clinical Center; the Seattle Institute for Biomedical and Clinical Research; the University of Washington Alzheimer's Disease Research Center NIA AG05136; and an anonymous foundation.

REFERENCES

Agha, A., Rogers, B., Sherlock, M., O'Kelly, P., Tormey, W., Phillips, J., and Thompson, C. J. (2004a). Anterior pituitary dysfunction in survivors of traumatic brain injury. *J. Clin. Endocrinol. Metab.* 89, 4929–4936.

Agha, A., Thornton, E., O'Kelly, P., Tormey, W., Phillips, J., and Thompson, C. J. (2004b). Posterior pituitary dysfunction after traumatic brain injury. *J. Clin. Endocrinol. Metab.* 89, 5987–5992.

Agha, A., Sherlock, M., Phillips, J., Tormey, W., and Thompson, C. J. (2005). The natural history of post-traumatic neurohypophysial dysfunction. *Eur. J. Endocrinol.* 152, 371–377.

Agha, A., and Thompson, C. J. (2005). High risk of hypogonadism after traumatic brain injury: clinical implications. *Pituitary* 8, 245–249.

Aimaretti, G., Ambrosio, M. R., Di Somma, C., Fusco, A., Cannavò, S., Gasperi, M., Scaroni, C., De Marinis, L., Benvenga, S., degli Uberti, E. C., Lombardi, G., Mantero, F., Martino, E., Giordano, G., and Ghigo, E. (2004). Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. *Clin. Endocrinol. (Oxf.)* 61, 320–326.

Aimaretti, G., Ambrosio, M. R., Di Somma, C., Gasperi, M., Cannavò, S., Scaroni, C., Fusco, A., Del Monte, P., De Menis, E., Faustini-Fustini, M., Grimaldi, F., Logoluso, F., Razzore, P., Rovere, S., Benvenga, S., degli Uberti, E. C., De Marinis, L., Lombardi, G., Mantero, F., Martino, E., Giordano, G., and Ghigo, E. (2005). Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. *J. Clin. Endocrinol. Metab.* 90, 6085–6092.

American Congress of Rehabilitation Medicine. (1993). Definition of mild traumatic brain injury. *J. Head Trauma Rehabil.* 8, 86–87.

Bavisetty, S., McArthur, D. L., Dusick, J. R., Wang, C., Cohan, P., Boscardin, W. J., Swerdloff, R., Levin, H., Chang, D. J., Muizelaar, J. P., and Kelly, D. F. (2008). Chronic hypopituitarism after traumatic brain injury: risk assessment and relationship to outcome. *Neurosurgery* 62, 1080–1093; discussion 1093–1084.

Behan, L. A., and Agha, A. (2007). Endocrine consequences of adult traumatic brain injury. *Horm. Res.* 68(Suppl. 5), 18–21.

Behan, L. A., Phillips, J., Thompson, C. J., and Agha, A. (2008). Neuroendocrine disorders after traumatic brain injury. *J. Neurol. Neurosurg. Psychiatr.* 79, 753–759.

Berg, C., Oeffner, A., Schumm-Draeger, P. M., Badorrek, F., Brabant, G., Gerbert, B., Bornstein, S., Zimmermann, A., Weber, M., Broecker-Preuss, M., Mann, K., and Herrmann, B. L. (2010). Prevalence of anterior pituitary dysfunction in patients following traumatic brain injury in a German multi-centre screening program. *Exp. Clin. Endocrinol. Diabetes* 118, 139–144.

Blair, J. C. (2010). Prevalence, natural history and consequences of post-traumatic hypopituitarism: a case for endocrine surveillance. *Br. J. Neurosurg.* 24, 10–17.

Bondanelli, M., De Marinis, L., Ambrosio, M. R., Monesi, M., Valle, D., Zatelli, M. C., Fusco, A., Bianchi, A., Farneti, M., and Degli Uberti, E. C. (2004). Occurrence of pituitary dysfunction following traumatic brain injury. *J. Neurotrauma* 21, 685–696.

Bushe, C., Sniadecki, J., Bradley, A. J., and Poole Hoffmann, V. (2010). Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia. *J. Psychopharmacol. (Oxford)* 24, 1001–1009.

Bushnik, T., Englander, J., and Katznelson, L. (2007). Fatigue after TBI: association with neuroendocrine abnormalities. *Brain Inj.* 21, 559–566.

Byerly, M., Suppes, T., Tran, Q. V., and Baker, R. A. (2007). Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent

developments and current perspectives. *J. Clin. Psychopharmacol.* 27, 639–661.

Campbell, A. (2010). Oxytocin and human social behavior. *Pers. Soc. Psychol. Rev.* 14, 281–295.

Carboni, L., Negri, M., Michielin, F., Bertani, S., Fratte, S. D., Oliosi, B., and Cavanni, P. (2011). Slow dissociation of partial agonists from the D2 receptor is linked to reduced prolactin release. *Int. J. Neuropsychopharmacol.* doi: 10.1017/S1461145711000824. [Epub ahead of print].

Coccaro, E. F., Kavoussi, R. J., Hauger, R. L., Cooper, T. B., and Ferris, C. F. (1998). Cerebrospinal fluid vasopressin levels: correlates with aggression and serotonin function in personality-disordered subjects. *Arch. Gen. Psychiatry* 55, 708–714.

Colao, A. (2008). The GH-IGF-I axis and the cardiovascular system: clinical implications. *Clin. Endocrinol. (Oxf.)* 69, 347–358.

Colao, A., Di Somma, C., Savanelli, M. C., De Leo, M., and Lombardi, G. (2006a). Beginning to end: cardiovascular implications of growth hormone (GH) deficiency and GH therapy. *Growth Horm. IGF Res.* 16(Suppl. A), S41–48.

Colao, A., Di Somma, C., Spiezia, S., Rota, F., Pivonello, R., Savastano, S., and Lombardi, G. (2006b). The natural history of partial growth hormone deficiency in adults: a prospective study on the cardiovascular risk and atherosclerosis. *J. Clin. Endocrinol. Metab.* 91, 2191–2200.

Corneli, G., Di Somma, C., Prodam, F., Bellone, J., Bellone, S., Gasco, V., Baldelli, R., Rovere, S., Schneider, H. J., Gargantini, L., Gastaldi, R., Ghizzoni, L., Valle, D., Salerno, M., Colao, A., Bona, G., Ghigo, E., Maghnie, M., and Aimaretti, G. (2007). Cut-off limits of the GH response to GHRH plus arginine test and IGF-I levels for the diagnosis of GH deficiency in late adolescents and young adults. *Eur. J. Endocrinol.* 157, 701–708.

Corona, G., Mannucci, E., Jannini, E. A., Lotti, F., Ricca, V., Monami, M., Boddi, V., Bandini, E., Balercia, G., Forti, G., and Maggi, M. (2009). Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. *J. Sex. Med.* 6, 1457–1466.

de Kloet, C. S., Vermetten, E., Geuze, E., Wiegant, V. M., and Westenberg, H. G. (2008). Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder. *J. Psychiatr. Res.* 42, 192–198.

Department of Veterans Affairs/Department of Defense. (2009). *VA/DoD Clinical Practice Guideline for Management of Concussion/Mild Traumatic Brain Injury (mTBI)*. Washington, DC: Department of Veterans Affairs, Department of Defense.

Doty, R. L., Marcus, A., and Lee, W. W. (1996). Development of the 12-item cross-cultural smell identification test (CC-SIT). *Laryngoscope* 106, 353–356.

Dusick, J. R., Wang, C., Cohan, P., Swerdloff, R., and Kelly, D. F. (2008). Chapter 1: pathophysiology of hypopituitarism in the setting of brain injury. *Pituitary*. doi: 10.1007/s11102-008-0130-6. [Epub ahead of print].

Englander, J., Bushnik, T., Oggins, J., and Katznelson, L. (2010). Fatigue after traumatic brain injury: association with neuroendocrine, sleep, depression and other factors. *Brain Inj.* 24, 1379–1388.

Falleti, M. G., Maruff, P., Burman, P., and Harris, A. (2006). The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. *Psychoneuroendocrinology* 31, 681–691.

Faul, M., Xu, L., Wald, M. M., and Coronado, V. G. (2010). *Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002–2006*. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control.

Goekoop, J. G., De Winter, R. F., Wolterbeek, R., Spinhoven, P., Zitman, F. G., and Wiegant, V. M. (2009). Reduced cooperativeness and reward-dependence in depression with above-normal plasma vasopressin concentration. *J. Psychopharmacol. (Oxford)* 23, 891–897.

Götherström, G., Bengtsson, B.-Å., Bosaeus, I., Johannsson, G., and Svensson, J. (2007a). A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. *J. Clin. Endocrinol. Metab.* 92, 1442–1445.

Götherström, G., Bengtsson, B.-Å., Bosaeus, I., Johannsson, G., and Svensson, J. (2007b). Ten-year GH replacement increases bone mineral density in hypopituitary patients with adult onset GH deficiency. *Eur. J. Endocrinol.* 156, 55–64.

Götherström, G., Elbornsson, M., Stibrant-Sunnerhagen, K., Bengtsson, B.-Å., Johannsson, G., and Svensson, J. (2009). Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. *J. Clin. Endocrinol. Metab.* 94, 809–816.

Guerrero, A. F., and Alfonso, A. (2010). Traumatic brain injury-related hypopituitarism: a review and recommendations for screening combat veterans. *Mil. Med.* 175, 574–580.

Haddad, P. M., and Wieck, A. (2004). Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. *Drugs* 64, 2291–2314.

Hadjadj, S., Faure-Gerard, C., Ragot, S., Millet, C., Duengler, F., Torremocha, F., Chatellier, G., Bataille, B., and Marechaud, R. (2007). Diagnostic strategy for growth hormone deficiency: relevance of IGF-1 determination as a screening test. *Ann. Endocrinol. (Paris)* 68, 449–455.

Hartman, M. L., Crowe, B. J., Biller, B. M. K., Ho, K. K., Clemmons, D. R., and Chipman, J. J. (2002). Which patients do not require a GH stimulation test for the diagnosis of adult GH deficiency? *J. Clin. Endocrinol. Metab.* 87, 477–485.

Heinrichs, M., Von Dawans, B., and Domes, G. (2009). Oxytocin, vasopressin, and human social behavior. *Front. Neuroendocrinol.* 30, 548–557.

High, W. M. Jr., Briones-Galang, M., Clark, J. A., Gilkison, C., Mossberg, K. A., Zgaljardic, D. J., Masel, B. E., and Urban, R. J. (2010). Effect of growth hormone replacement therapy on cognition after traumatic brain injury. *J. Neurotrauma* 27, 1565–1575.

Ho, K. K. Y. (2007). Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH research society in association with the European society for pediatric endocrinology, Lawson Wilkins society, European society of endocrinology, Japan endocrine society, and endocrine society of Australia. *Eur. J. Endocrinol.* 157, 695–700.

Holmin, S., and Mathiesen, T. (1999). Long-term intracerebral inflammatory response after experimental focal brain injury in rat. *Neuroreport* 10, 1889–1891.

Holt, R. I. (2008). Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. *J. Psychopharmacol. (Oxford)* 22, 28–37.

Inder, W. J., and Castle, D. (2011). Antipsychotic-induced hyperprolactinaemia. *Aust. N. Z. J. Psychiatry* 45, 830–837.

Juul, A., Kastrup, K. W., Pedersen, S. A., and Skakkebaek, N. E. (1997). Growth hormone (GH) provocative retesting of 108 young adults with childhood-onset GH deficiency and the diagnostic value of insulin-like growth factor I (IGF-I) and IGF-binding protein-3. *J. Clin. Endocrinol. Metab.* 82, 1195–1201.

Kasturi, B. S., and Stein, D. G. (2009). Traumatic brain injury causes long-term reduction in serum growth hormone and persistent astrocytosis in the cortico-hypothalamo-pituitary axis of adult male rats. *J. Neurotrauma* 26, 1315–1324.

Kelestimur, F., Tanriverdi, F., Atmaca, H., Unluhizarci, K., Selcuklu, A., and Casanueva, F. F. (2004). Boxing as a sport activity associated with isolated GH deficiency. *J. Endocrinol. Invest.* 27, RC28–RC32.

Kelly, D. F., Gonzalo, I. T., Cohan, P., Berman, N., Swerdloff, R., and Wang, C. (2000). Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. *J. Neurosurg.* 93, 743–752.

Kelly, D. F., MacArthur, D. L., Levin, H., Swimmer, S., Dusick, J. R., Cohan, P., Wang, C., and Swerdloff, R. (2006). Neurobehavioral and quality of life changes associated with growth hormone insufficiency after complicated mild, moderate, or severe traumatic brain injury. *J. Neurotrauma* 23, 928–942.

Klose, M., Juul, A., Struck, J., Morgenthaler, N. G., Kosteljanetz, M., and Feldt-Rasmussen, U. (2007). Acute and long-term pituitary insufficiency in traumatic brain injury: a prospective single-centre study. *Clin. Endocrinol. (Oxf.)* 67, 598–606.

Kokshoorn, N. E., Smit, J. W., Nieuwlaat, W. A., Tiemensma, J., Bisschop, P. H., Groote Veldman, R., Roelfsema, F., Franken, A. A., Wassenaar, M. J., Biermasz, N. R., Romijn, J. A., and Pereira, A. M. (2011). Low prevalence of hypopituitarism after traumatic brain injury: a multicenter study. *Eur. J. Endocrinol.* 165, 225–231.

Kokshoorn, N. E., Wassenaar, M. J., Biermasz, N. R., Roelfsema, F., Smit, J. W., Romijn, J. A., and Pereira, A. M. (2010). Hypopituitarism following traumatic brain injury: prevalence is affected by the use of different dynamic tests and different normal values. *Eur. J. Endocrinol.* 162, 11–18.

Krahulik, D., Zapletalova, J., Frysak, Z., and Vaverka, M. (2010). Dysfunction of hypothalamic-hypophyseal axis after traumatic brain injury

in adults. *J. Neurosurg.* 113, 581–584.

Kreitschmann-Andermahr, I., Poll, E. M., Reineke, A., Gilsbach, J. M., Brabant, G., Buchfelder, M., Fassbender, W., Faust, M., Kann, P. H., and Wallaschofski, H. (2008). Growth hormone deficient patients after traumatic brain injury – baseline characteristics and benefits after growth hormone replacement – an analysis of the German KIMS database. *Growth Horm. IGF Res.* 18, 472–478.

Leal-Cerro, A., Flores, J. M., Rincon, M., Murillo, F., Pujol, M., Garcia-Pesquera, F., Dieguez, C., and Casanueva, F. F. (2005). Prevalence of hypopituitarism and growth hormone deficiency in adults long-term after severe traumatic brain injury. *Clin. Endocrinol. (Oxf.)* 62, 525–532.

Lieberman, S. A., Oberoi, A. L., Gilkison, C. R., Masel, B. E., and Urban, R. J. (2001). Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. *J. Clin. Endocrinol. Metab.* 86, 2752–2756.

Lu, J., Goh, S. J., Tng, P. Y., Deng, Y. Y., Ling, E. A., and Moochhala, S. (2009). Systemic inflammatory response following acute traumatic brain injury. *Front. Biosci.* 14, 3795–3813.

Maghnie, M., Aimaretti, G., Bellone, S., Bona, G., Bellone, J., Baldelli, R., De Sanctis, C., Gargantini, L., Gastaldi, R., Ghizzoni, L., Secco, A., Tinelli, C., and Ghigo, E. (2005). Diagnosis of GH deficiency in the transition period: accuracy of insulin tolerance test and insulin-like growth factor-I measurement. *Eur. J. Endocrinol.* 152, 589–596.

Maric, N. P., Doknic, M., Pavlovic, D., Pekic, S., Stojanovic, M., Jasovic-Gasic, M., and Popovic, V. (2010). Psychiatric and neuropsychological changes in growth hormone-deficient patients after traumatic brain injury in response to growth hormone therapy. *J. Endocrinol. Invest.* 33, 770–775.

Martínez-Martín, P., Gil-Nagel, A., Gracia, L. M., Gómez, J. B., Martínez-Sarriés, J., and Bermejo, F. (1994). Unified Parkinson's disease rating scale characteristics and structure. The Cooperative Multicentric Group. *Mov. Disord.* 9, 76–83.

Masel, B. E. (2004). Rehabilitation and hypopituitarism after traumatic brain injury. *Growth Horm. IGF Res.* 14(Suppl. A), S108–S113.

Masel, B. E. (2005). Traumatic brain injury induced hypopituitarism: the need and hope of rehabilitation. *Pituitary* 8, 263–266.

McGauley, G. A. (1989). Quality of life assessment before and after growth hormone treatment in adults with growth hormone deficiency. *Acta Paediatr. Scand. Suppl.* 356, 70–72; discussion 73–74.

Merali, Z., Kent, P., Du, L., Hrdina, P., Palkovits, M., Faludi, G., Poulter, M. O., Bédard, T., and Anisman, H. (2006). Corticotropin-releasing hormone, arginine vasopressin, gastrin-releasing peptide, and neuromedin B alterations in stress-relevant brain regions of suicides and control subjects. *Biol. Psychiatry* 59, 594–602.

Military Health System. (2011). *DoD Worldwide Numbers for Traumatic Brain Injury*. Available at: http://www.health.mil/Research/TBI_Numbers.aspx [accessed].

Montgomery, J., Winterbottom, E., Jessani, M., Kohegyi, E., Fulmer, J., Seamonds, B., and Josiassen, R. C. (2004). Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. *J. Clin. Psychiatry* 65, 1491–1498.

Mossberg, K. A., Masel, B. E., Gilkison, C. R., and Urban, R. J. (2008). Aerobic capacity and growth hormone deficiency after traumatic brain injury. *J. Clin. Endocrinol. Metab.* 93, 2581–2587.

National Center for Injury Prevention and Control. (2003). *Report to Congress on Mild Traumatic Brain Injury in the United States: Steps to Prevent a Serious Public Health Problem*. Atlanta, GA: Centers for Disease Control and Prevention.

Park, K. D., Kim, D. Y., Lee, J. K., Nam, H.-S., and Park, Y.-G. (2010). Anterior pituitary dysfunction in moderate-to-severe chronic traumatic brain injury patients and the influence on functional outcome. *Brain Inj.* 24, 1330–1335.

Pavlovic, D., Pekic, S., Stojanovic, M., Zivkovic, V., Djurovic, B., Jovanovic, V., Miljic, N., Medic-Stojanoska, M., Doknic, M., Miljic, D., Djurovic, M., Casanueva, F., and Popovic, V. (2010). Chronic cognitive sequelae after traumatic brain injury are not related to growth hormone deficiency in adults. *Eur. J. Neurol.* 17, 696–702.

Popovic, V., Pekic, S., Pavlovic, D., Maric, N., Jasovic-Gasic, M., Djurovic, B., Medic Stojanoska, M., Zivkovic, V., Stojanovic, M., Doknic, M., Milic, N., Djurovic, M., Dieguez, C., and Casanueva, F. F. (2004). Hypopituitarism as a consequence of traumatic brain injury (TBI) and its possible relation with cognitive disabilities and mental distress. *J. Endocrinol. Invest.* 27, 1048–1054.

Powner, D. J., Boccalandro, C., Alp, M. S., and Vollmer, D. G. (2006). Endocrine failure after traumatic brain injury in adults. *Neurocrit. Care* 5, 61–70.

Prodam, F., Pagano, L., Corneli, G., Golisano, G., Belcastro, S., Busti, A., Gasco, V., Beccuti, G., Grottoli, S., Di Somma, C., Colao, A., Ghigo, E., and Aimaretti, G. (2008). Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency. *J. Endocrinol. Invest.* 31, 6–11.

Purba, J. S., Hoogendijk, W. J., Hofman, M. A., and Swaab, D. F. (1996). Increased number of vasopressin- and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. *Arch. Gen. Psychiatry* 53, 137–143.

R Development Core Team (2011). *R: A Language and Environment for Statistical Computing*. R Foundation for Statistical Computing, Vienna, Austria. Available at: http://www.R-project.org/

Regal, M., Páramo, C., Sierra, S. M., and García-Mayor, R. V. (2001). Prevalence and incidence of hypopituitarism in an adult Caucasian population in northwestern Spain. *Clin. Endocrinol. (Oxf.)* 55, 735–740.

Reimunde, P., Quintana, A., Castanon, B., Casteleiro, N., Vilarnovo, Z., Otero, A., Devesa, A., Otero-Cepeda, X. L., and Devesa, J. (2011). Effects of growth hormone (GH) replacement and cognitive rehabilitation in patients with cognitive disorders after traumatic brain injury. *Brain Inj.* 25, 65–73.

Rosén, T., Wirén, L., Wilhelmsen, L., Wiklund, I., and Bengtsson, B.-Å. (1994). Decreased psychological well-being in adult patients with growth hormone deficiency. *Clin. Endocrinol. (Oxf.)* 40, 111–116.

Schneider, H. J., Schneider, M., Kreitschmann-Andermahr, I., Tuschy, U., Wallaschofski, H., Fleck, S., Faust, M., Renner, C. I. E., Kopczak, A., Saller, B., Buchfelder, M., Jordan, M., and Stalla, G. K. (2011). Structured assessment of hypopituitarism after traumatic brain injury and aneurysmal subarachnoid hemorrhage in 1242 patients: the German interdisciplinary database. *J. Neurotrauma* 28, 1693–1698.

Schneider, H. J., Schneider, M., Saller, B., Petersenn, S., Uhr, M., Husemann, B., Von Rosen, F., and Stalla, G. K. (2006). Prevalence of anterior pituitary insufficiency 3 and 12 months after traumatic brain injury. *Eur. J. Endocrinol.* 154, 259–265.

Schneider, M., Schneider, H. J., and Stalla, G. K. (2005). Anterior pituitary hormone abnormalities following traumatic brain injury. *J. Neurotrauma* 22, 937–946.

Schneider, M., Schneider, H. J., Yassouridis, A., Saller, B., Von Rosen, F., and Stalla, G. K. (2008). Predictors of anterior pituitary insufficiency after traumatic brain injury. *Clin. Endocrinol. (Oxf.)* 68, 206–212.

Seeman, P. (2010). Dopamine D2 receptors as treatment targets in schizophrenia. *Clin. Schizophr. Relat. Psychoses* 4, 56–73.

Srinivasan, L., Roberts, B., Bushnik, T., Englander, J., Spain, D. A., Steinberg, G. K., Ren, L., Sandel, M. E., Al-Lawati, Z., Teraoka, J., Hoffman, A. R., and Katznelson, L. (2009). The impact of hypopituitarism on function and performance in subjects with recent history of traumatic brain injury and aneurysmal subarachnoid haemorrhage. *Brain Inj.* 23, 639–648.

Stokes, A., and Gallagher, J. (2011). "Pituitary deficiencies in active duty military patients with a history of mild traumatic brain injury," in *3rd Federal Interagency Conference on Traumatic Brain Injury*, Washington, DC.

Svensson, J., Bengtsson, B.-Å., Rosén, T., Odén, A., and Johannsson, G. (2004a). Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. *J. Clin. Endocrinol. Metab.* 89, 3306–3312.

Svensson, J., Mattsson, A., Rosén, T., Wirén, L., Johannsson, G., Bengtsson, B.-Å., and Koltowska Häggström, M. (2004b). Three-years of growth hormone (GH) replacement therapy in GH-deficient adults: effects on quality of life, patient-reported outcomes and healthcare consumption. *Growth Horm. IGF Res.* 14, 207–215.

Svensson, J., Finer, N., Bouloux, P., Bevan, J., Jonsson, B., Mattsson, A. F., Lundberg, M., Harris, P. E., Koltowska-Häggström, M., and Monson, J. P. (2007). Growth hormone (GH) replacement therapy in GH deficient adults: predictors of one-year metabolic and clinical

response. *Growth Horm. IGF Res.* 17, 67–76.

Tanielian, T. L., Jaycox, L., and RAND Corporation. (2008). *Invisible Wounds of War: Psychological and Cognitive Injuries, their Consequences, and Services to Assist Recovery*. Santa Monica, CA: RAND.

Tanriverdi, F., Agha, A., Aimaretti, G., Casanueva, F. F., Kelestimur, F., Klose, M., Masel, B. E., Pereira, A. M., Popovic, V., and Schneider, H. J. (2011). Manifesto for the current understanding and management of traumatic brain injury-induced hypopituitarism. *J. Endocrinol. Invest.* 34, 541–543.

Tanriverdi, F., Senyurek, H., Unluhizarci, K., Selcuklu, A., Casanueva, F. F., and Kelestimur, F. (2006). High risk of hypopituitarism after traumatic brain injury: a prospective investigation of anterior pituitary function in the acute phase and 12 months after trauma. *J. Clin. Endocrinol. Metab.* 91, 2105–2111.

Tanriverdi, F., Taheri, S., Ulutabanca, H., Caglayan, A. O., Ozkul, Y., Dundar, M., Selcuklu, A., Unluhizarci, K., Casanueva, F. F., and Kelestimur, F. (2008a). Apolipoprotein E3/E3 genotype decreases the risk of pituitary dysfunction after traumatic brain injury due to various causes: preliminary data. *J. Neurotrauma* 25, 1071–1077.

Tanriverdi, F., Ulutabanca, H., Unluhizarci, K., Selcuklu, A., Casanueva, F. F., and Kelestimur, F. (2008b). Three years prospective investigation of anterior pituitary function after traumatic brain injury: a pilot study. *Clin. Endocrinol. (Oxf.)* 68, 573–579.

Tanriverdi, F., Unluhizarci, K., Kocyigit, I., Tuna, I. S., Karaca, Z., Durak, A. C., Selcuklu, A., Casanueva, F. F., and Kelestimur, F. (2008c). Brief communication: pituitary volume and function in competing and retired male boxers. *Ann. Intern. Med.* 148, 827–831.

Tanriverdi, F., Unluhizarci, K., Coksevim, B., Selcuklu, A., Casanueva, F. F., and Kelestimur, F. (2007). Kickboxing sport as a new cause of traumatic brain injury-mediated hypopituitarism. *Clin. Endocrinol. (Oxf.)* 66, 360–366.

Tanriverdi, F., Unluhizarci, K., Karaca, Z., Casanueva, F. F., and Kelestimur, F. (2010a). Hypopituitarism due to sports related head trauma and the effects of growth hormone replacement in retired amateur boxers. *Pituitary* 13, 111–114.

Tanriverdi, F., Unluhizarci, K., and Kelestimur, F. (2010b). Pituitary function in subjects with mild traumatic brain injury: a review of literature and proposal of a screening strategy. *Pituitary* 13, 146–153.

Terrio, H., Brenner, L. A., Ivins, B. J., Cho, J. M., Helmick, K., Schwab, K., Scally, K., Bretthauer, R., and Warden, D. (2009). Traumatic brain injury screening: preliminary findings in a US Army Brigade Combat Team. *J. Head Trauma Rehabil.* 24, 14–23.

Tomlinson, J. W., Holden, N., Hills, R. K., Wheatley, K., Clayton, R. N., Bates, A. S., Sheppard, M. C., and Stewart, P. M. (2001). Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. *Lancet* 357, 425–431.

Urban, R. J., Harris, P., and Masel, B. (2005). Anterior hypopituitarism following traumatic brain injury. *Brain Inj.* 19, 349–358.

Van Cauter, E., Kerkhofs, M., Caufriez, A., Van Onderbergen, A., Thorner, M. O., and Copinschi, G. (1992). A quantitative estimation of growth hormone secretion in normal man: reproducibility and relation to sleep and time of day. *J. Clin. Endocrinol. Metab.* 74, 1441–1450.

van der Eerden, A. W., Twickler, M. T., Sweep, F. C., Beems, T., Hendricks, H. T., Hermus, A. R., and Vos, P. E. (2010). Should anterior pituitary function be tested during follow-up of all patients presenting at the emergency department because of traumatic brain injury? *Eur. J. Endocrinol.* 162, 19–28.

van Londen, L., Goekoop, J. G., Van Kempen, G. M. V., Frankhuijzen-Sierevogel, A. C., Wiegant, V. M., Van Der Velde, E. A., and De Wied, D. (1997). Plasma levels of arginine vasopressin elevated in patients with major depression. *Neuropsychopharmacology* 17, 284–292.

Verhelst, J., and Abs, R. (2009). Cardiovascular risk factors in hypopituitary GH-deficient adults. *Eur. J. Endocrinol.* 161(Suppl. 1), S41–S49.

Zgaljardic, D. J., Guttikonda, S., Grady, J. J., Gilkison, C. R., Mossberg, K. A., High, W. M. Jr., Masel, B. E., and Urban, R. J. (2011). Serum IGF-1 concentrations in a sample of patients with traumatic brain injury as a diagnostic marker of growth hormone secretory response to glucagon stimulation testing. *Clin. Endocrinol. (Oxf.)* 74, 365–369.

Ziebell, J. M., and Morganti-Kossmann, M. C. (2010). Involvement of pro- and anti-inflammatory cytokines and chemokines in the pathophysiology of traumatic brain injury. *Neurotherapeutics* 7, 22–30.

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 02 December 2011; paper pending published: 27 December 2011; accepted: 17 January 2012; published online: 07 February 2012.

Citation: Wilkinson CW, Pagulayan KF, Petrie EC, Mayer CL, Colasurdo EA, Shofer JB, Hart KL, Hoff D, Tarabochia MA and Peskind ER (2012) High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury. Front. Neur. ***3****:11. doi: 10.3389/fneur.2012.00011*

This article was submitted to Frontiers in Neurotrauma, a specialty of Frontiers in Neurology.

Copyright © 2012 Wilkinson, Pagulayan, Petrie, Mayer, Colasurdo, Shofer, Hart, Hoff, Tarabochia and Peskind. This is an open-access article distributed under the terms of the Creative Commons Attribution Non Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.

http://edrv.endojournals.org/cgi/content/meeting_abstract/32/03_MeetingAbstracts/OR16-4?sid=0d1fb031-b4ca-409e-abc5-d4979dfea30b

Endocr Rev, Vol. 32 (03_MeetingAbstracts): OR16-4
Copyright © 2011 by The Endocrine Society

Chronic Hypopituitarism after Blast Concussion Mild Traumatic Brain Injury in Iraq/Afghanistan Combat Veterans

Charles W Wilkinson, PhD[2], Elaine R Peskind, MD[2], Elizabeth A Colasurdo[2] and Jane B Shofer, MS[1]

Department of Psychiatry and Behavioral Sciences (JBS), University of Washington, Seattle, WA
Geriatric Research, Education and Clinical Center (CWW,ERP,EAC), Veterans Affairs Puget Sound Health Care System, Seattle, WA

Studies of civilian traumatic brain injury (TBI) from all causes have found evidence of chronic hypopituitarism, as defined by deficient production of one or more pituitary hormones measured at least one year after injury, in 33-50% of cases (1). Its occurrence has not been found to be related to trauma severity (1,2). Hypopituitarism is associated with non-specific behavioral symptoms that can be mistaken for PTSD, including fatigue, anxiety, depression, irritability, insomnia, poor concentration and memory, and decreased quality of life (1). Despite these findings, the prevalence of hypopituitarism after blast concussion mild TBI, the signature injury of combat in Iraq and Afghanistan, has not yet been investigated. Mild TBI (mTBI) is characterized by brief loss of consciousness or loss of memory for events surrounding the trauma or any alteration of mental state (disorientation, confusion). In order to determine the frequency of pituitary dysfunction after blast concussion mTBI, we are measuring pituitary and target organ hormones in blood samples from Iraq/Afghanistan Veterans with mTBI taken at least one year subsequent to their last blast exposure. Most have experienced multiple blast exposures. Criteria for identifying abnormal circulating levels of LH, FSH, total testosterone, prolactin, ACTH, cortisol, TSH, free thyroxine, GH, IGF-I, and arginine vasopressin (AVP) were derived from RIA or EIA measurement of basal morning concentrations in a large group of male non-Veteran control subjects. In general, values below the 5th percentile or above the 95th percentile were defined as abnormal. When both pituitary and target organ hormones were measured for a given axis, a specific combination of criteria signaled dysfunction of that axis. Using the criteria defined in controls, 10 of 26 Veterans with blast mTBI were found to have abnormal hormone levels in one or more pituitary axes. Seven mTBI subjects exhibited deviant plasma AVP concentrations, either above or below the 5th-95th percentile normal range. The frequency of abnormally low or abnormally elevated AVP levels has been found to be relatively high in the acute stage of non-blast TBI, but it tends to decline with time. These preliminary findings suggest that the prevalence of hypopituitarism after blast concussion mTBI is similar to that in other forms of TBI, and that recovery and rehabilitation of blast-exposed Veterans may be facilitated by comprehensive screening for pituitary dysfunction.

(1) Ghigo E et al., Brain Inj, 2005; 19:711(2) Lieberman SA et al., J Clin Endocrinol Metab 2001; 86:2752

Nothing to Disclose: CWW, ERP, EAC, JBS

http://tbi-interagency-conference.org/materials/presentations/TBI-59.html

Federal Interagency Conference on Traumatic Brain Injury

Structural and Functional Neuroimaging, Pituitary Dysfunction, and Animal Modeling in Blast Concussion Mild Traumatic Brain Injury

Presentation Type:

Symposium

General Subject Classification:

Mild TBI and Concussion

Time / Location:

Tue, 6/14, 2:15 PM
Columbia Hall 7

Presenter(s):

- David G. Cook, PhD
  University of Washington
  dgcook@uw.edu
- Rajendra Morey, MD, MS
  Department of Psychiatry and Behavioral Sciences,Duke-UNC Brain Imaging and Analysis Center Duke University Medical Center
  rajendra.morey@duke.edu
- Elaine R. Peskind, MD
  VA Northwest Network Mental Illness Research, Education, and Clinical Center
  peskind@uw.edu

- Charles W. Wilkinson, PhD
  University of Washington
  wilkinso@uw.edu

Objectives:

- To understand the state-of-the-art in neuroimaging techniques for mTBI and the results of multi-modal imaging in Veterans and Service Members with repetitive blast mTBI.
- To recognize the importance of pituitary dysfunction in head trauma and potential need for screening for and treatment of pituitary and target organ hormone abnormalities in Veterans and Service Members with mTBI to improve symptoms and quality of life.
- To recognize the need for valid animal models of blast trauma mTBI and how they may be used to elucidate pathophysiological mechanisms of as well as genetic risk factors for blast concussion mTBI.

Abstract:

Repetitive blast concussion mild traumatic brain injury (mTBI) is recognized as the "signature injury" of OIF/OEF deployment. However, controversy regarding the etiology, course, and treatment of persistent somatic, cognitive and behavioral symptoms remains. This symposium addresses whether these chronic symptoms in OIF/OEF Veterans and warriors reflect persistent structural and/or functional brain changes.

Dr. Peskind (VISN-20 MIRECC) used multi-modal structural and functional neuroimaging in OIF/OEF Veterans: 35 with mTBI and 13 controls. Findings in mTBI include: 1) decreased white matter integrity in optic radiations, inferior longitudinal fasciculus, brainstem, and cerebellar peduncles by diffusion tensor imaging (DTI); 2) decreased macromolecular proton-bound fraction in white and gray matter by cross-relaxation imaging; and 3) glucose hypometabolism in posterior cingulate and biparietal lobes by FDG-PET supported by default state fMRI (all $p<0.05$, corrected). Findings in mTBI were unassociated with PTSD.

Dr. Morey (VISN-6 MIRECC) examined whole brain white matter integrity in 30 Service Members and Veterans with mTBI and 42 controls. High direction DTI revealed widely distributed disruption of white matter integrity in mTBI (corpus callosum, forceps minor and major, superior and posterior corona radiata, internal capsule, superior longitudinal fasciculus ($p<0.05$; corrected) predicted by severity of acute mTBI symptoms but not current PTSD and depression.

Dr. Wilkinson (VISN-20 GRECC). While civilian impact mTBI is associated with 30-70% incidence of hypopituitarism, blast-related pituitary dysfunction has not been investigated. Findings of screening for pituitary and target-organ hormone abnormalities in mTBI Veterans who have complementary neuroimaging data will be presented.

Dr. Cook (VISN-20 GRECC) is addressing a mouse model of repetitive mTBI to understand pathophysiologic and genetic underpinnings of blast mTBI brain changes. A novel shock-tube based on blast exposures in OIF/OEF Veterans has been constructed. The design and operational properties of the shock tube and preliminary findings from mice with repetitive mild blast exposures will be presented.

http://www.nature.com/npp/journal/v36/n1s/full/npp2011293a.html

Neuropsychopharmacology (2011) **36,** S324–S449. doi:10.1038/npp.2011.293

152. Chronic Pituitary Dysfunction after Blast-related Mild Traumatic Brain Injury

Charles W. Wilkinson*, Elaine R. Peskind, Elizabeth A. Colasurdo, Kathleen F. Pagulayan, Jane B. Shofer

VA Puget Sound HCS, Seattle, USA

Background: Studies of civilian traumatic brain injury (TBI) from all causes have found evidence of chronic hypopituitarism, as defined by deficient production of one or more pituitary hormones measured at least one year after injury, in 25-50% of cases. Its frequency of occurrence has not been found to be related to trauma severity. The most common anterior pituitary dysfunctions reported were growth hormone deficiency (GHD) and hypogonadism. Hypopituitarism, and in particular adult GHD, is associated with non-specific behavioral symptoms that can be mistaken for PTSD, including fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, poor concentration and memory, and decreased quality of life. Despite the high frequency of hypopituitarism after civilian TBI, the prevalence of hypopituitarism after blast-related mild TBI, the signature injury of combat in Iraq and Afghanistan, has not yet been investigated. Mild TBI (mTBI) is characterized by brief loss or alteration of consciousness. The mechanisms of injury of blast mTBI are very complex and poorly understood. Blast is propagated directly through the skull and indirectly via blood vessels, and reflections of blast waves in a closed space can redirect and magnify their effects. The pituitary is vulnerable to compression due to its confinement in the sella turcica, and the narrow pituitary stalk (2-3 mm diameter) is subject to torsional and rotational forces resulting from brain movement.

Methods: In order to determine the frequency of pituitary dysfunction after blast-related mTBI, we are measuring pituitary and target organ hormones in blood samples taken from Iraq/Afghanistan Veterans with mTBI at least one year subsequent to their last blast exposure, and from Veterans after deployment in Iraq/Afghanistan without blast exposure. Criteria for identifying abnormal circulating levels of luteinizing hormone (LH), follicle-stimulating hormone, total testosterone, prolactin, adrenocorticotropin, cortisol, thyroid-stimulating hormone, free thyroxine, growth hormone, insulin-like growth factor-I (IGF-I), oxytocin, and arginine vasopressin (AVP) were derived from determinations of normative ranges of basal morning hormone concentrations in a group of male non-Veteran control subjects. In general, hormone concentrations below the 5th percentile or above the 95th percentile were defined as abnormal. When both pituitary and target organ hormones were measured for a given axis, a specific combination of criteria defined dysfunction of that axis.

Results: Based on the normative ranges defined by hormone measurements in control subjects, 11 of 26, or 42%, of Veterans with blast mTBI were found to have abnormal hormone levels in

one or more pituitary axes. Five Veterans with mTBI were found to have probable GHD, based on age-adjusted IGF-I concentrations below the 10th percentile concentration of the reference control group. Three Veterans in the mTBI group were found to have probable hypogonadism on the basis of abnormally low testosterone and LH concentrations. Six of the mTBI group were found to have abnormal levels of the posterior pituitary hormones oxytocin and/ or AVP. None of the non-blast-exposed Veterans were found to have hormone abnormalities.

Discussion: These preliminary findings suggest that the prevalence of hypopituitarism after blast-related mTBI is similar to that in other forms of TBI. Consistent with earlier studies of TBI from all causes, GH and gonadotropin deficiencies were most frequent. Posttraumatic hypopituitarism is associated with a constellation of neuropsychiatric symptoms and diminished quality of life similar to PTSD that are largely amenable to successful treatment with hormone replacement. Routine screening for pituitary dysfunction after blast mTBI shows promise for appropriately directing diagnostic and therapeutic decisions that may otherwise remain unconsidered and for markedly facilitating recovery and rehabilitation.

Disclosure: C. Wilkinson: None. **E. Peskind:** None. **E. Colasurdo:** None. **K. Pagulayan:** None. **J. Shofer:** None.

Chronic Pituitary Dysfunction after Blast-related Mild Traumatic Brain Injury

Charles W. Wilkinson[1], Elaine R. Peskind[1], Elizabeth A. Colasurdo[1], Kathleen F. Pagulayan[1], Jane B. Shofer[2] [1]VA Puget Sound HCS, Seattle, WA, United States; [2]University of Washington, Seattle, WA, United States

ABSTRACT #1745

Background: Studies of civilian traumatic brain injury (TBI) from all causes have found evidence of chronic hypopituitarism, as defined by deficient production of one or more pituitary hormones measured at least one year after injury, in 25-50% of cases. Its frequency of occurrence has not been found to be related to trauma severity. The most common anterior pituitary dysfunctions reported were growth hormone deficiency (GHD) and hypogonadism. Hypopituitarism, and in particular adult GHD, is associated with non-specific behavioral symptoms that can be mistaken for PTSD, including fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, poor concentration and memory, and decreased quality of life. Despite the high frequency of hypopituitarism after civilian TBI, the prevalence of hypopituitarism after blast-related mild TBI, the signature injury of combat in Iraq and Afghanistan, has not yet been investigated. Mild TBI (mTBI) is characterized by brief loss or alteration of consciousness. The mechanisms of injury of blast mTBI are very complex and poorly understood. Blast is propagated directly through the skull and indirectly via blood vessels, and reflections of blast waves in a closed space can redirect and magnify their effects. The pituitary is vulnerable to compression due to its confinement in the sella turcica, and the narrow pituitary stalk (2-3 mm diameter) is subject to torsional and rotational forces resulting from brain movement.

Methods: In order to determine the frequency of pituitary dysfunction after blast-related mTBI, we are measuring pituitary and target organ hormones in blood samples taken from Iraq/Afghanistan Veterans with mTBI at least one year subsequent to their last blast exposure, and from Veterans after deployment in Iraq/Afghanistan without blast exposure. Criteria for identifying abnormal circulating levels of luteinizing hormone (LH), follicle-stimulating hormone, total testosterone, prolactin, adrenocorticotropin, cortisol, thyroid-stimulating hormone, free thyroxine, growth hormone, insulin-like growth factor-I (IGF-I), oxytocin, and arginine vasopressin (AVP) were derived from determinations of normative ranges of basal morning hormone concentrations in a group of male non-Veteran control subjects. In general, hormone concentrations below the 5th percentile or above the 95th percentile were defined as abnormal. When both pituitary and target organ hormones were measured for a given axis, a specific combination of criteria defined dysfunction of that axis.

Results: Based on the normative ranges defined by hormone measurements in control subjects, 11 of 26, or 42%, of Veterans with blast mTBI were found to have abnormal hormone levels in one or more pituitary axes. Five Veterans with mTBI were found to have probable GHD, based on age-adjusted IGF-I concentrations below the 10th percentile concentration of the reference control group. Three Veterans in the mTBI group were found to have probable hypogonadism on the basis of abnormally low testosterone and LH concentrations. Six of the mTBI group were found to have abnormal levels of the posterior pituitary hormones oxytocin and/ or AVP. None of the non-blast-exposed Veterans were found to have hormone abnormalities.

Discussion: These preliminary findings suggest that the prevalence of hypopituitarism after blast-related mTBI is similar to that in other forms of TBI. Consistent with earlier studies of TBI from all causes, GH and gonadotropin deficiencies were most frequent. Posttraumatic hypopituitarism is associated with a constellation of neuropsychiatric symptoms and diminished quality of life similar to PTSD that are largely amenable to successful treatment with hormone replacement. Routine screening for pituitary dysfunction after blast mTBI shows promise for appropriately directing diagnostic and therapeutic decisions that may otherwise remain unconsidered and for markedly facilitating recovery and rehabilitation.

BACKGROUND

- Recent studies have found a prevalence of chronic hypopituitarism, defined as deficient hormone production in one or more pituitary hormonal axes, of 25-50% after traumatic brain injury (TBI).
- The pituitary is extremely vulnerable to damage as a result of TBI. It is tethered to the brain by a narrow stalk (2-3 mm in diameter) subject to torsional and rotational forces caused by brain movement and is almost completely encased in a bony pocket, the sella turcica, and vulnerable to compression by brain movement or edema.
- The most common pituitary disorders resulting from TBI are adult growth hormone deficiency (GHD) and hypogonadism.
- Chronic posttraumatic hypopituitarism (PTHP) may be reflected by a markedly different hormone profile than that seen acutely, but after 6-12 months, PTHP is generally considered permanent.
- Hypopituitarism, particularly adult GHD, is characterized by symptoms that include fatigue, sleep disorders, cognitive deficiencies, social isolation, depression, anxiety, irritability, sexual dysfunction, reduced quality of life (QoL), deleterious changes in body composition, and increased cardiovascular mortality.
- Seventy-five percent of TBI are concussions, classified as mild TBI (mTBI) and defined as head trauma resulting in any one of the following:
  - o Loss of consciousness for 30 minutes or less
  - o Alteration of mental state (feeling dazed, disoriented, confused) for up to 24 hours
  - o Loss of memory for events immediately before or after the trauma.
- US military personnel deployed to Iraq or Afghanistan experience a high frequency of blast concussions, but no studies investigating the prevalence of hypopituitarism after blast mTBI have yet been published.

METHODS

- Twelve pituitary and target-organ hormones were measured in blood samples from two groups:
  - o T group (n=26): Male Veterans of deployment to Iraq or Afghanistan with blast mTBI occurring one year or more prior to blood sampling
  - o DC group (n=7): Male Veterans with similar deployment histories but without blast exposure or history of head injury.
- Hormones measured:
  - o Growth hormone (GH)
  - o Insulin-like growth factor-I (IGF-I)
  - o Luteinizing hormone (LH)
  - o Follicle-stimulating hormone (FSH)
  - o Prolactin (PRL)
  - o Total testosterone (tTest)
  - o Adrenocorticotropin (ACTH)
  - o Cortisol (Cort)
  - o Thyroid-stimulating hormone (TSH)
  - o Free thyroxine (fT4)
  - o Arginine vasopressin (AVP)
  - o Oxytocin (OT)
- Hormone deficiencies were defined by comparison with reference ranges derived from a sample of non-Veteran community control subjects.

Table 1. Demographic and blast exposure data for the DC and T groups. Individuals in the T group are divided on the basis of post hoc identification of PTHP.

	DC (n=7)	mTBI without PTHP (n=15)	mTBI with PTHP (n=11)
A. Demographics			
Age (years)	31.1 ± 3.3 [23-47]	29.7 ± 1.8 [24-46]	28.8 ± 1.5 [25-41]
Education (years)	14.0 ± 0.7 [12-17]	13.3 ± 0.4 [11-16]	13.6 ± 0.5 [12-16]
Body mass index (BMI)	28.5 ± 2.1 [n=5]#	27.9 ± 1.3 [n=14]#	29.0 ± 1.3 [n=10]#
B. Blast exposure			
Blast exposures meeting ACRM criteria for mTBI	0	11.1 ± 3.3 [1-52]	14.6 ± 5.4 [4-66]
Blast exposures with loss of consciousness (LOC)	0	1.3 ± 0.3 [0-4]	0.6 ± 0.2 [0-2]
Lifetime events with LOC	0.1 ± 0.1 [0-1]	3.1 ± 0.7 [0-11]	1.3 ± 0.4 [0-3]
Time since last blast exposure (months)		45.2 ± 4.2 [14-66]	47.4 ± 4.3 [20-67]

BMIs not recorded for all participants

Figure 1. Concentrations of IGF-I in 26 T group participants (○) and 7 DC group participants (▲). The red line represents the age-adjusted 10th percentile of the reference group IGF-I concentration. IGF-I values below this line indicate probable GHD.



Figure 2. Concentrations of LH (left panel) and total testosterone (right panel) in T (○) and DC (▲) groups. The colored circles represent individuals who met both criteria for hypogonadism: an LH level below the 10th percentile of the reference sample and a testosterone concentration below the 5th percentile.



RESULTS

- Participants in the DC and T groups did not differ significantly in age, education, or body mass index (BMI) (Table 1). Post hoc separation of the T group into individuals with or without PTHP revealed equivalent blast exposure histories for the two sub-groups.

Growth Hormone Deficiency

- Measurement of serum concentrations of IGF-I provided provisional identification of participants with GHD.
  - o GH stimulates renal production of IGF-I, and markedly low concentrations of IGF-I are strong indicators of GHD.
  - o IGF-I concentrations decline considerably with increasing age, and screening criteria must be adjusted for age.
- Five individuals in the T group were found with IGF-I levels below the age-adjusted 10th percentile of IGF-I concentrations in the reference group that was considered indicative of probable GHD (Figure 1, Table 2).
- GHD is associated with multiple behavioral and cognitive symptoms and diminished QoL similar to characteristics of PTSD.

Hypogonadism

- Our criteria for hypogonadism were a testosterone concentration below the 5th percentile of the reference range together with an LH or FSH below the 10th percentile cutoff. Three participants in the T group met these criteria for hypogonadism (Figure 2, Table 2).

Prolactin abnormalities

- Extreme PRL levels (below the 5th or above the 95th percentile) were measured in two of the three participants with probable hypogonadism (Table 2). Both hypo- and hyperprolactinemia are associated with sexual dysfunction.

Posterior pituitary hormone abnormalities

- Criteria for AVP abnormalities were a concentration above the 95th percentile of the reference sample or levels below the 5th percentile together with a urine specific gravity less than 1.003.
- The criterion for OT deficiency was a concentration below the 5th percentile cutoff level.
- Four participants were found with abnormal AVP levels and four were observed with OT deficiency. Two of these individuals were deficient in both hormones suggesting the possibility of hypothalamic damage or disruption of the pituitary stalk.
- Elevated AVP levels have been associated with PTSD, depression, schizophrenia, and other psychiatric disorders, but a causal relationship has not been established.
- In contrast, there is evidence of a positive association of OT with social bonding, mediation of social support, and positive social interactions.

Summary of Results

- **Eleven of 26 (42%) participants with blast mTBI were found to have hormonal abnormalities in one or more pituitary axes. None of the deployment control subjects were found to have hormonal abnormalities of any kind.**

Table 2. Concentrations of 12 pituitary and target-organ hormones in samples from the 26 participants in the T group. Abnormal hormone values are indicated by the orange highlighting. Hormone abbreviations are identified in the Methods section above.

Subj.	Age	ACTH pg/ml	Cort µg/dl	LH mIU/ml	FSH U/L	tTest ng/dl	PRL ng/ml	TSH µIU/ml	fT4 ng/dl	IGF-I ng/ml	GH pg/ml	AVP pg/ml	OT pg/ml
T-1	24	24	6.6	2.58	0.46	473	12.5	1.70	1.29	190	58	3.4	64
T-2	26	20	11.9	2.03	---	669	9.6	1.92	1.67	185	71	12.3	181
T-3	27	22	10.2	5.15	2.05	557	13.0	1.59	1.59	164	50	4.0	166
T-4	33	19	7.5	2.03	2.06	252	54.9	1.17	1.22	110	11	8.0	88
T-5	38	24	12.8	2.11	2.33	362	14.9	1.16	1.18	133	0	0.4	71
T-6	46	29	12.1	1.95	1.41	402	11.1	1.08	1.09	143	152	0.7	61
T-7	26	28	14.1	3.34	1.63	559	12.0	2.26	1.29	172	223	0.0	39
T-8	25	35	11.3	2.72	4.02	401	11.9	1.13	1.55	141	294	0.2	44
T-9	24	39	12.0	4.81	3.28	730	14.4	1.16	1.05	251	1288	8.0	52
T-10	26	30	9.6	1.97	2.43	520	12.3	2.41	1.39	230	68	0.2	22
T-11	28	31	10.2	1.64	2.38	382	9.2	1.30	1.22	182	0	1.1	36
T-12	27	27	9.9	7.27	5.70	715	13.0	1.57	1.38	198	60	12.0	55
T-13	31	40	7.8	1.92	1.18	253	6.3	2.24	1.14	187	0	6.4	50
T-14	30	36	8.8	2.66	2.51	390	12.0	3.75	1.13	151	310	0.5	19
T-15	27	16	7.4	2.27	3.56	377	10.1	1.40	1.14	168	42	4.4	85
T-16	28	25	11.7	2.64	4.01	380	21.5	0.65	1.52	126	0	0.9	190
T-17	25	26	11.2	9.32	3.00	465	17.1	1.26	1.25	197	0	4.8	151
T-18	24	30	14.2	3.65	2.21	556	12.2	1.27	1.30	179	60	4.3	32
T-19	30	32	18.6	5.44	3.01	457	11.7	1.55	1.13	190	66	0.0	46
T-20	28	17	25.0	6.65	3.91	309	10.4	0.79	1.31	210	1696	7.9	519
T-22	25	21	17.6	4.00	4.48	588	12.8	1.09	1.24	227	110	0.0	21
T-23	29	11	8.7	2.52	2.55	554	8.9	1.34	1.35	166	95	4.0	199
T-25	25	8	7.7	2.24	4.34	463	7.2	1.42	1.23	146	813	2.1	25
T-26	26	9	6.8	5.94	1.14	488	8.4	0.81	1.18	185	42	0.9	457
T-27	43	29	7.5	2.52	3.89	263	7.1	0.60	1.04	126	13	2.6	50
T-28	41	15	11.1	2.11	2.64	264	15.3	1.22	1.11	86	375	8.4	0

CONCLUSIONS

- In this preliminary study, the proportion of Veterans with blast mTBI with evidence of PTHP was similar to that in previous studies of TBI from all causes in the general population.
- Consistent with earlier studies, the most frequent anterior pituitary disorders found were GHD and hypogonadism.
- PTHP has been associated with a constellation of neuropsychiatric and cognitive symptoms and diminished QoL similar to PTSD.
- Unlike PTSD, PTHP is readily amenable to treatment, and most deficiencies can be ameliorated with hormone replacement therapy.
- Therefore, routine screening for pituitary dysfunction after blast concussion shows promise for appropriately directing diagnostic and therapeutic decisions that otherwise may remain unconsidered and for markedly facilitating recovery and rehabilitation.

Acknowledgments: This work was supported by U.S. Department of Defense Congressionally Directed Medical Research Program Concept Award PT090753; the Geriatric Research, Education and Clinical Center and the Research and Development Service of the VA Puget Sound Health Care System; the VA Northwest Network Mental Illness Research, Education and Clinical Center; the Seattle Institute for Biomedical and Clinical Research; the University of Washington Alzheimer's Disease Research Center NIA AG05136; and an anonymous foundation.

Chronic Pituitary Dysfunction Associated With Cognitive and Neuropsychiatric Deficits After Blast-Related Concussion

Charles W. Wilkinson[1,2*], Kathleen F. Pagulayan[2,3], Jane B. Shofer[3], Elaine R. Peskind[2,3]

[1]Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington, USA; [2]Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; [3]VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington, USA

ABSTRACT

Objective: Studies of traumatic brain injury from all causes have found evidence of chronic pituitary dysfunction in 25-50% of cases. Posttraumatic hypopituitarism (PTHP), particularly adult growth hormone deficiency (GHD), is associated with symptoms that include fatigue, anxiety, depression, irritability, sleep disturbances, sexual dysfunction, cognitive deficits, decreased quality of life, and increased cardiovascular mortality. This study investigates the prevalence of chronic PTHP after blast-related concussion.
Design: Concentrations of 12 pituitary and target-organ hormones were measured in blood samples from US military Veterans who had sustained blast concussions during deployment to Iraq and Afghanistan, and from a similar group without blast exposure, to determine the frequencies of PTHP and of specific hormonal deficits.
Results: Eleven of 26, or 42%, of subjects with blast-related concussions were found with abnormal hormone levels in one or more pituitary axes. Five individuals were found with probable GHD, and three blast-exposed participants showed evidence of hypogonadism. Veterans without blast exposure had no hormonal abnormalities.
Conclusions: There is a high prevalence of concussion-related PTHP, but consequent neuropsychiatric and behavioral symptoms are amenable to successful hormonal replacement therapy. Screening for hormone deficiencies after concussions shows promise for appropriately directing diagnostic and therapeutic decisions that may otherwise remain unconsidered.

OBJECTIVE

The Pituitary Gland & TBI

- The pituitary gland is a small gland (about the size of a garbanzo bean) located just below the base of the brain (Fig. 1A) that is often called the "master gland." The hormones it secretes control the function of the other endocrine glands (thyroid, adrenal, testes, ovaries) and directly affect many critical bodily functions.
- Recent studies have found that long-lasting pituitary hormone abnormalities (hypopituitarism) occur in 25-50% of individuals suffering traumatic brain injury (TBI).
- The frequency of hypopituitarism after TBI has not been found to be related to the severity of the trauma.

A.



B.



Figure 1: A. The arrow indicates the position and size of the pituitary gland in relation to the brain. **B.** Enlarged view of the pituitary gland indicating its anterior and pituitary lobes, the pituitary stalk which connects it with the hypothalamus, and the "pocket" (sella turcica) in the sphenoid bone that surrounds it and restricts its movement.

- The pituitary gland is extremely vulnerable to damage as a result of TBI because:
  - The gland is attached to the brain by a narrow stalk of tissue (2-3 mm in diameter) that carries its blood and nerve supply (Fig. 1B). This stalk is subject to torsional and rotational forces generated by brain movement.
  - In addition, the pituitary is almost completely encased in a bony pocket, the sella turcica, and is vulnerable to tissue damage from compression due to brain movement or edema.
- The most common pituitary disorders resulting from TBI are growth hormone deficiency (GHD) and sex hormone deficiencies (hypogonadism).
- Although a large number of temporary pituitary hormone abnormalities may occur immediately after the trauma, these often resolve during the succeeding weeks or months. However, new hormonal problems may emerge during the same period and they and some original deficiencies may persist.
- After 6-12 months, the remaining chronic pituitary dysfunctions are generally considered to be permanent
- Hypopituitarism, particularly GHD, is characterized by symptoms that include fatigue, sleep disorders, difficulties with learning and memory, social isolation, depression, anxiety, irritability, sexual disorders, and reduced quality of life (QoL).
- Hypopituitarism may also result in undesirable changes in body composition -- increased body fat, and decreased muscle mass and bone density -- as well as elevated blood lipid levels and increased risk of cardiovascular disease.

Mild Traumatic Brain Injury (mTBI)

Seventy-five percent of all cases of TBI are classified as mTBI, often referred to as concussion.

- mTBI is defined by the American Congress of Rehabilitation Medicine as head trauma resulting in any one of the following:
  - Loss of consciousness (LOC) for 30 minutes or less
  - Alteration of mental state (feeling dazed, disoriented, confused) for up to 24 hours
  - Loss of memory for events immediately before or after the trauma

Blast mTBI in US Military Personnel

- mTBI sustained from explosive blasts is one of the most common combat injuries resulting from deployment to Iraq or Afghanistan and is often referred to as the "signature injury" of these conflicts.
- During the first 9 months of 2011, more than 20,000 service members were *medically diagnosed* with mTBI. It is highly probable that many more blast concussions were unreported.
- However, no studies investigating the frequency of hypopituitarism after blast mTBI have been published until now: http://www.frontiersin.org/neurotrauma/abstract/19980

DESIGN

- Blood samples collected under resting conditions were obtained from three groups of individuals:
  - A community control group that was used to establish reference ranges for normal pituitary hormone concentration in healthy non-Veteran men.
  - Male Veterans of deployment to Iraq or Afghanistan with blast mTBI occurring one year or more prior to blood sampling: T group (n=26).
  - Male Veterans with similar deployment experience but without blast exposure or history of head injury: DC group (n=7).
- Twelve hormones were measured in each sample. They are hormones produced by the pituitary gland or "target-organ hormones" produced by other endocrine glands regulated by the pituitary:

Pituitary Hormones
- Growth Hormone (GH)
- Thyroid-stimulating hormone (TSH)
- Adrenocorticotropin (ACTH)
- Luteinizing hormone (LH)
- Follicle-stimulating hormone (FSH)
- Prolactin (PRL)
- Arginine vasopressin (AVP)
- Oxytocin (OT)

Target-Organ Hormones
- Insulin-like growth factor-I (IGF-I)
- Free thyroxine (fT4)
- Cortisol (Cort)
- Total testosterone (tTest)

  - GH stimulates IGF-I synthesis by the liver; TSH stimulates thyroid gland secretion of fT4 (thyroid hormone); ACTH stimulates cortisol secretion by the adrenal gland; LH, FSH, and PRL regulate testicular testosterone secretion and spermatogenesis.
- Hormone deficiencies were defined by comparison with reference ranges calculated from hormone concentrations in blood samples from the healthy community control individuals.
- Hormone concentrations measured in this study are meant only to be tools for preliminary screening for pituitary abnormalities.
- These measurements by themselves are not adequate to diagnose hormonal disorders, but they can be useful in determining which patients should be followed up for clinical diagnosis by a physician.

RESULTS

- There were no significant differences in age, education or body mass index (BMI) between study participants in the DC and T groups.
- Participants in the T group without signs of PTHP were found to have similar blast exposures to those with abnormal hormone levels.

Growth Hormone Deficiency

- Blood concentrations of IGF-I, produced by the liver in response to GH, are indirect but more reliable indicators of GHD than direct measurement of GH. IGF-I levels normally decline with age, so determinations of normal ranges must be adjusted for age.
- Five individuals in the T group were found to have IGF-I levels below the age-adjusted 10th percentile (i.e., in the lowest 10%) of IGF-I concentrations in the reference community control group. These low values were considered to indicate probable GHD (Table 1).
- GHD is associated with multiple problems related to mood and behavior, impaired learning and memory, and diminished QoL. These characteristics are similar to those of PTSD.

Subj.	Age	ACTH pg/ml	Cort µg/dl	LH mIU/ml	FSH U/L	tTest ng/dl	PRL ng/ml	TSH µIU/ml	fT4 ng/dl	IGF-I ng/ml	GH pg/ml	AVP pg/ml	OT pg/ml
T-1	24	24	6.6	2.58	0.46	473	12.5	1.70	1.29	190	58	3.4	64
T-2	26	20	11.9	2.03	---	669	9.6	1.92	1.67	185	71	12.3	181
T-3	27	22	10.2	5.15	2.05	557	13.0	1.59	1.59	164	50	4.0	166
T-4	33	19	7.5	2.03	2.06	252	54.9	1.17	1.22	110	11	8.0	88
T-5	38	24	12.8	2.11	2.33	362	14.9	1.16	1.18	133	0	0.4	71
T-6	46	29	12.1	1.95	1.41	402	11.1	1.08	1.09	143	152	0.7	61
T-7	26	28	14.1	3.34	1.63	559	12.0	2.26	1.29	172	223	0.0	39
T-8	25	35	11.3	2.72	4.02	401	11.9	1.13	1.55	141	294	0.2	44
T-9	24	39	12.0	4.81	3.28	730	14.4	1.16	1.05	251	1288	8.0	52
T-10	26	30	9.6	1.97	2.43	520	12.3	2.41	1.39	230	68	0.2	22
T-11	28	31	10.2	1.64	2.38	382	9.2	1.30	1.22	182	0	1.1	36
T-12	27	27	9.9	7.27	5.70	715	13.0	1.57	1.38	198	60	12.0	55
T-13	31	40	7.8	1.92	1.18	253	6.3	2.24	1.14	187	0	6.4	50
T-14	30	36	8.8	2.66	2.51	390	12.0	3.75	1.13	151	310	0.5	19
T-15	27	16	7.4	2.27	3.56	377	10.1	1.40	1.14	168	42	4.4	85
T-16	28	25	11.7	2.64	4.01	380	21.5	0.65	1.52	126	0	0.9	190
T-17	25	26	11.2	9.32	3.00	465	17.1	1.26	1.25	197	0	4.8	151
T-18	24	30	14.2	3.65	2.21	556	12.2	1.27	1.30	179	60	4.3	32
T-19	30	32	18.6	5.44	3.01	457	11.7	1.55	1.13	190	66	0.0	46
T-20	28	17	25.0	6.65	3.91	309	10.4	0.79	1.31	210	1696	7.9	519
T-22	25	21	17.6	4.00	4.48	588	12.8	1.09	1.24	227	110	0.0	21
T-23	29	11	8.7	2.52	2.55	554	8.9	1.34	1.35	166	95	4.0	199
T-25	25	8	7.7	2.24	4.34	463	7.2	1.42	1.23	146	813	2.1	25
T-26	26	9	6.8	5.94	1.14	488	8.4	0.81	1.18	185	42	0.9	457
T-27	43	29	7.5	2.52	3.89	263	7.1	0.60	1.04	126	13	2.6	50
T-28	41	15	11.1	2.11	2.64	264	15.3	1.22	1.11	86	375	8.4	0

Table 1. Concentrations of 12 pituitary and target-organ hormones in samples from the 26 Veterans in the T group. Abnormal hormone values are indicated by the orange highlighting. Hormone abbreviations are identified in the Methods section above.



Figure 2. Concentrations of LH (left panel) and total testosterone (right panel) in T (●) and DC (▲) groups. Individuals who met both criteria for hypogonadism (●): an LH level below the 10th percentile of the reference sample and a testosterone concentration below the 5th percentile.

Hypogonadism

- Our criteria for hypogonadism were a testosterone concentration below the 5th percentile of the reference range together with an LH or FSH below the 10th percentile cutoff.
- Three Veterans in the T group met these criteria for hypogonadism (Fig. 2, Table 1).

Prolactin Abnormalities

- Extreme PRL levels (below the 5th or above the 95th percentile) were measured in two of the three participants with probable hypogonadism (Table 1). PRL concentrations at either extreme are associated with sexual dysfunction.

Posterior Pituitary Hormone Abnormalities

- Two hormones, AVP and OT, are secreted from the posterior, rather than the anterior pituitary (Fig. 1B).
- Criteria for AVP abnormalities were a concentration above the 95th percentile of the reference sample, or levels below the 5th percentile together with a urine specific gravity less than 1.003.
- The criterion for OT deficiency was a concentration below the 5th percentile cutoff.
- Four Veterans with mTBI were found to have abnormal AVP levels and four were observed with OT deficiency.
- Two of these individuals were deficient in both hormones suggesting the possibility of hypothalamic damage or disruption of the pituitary stalk.
- Elevated AVP levels have been associated with PTSD, depression, schizophrenia, and other psychiatric disorders, but a definite causal relationship has not been established.
- In contrast, there is evidence of a positive association of OT with social bonding, mediation of social support, and positive social interactions suggesting the possibility that low OT levels may reflect difficulties in social situations.

SUMMARY OF RESULTS

• Eleven of 26 (42%) of the Veterans with blast mTBI (T group) were found to have abnormal concentrations of one or more pituitary hormones.

• None of the Veterans in the deployment control (DC) group were found to have hormonal abnormalities of any kind.

CONCLUSIONS

In this preliminary study, the proportion of Veterans with blast mTBI with evidence of PTHP was similar to that in previous studies of TBI from all causes in the general population.

- In agreement with earlier studies of pituitary disorders resulting from TBI from all causes and severity, the most frequent anterior pituitary disorders found were GHD and hypogonadism.
- Posttraumatic hypopituitarism (PTHP) has been associated with diminished QoL and a variety of psychiatric, behavioral, and cognitive symptoms that show marked overlap with symptoms of PTSD.
- Unlike PTSD, PTHP is readily amenable to treatment, and if correctly identified, most deficiencies and their symptoms can be counteracted with hormone replacement therapy.
- Therefore, routine screening for hypopituitarism after blast mTBI shows promise for appropriately directing diagnostic and therapeutic decisions that otherwise may remain unconsidered. Adoption of pituitary screening may significantly facilitate recovery and rehabilitation in a substantial proportion of individuals who have suffered TBI.

Acknowledgments: This work was supported by U.S. Department of Defense Congressionally Directed Medical Research Program Concept Award PT090753; the Geriatric Research, Education and Clinical Center and the Research and Development Service of the VA Puget Sound Health Care System; the VA Northwest Network Mental Illness Research, Education and Clinical Center; the Seattle Institute for Biomedical and Clinical Research; the University of Washington Alzheimer's Disease Research Center NIA AG05136; and an anonymous foundation.

http://informahealthcare.com/doi/pdf/10.3109/02699052.2012.660091

Brain Injury, April–May 2012; 26(4–5): 309–792

ABSTRACTS

Accepted Abstracts from the International Brain Injury Association's Ninth World Congress on Brain Injury

March 21–25, 2012
Edinburgh International Convention Centre
Edinburgh, Scotland

0804

Prevalence and Characteristics of Chronic Pituitary Dysfunction after Blast-related Mild Traumatic Brain Injury

Charles W. Wilkinson[1,2], Elaine R. Peskind[1,2], Elizabeth A. Colasurdo[1], Kathleen F. Pagulayan[1,2], Jane B. Shofer[2]
[1]VA Puget Sound Health Care System, Seattle, Washington, USA,
[2]University of Washington, Seattle, Washington, USA

Objectives: Studies of civilian traumatic brain injury (TBI) from all causes have found evidence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones measured at least one year after injury, in 25–50% of cases. The most common pituitary disorders found were growth hormone deficiency (GHD) and hypogonadism. Hypopituitarism, and in particular adult GHD, is associated with non-specific behavioral symptoms that can be mistaken for PTSD, including fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, poor concentration and memory, and decreased quality of life. Despite the high frequency of pituitary dysfunction after civilian TBI, the occurrence of posttraumatic hypopituitarism after blast-related mild TBI (mTBI), an extremely common injury in modern military operations, has not been characterized. The objective of this study is to evaluate the prevalence and specific nature of pituitary hormone abnormalities consequent to blast mTBI.
Methods: Concentrations of twelve pituitary and target-organ hormones were measured by radioimmunoassay or enzyme-linked immunosorbent assay of blood samples taken from two groups of US military Veterans of combat in Iraq and/or Afghanistan. One group consisted of participants with blast-related mTBI whose last blast exposure was at least one year prior to entry in the study. The other group consisted of participants with similar military deployment experience but without blast exposure. Criteria for identifying abnormal circulating levels of luteinizing hormone (LH), follicle-stimulating hormone, total testosterone, prolactin, adrenocorticotropin (ACTH), cortisol, thyroid-stimulating hormone, free thyroxine, growth hormone, insulin-like growth factor-I (IGF-I), oxytocin, and arginine vasopressin (AVP) were derived from determinations of normative ranges in a group of male non-Veteran control subjects.

Results: Eleven of 26, or 42%, of participants with blast mTBI were found to have abnormal hormone levels relative to the normative ranges in one or more pituitary axes. Five members of the mTBI group were found to have probable GHD, based on their age-adjusted IGF-I concentrations. Three of the mTBI subjects were found to have abnormally low testosterone and LH concentrations consistent with hypogonadism. Six of the mTBI group were found to have abnormal levels of the posterior pituitary hormones oxytocin and/ or AVP. None of the nonblast-exposed Veterans had any abnormal hormone concentrations.
Conclusions: These preliminary findings suggest that the prevalence of hypopituitarism after blast-related mTBI is similar to that in other forms of TBI. Pituitary hormone deficiencies are associated with a constellation of neuropsychiatric symptoms and diminished quality of life similar to those of PTSD but which are amenable to successful treatment with hormone replacement. Routine screening for pituitary dysfunction after blast mTBI shows promise for appropriately directing diagnostic and therapeutic decisions that may otherwise remain unconsidered and for markedly facilitating recovery and rehabilitation.

Supported by DoD PT0753; GRECC, Northwest Network MIRECC, and R&D Service, VA Puget Sound HCS.

ICE/ECE 2012
05 May 2012 - 09 May 2012
Florence, Italy
European Society of Endocrinology

http://www.endocrine-abstracts.org/ea/0029/ea0029p1436.htm

Endocrine Abstracts (2012) **29** P1436

Blast concussion is associated with high frequency of pituitary dysfunction

C. Wilkinson[1,2], K. Pagulayan[1,2], E. Colasurdo[1], J. Shofer[2] & E. Peskind[1,2]

[1]VA Puget Sound Health Care System, Seattle, Washington, USA; [2]University of Washington, Seattle, Washington, USA.

Introduction: Studies of traumatic brain injury from all causes have found evidence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones at least 1 year after injury, in 25–50% of cases. Most studies found the occurrence of posttraumatic hypopituitarism (PTHP) to be unrelated to injury severity. Growth hormone deficiency (GHD) and hypogonadism were reported most frequently. Hypopituitarism, and in particular adult GHD, is associated with symptoms that resemble those of PTSD, including fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, cognitive deficiencies, and decreased quality of life. However, the prevalence of chronic PTHP after blast-related concussion, or mild TBI (mTBI), an extremely common injury in modern military operations, has not been characterized.

Design: We measured concentrations of 12 pituitary and target-organ hormones in two groups of male US Veterans of combat in Iraq or Afghanistan. One group consisted of participants with blast-related mTBI whose last blast exposure was at least 1 year prior to the study. The other consisted of Veterans with similar military deployment histories but without blast exposure.

Results: In total, 11 of 26, or 42% of participants with blast concussions were found to have abnormal hormone levels in one or more pituitary axes, a prevalence similar to that after other types of TBI. Five members of the mTBI group were found with markedly low age-adjusted IGFI levels indicative of probable GHD, and three had testosterone and gonadotropin concentrations consistent with hypogonadism. Five of the blast concussion group exhibited abnormal vasopressin and/or oxytocin levels suggestive of posterior pituitary dysfunction. Indications of dysfunction in multiple hormonal axes were observed in five Veterans with mTBI. None of the deployment control subjects exhibited any hormonal abnormalities.

Conclusion: Blast mTBI is associated with a high frequency of PTHP. If symptoms characteristic of both PTHP and PTSD can be linked to pituitary dysfunction, they may be amenable to treatment with hormone replacement. Routine screening for chronic hypopituitarism after blast concussion shows promise for appropriately directing diagnostic and therapeutic decisions that otherwise may remain unconsidered and for markedly facilitating recovery and rehabilitation.

Declaration of interest: The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research project.

Funding: This work was supported, however funding details unavailable.

Blast Concussion Is Associated with High Frequency of Pituitary Dysfunction

C. W. Wilkinson[1, 2], K. F. Pagulayan[3, 2], E. A. Colasurdo[1], J. B. Shofer[2], E. R. Peskind[3, 2]

1. Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, United States. 2. Department of Psychiatry and Behavioral Sciences,University of Washington, Seattle, WA, United States. 3. VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, United States.

ABSTRACT P1436

INTRODUCTION

Studies of traumatic brain injury from all causes have found evidence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones at least one year after injury, in 25-50% of cases. Most studies found the occurrence of posttraumatic hypopituitarism (PTHP) to be unrelated to injury severity. Growth hormone deficiency (GHD) and hypogonadism were reported most frequently. Hypopituitarism, and in particular adult GHD, is associated with symptoms that resemble those of PTSD, including fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, cognitive deficiencies, and decreased quality of life. However, the prevalence of chronic PTHP after blast-related concussion, or mild traumatic brain injury (mTBI), an extremely common injury in modern military operations, has not been characterized.

DESIGN

We measured concentrations of 12 pituitary and target-organ hormones in two groups of male US Veterans of combat in Iraq or Afghanistan. One group consisted of participants with blast-related mTBI whose last blast exposure was at least one year prior to the study. The other consisted of Veterans with similar military deployment histories but without blast exposure.

RESULTS

Eleven of 26, or 42% of participants with blast concussions were found to have abnormal hormone levels in one or more pituitary axes, a prevalence similar to that after other types of TBI. Five members of the mTBI group were found with markedly low age-adjusted insulin-like growth factor-I (IGF-I) levels indicative of probable GHD, and three had testosterone and gonadotropin concentrations consistent with hypogonadism. Six of the blast concussion group exhibited abnormal vasopressin and/or oxytocin levels suggestive of posterior pituitary dysfunction. Indications of dysfunction in multiple hormonal axes were observed in five Veterans with mTBI. None of the deployment control subjects exhibited any hormonal abnormalities.

CONCLUSION

Blast mTBI is associated with a high frequency of PTHP. If symptoms characteristic of both PTHP and PTSD can be linked to pituitary dysfunction, they may be amenable to treatment with hormone replacement. Routine screening for chronic hypopituitarism after blast concussion shows promise for appropriately directing diagnostic and therapeutic decisions that otherwise may remain unconsidered and for markedly facilitating recovery and rehabilitation.

Pituitary Dysfunction After Traumatic Brain Injury (TBI)

- The estimated prevalence of hypopituitarism from all causes in the general population is 300 cases per million, or 0.03%.
- However, the prevalence of hypopituitarism after TBI from all causes has been reported to be in the range of 25-50%.
- The frequency of occurrence of posttraumatic hypopituitarism (PTHP) has generally not been found to be related to trauma severity.
- The most common anterior pituitary dysfunctions found were growth hormone deficiency (GHD) and hypogonadism.
- Hypopituitarism, and in particular adult GHD, is associated with non-specific psychological and physical symptoms that can be mistaken for PTSD.
- These symptoms include fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, poor concentration and memory, deleterious effects on body composition, increased risk for hypertension and cardiovascular mortality, and decreased quality of life.

Mild TBI

Mild TBI (mTBI), or concussion, is defined as traumatically induced disruption of brain function manifested by:

- Brief (< 30 min) loss of consciousness,
- Amnesia for events surrounding the trauma (< 24 hr), OR
- Altered mental state (confusion, disorientation, etc.).

Rationale

Blast-induced mTBI is one of the most common injuries seen in modern military combat operations. Despite that fact and the high frequency of hypopituitarism that has been reported after TBI from other causes , no prior studies of the prevalence of hypopituitarism after blast concussion have been published.

Potential Mechanisms of Brain Injury Due to Blast Exposure

- Blast pressure is propagated directly through the skull and indirectly through the vasculature.
- Blast may produce rapid acceleration, deceleration and rotation of the brain.
- Reflections of blast waves in a closed space can alter and magnify their effects.
- Fragment impact, extreme heat, emitted gases, and electromagnetic waves may contribute to the injury.

Sources of Pituitary Damage in TBI

- Torsional forces from brain movement acting on the pituitary stalk
- Compression due to the pituitary's confinement in the sella turcica
- Vascular pressure surges
- Disruption of hypothalamic function and its vascular and neural input to the pituitary

Experimental Design

- Two groups of male US Veterans of deployment to Iraq and/or Afghanistan:
  - 1. **T** group (N=26) -- diagnosed with blast-induced mTBI
  - 2. **DC** group (N=7) -- not blast-exposed and without history of head injury (deployment controls)
- Basal concentrations of 12 pituitary and target-organ hormones were assayed with commercial radioimmunoassay or enzyme-linked immunosorbent assay kits.
- Hormones measured: total testosterone (tT), luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin (PRL), growth hormone (GH), insulin-like growth factor-I (IGF-I), adrenocorticotropin (ACTH), cortisol, thyroid-stimulating hormone (TSH), free thyroxine, vasopressin (AVP), and oxytocin (OT)
- Abnormal hormone levels were defined in relation to the distributions of hormone concentrations in a reference group of healthy community control subjects.
- Criteria for identification of abnormalities in each hormonal axis are shown in Table 1.

Axis	Definition Using Control Population and Lognormal Distribution
1. Adrenal insufficiency	Cortisol < 10th percentile (6.7 ug/dl), and ACTH < 10th percentile (17.7 pg/ml)
2. Thyroid deficiency	Free T4 < 5th percentile (0.87), and TSH < 50th percentile (2.39)
3. Hypogonadism	Total testosterone < 5th percentile (330) and either LH or FSH < 10th percentile (2.3, 1.3, respectively) OR (total testosterone < 5th percentile and prolactin > 95th percentile (32.0)
4. Vasopressin abnormality	Vasopressin > 95th percentile (9.46) OR vasopressin < 5th percentile (0.27) and urine specific gravity ≤ 1.003
5. Prolactin abnormality	Prolactin > 95th percentile (32.0) or prolactin < 5th percentile (6.7)
6. GH deficiency	Age-adjusted IGF-1 < 10th percentile
7. Oxytocin deficiency	Oxytocin < 5th percentile
Hypopituitarism	Dysfunction in at least one of axes 1-7.

Table 1. Operational definitions of dysfunctions of pituitary hormone axes based on comparisons with log-normal concentration distributions in age-matched healthy community control subjects.

Results

- Five individuals in the T group, but none in the DC group, were found with markedly low IGF-I levels strongly suggestive of GHD (Fig. 1).
- Three of the T group participants had LH and testosterone concentrations meeting the criteria for hypogonadism (Fig. 2).
- Prolactin
  - No prolactin abnormalities were observed in the DC group.
  - One of the T group was found with prolactin > 95th percentile of the reference control group range.
  - One of the T group was found with prolactin < 5th percentile.
  - Both of these T subjects also had sub-threshold LH and testosterone levels.
- No abnormalities in pituitary-adrenal or pituitary thyroid axes were observed in either subject group.
- Vasopressin
  - The DC group did not exhibit any abnormal AVP concentrations.
  - Two T-group subjects had AVP levels > 95th percentile of the reference range.
  - Two of the T group were found with AVP < 5th percentile and urine specific gravity < 1.003.
- Four of the T group and none of the DC group had OT levels < 5th percentile.
- Hormone concentrations of the T subjects who showed indications of hormonal abnormalities in one or more axes are shown in Table 2.



Fig. 1. The red line represents the age-adjusted 10th percentile of the distribution of basal IGF-I concentrations in the reference community control sample. IGF-I levels below that threshold were considered indicative of probable GHD: [▲] = DC (deployment control) group; [●] = T (blast mTBI) group. Measures of IGF-I provide low diagnostic sensitivity for identifying GHD but are highly specific indicators. The presence of normal or elevated IGF-I levels cannot exclude GHD.



Figure 2. The dual criteria for hypogonadism were a testosterone concentration below the 5th percentile of the reference group together with an LH or FSH level below the 10th percentile of each of those distributions. Only the three subjects in the T group whose data are represented by [●] met both conditions and were considered to be hypogonadal.

Subj.	LH mIU/ml	FSH U/L	tTest ng/dl	PRL ng/ml	IGF-I ng/ml	AVP pg/ml	OT pg/ml
T-2	2.03	---	669	9.6	185	12.3	181
T-4	2.03	2.06	252	54.9	110	8.0	88
T-8	2.72	4.02	401	11.9	141	0.2	44
T-10	1.97	2.43	520	12.3	230	0.2	22
T-12	7.27	5.70	715	13.0	198	12.0	55
T-13	1.92	1.18	253	6.3	187	6.4	50
T-14	2.66	2.51	390	12.0	151	0.5	19
T-16	2.64	4.01	380	21.5	126	0.9	190
T-22	4.00	4.48	588	12.8	227	0.0	21
T-25	2.24	4.34	463	7.2	146	2.1	25
T-28	2.11	2.64	264	15.3	86	8.4	0

Table 2. Basal hormone concentrations of the 11 members of the T group found to have abnormal values in at least one hormonal axis. Two of the subjects with blast mTBI exhibited dysfunction in two or more anterior pituitary axes, and two were deficient in both oxytocin and vasopressin.

Summary

- Eleven of 26, or 42%, of Veterans with blast-induced mTBI were found with hormone concentrations indicative of hypopituitarism.
- None of the deployment control subjects were found to have any hormone deficiencies.
- The most frequent anterior pituitary disorders were GHD and hypogonadism.
- Two T-group subjects were found to have sub-threshold levels of both AVP and OT suggesting disruption of axons in the pituitary stalk or hypothalamic damage in these individuals.

Conclusions

- Blast-induced mTBI carries a high risk for pituitary dysfunction.
- PTHP is associated with a constellation of symptoms and diminished quality of life similar to PTSD.
- Therefore, routine screening for pituitary dysfunction after blast concussion shows promise for:
  - Identifying those individuals whose symptoms are of neuroendocrine origin,
  - Directing diagnostic and therapeutic strategies that might otherwise remain unconsidered, and
  - Markedly facilitating recovery and rehabilitation after blast-induced mTBI.

Acknowledgments: This work was supported by U.S. Department of Defense Congressionally Directed Medical Research Program Concept Award PT090753; the Geriatric Research, Education and Clinical Center and the Research and Development Service of the VA Puget Sound Health Care System; the VA Northwest Network Mental Illness Research, Education and Clinical Center; the Seattle Institute for Biomedical and Clinical Research; the University of Washington Alzheimer's Disease Research Center NIA AG05136; and an anonymous foundation. Graphic Design by Natalia Czajkiewicz.

The FASEB Journal
The Journal of the Federation of American Societies for Experimental Biology

(*The FASEB Journal*. 2013;27:935.3)
© 2013 FASEB
935.3

Prevalence of chronic hypopituitarism after blast concussion

Charles W. Wilkinson[1,3], Elizabeth A. Colasurdo[1], Kathleen F. Pagulayan[2,3], Jane B. Shofer[3] and Elaine R. Peskind[2,3]

[1] Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA
[2] VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA
[3] Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA

Studies of traumatic brain injury (TBI) from all causes have reported a prevalence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones measured at least one year after injury, of 25–50%. Hypopituitarism is associated with fatigue, anxiety, depression, insomnia, cognitive dysfunction, and deleterious changes in body composition and cardiovascular function. However, the prevalence of hypopituitarism after blast concussion/mild TBI (mTBI) has not previously been investigated. We measured twelve pituitary and target organ hormones in blood samples from Veterans of deployment to Iraq or Afghanistan with mTBI and from Veterans of deployment without blast exposure. Criteria for identifying abnormal hormone levels were derived from measurement of basal hormone concentrations in male non-Veteran control subjects. Preliminary results indicate that 42% of individuals with blast mTBI exhibited abnormal hormone levels suggestive of pituitary dysfunction, with the most prevalent deficiencies being consistent with hypogonadism and growth hormone deficiency. These findings of a high frequency of hypopituitarism after blast concussion similar to that found in other forms of TBI provide support for the value of routine hormonal screening in facilitating the recovery and rehabilitation of blast-exposed Veterans. Supported by DoD PT0753 and the Dept. of Veterans Affairs.

PROGRAM # 935.3

PREVALENCE OF CHRONIC HYPOPITUITARISM AFTER BLAST CONCUSSION

Charles W. Wilkinson[1,3], Elizabeth A. Colasurdo[1], Kathleen F. Pagulayan[2,3], Jane B. Shofer[3], Elaine R. Peskind[2,3]

[1]Geriatric Research, Education and Clinical Center, [2]VA Northwest Network Mental Illness Research, Education and Clinical Center, VA Puget Sound Health Care System, Seattle, WA, [3]Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA

ABSTRACT

Studies of traumatic brain injury (TBI) from all causes have reported a prevalence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones measured at least one year after injury, of 25-50%. Hypopituitarism is associated with fatigue, anxiety, depression, insomnia, cognitive dysfunction, and deleterious changes in body composition and cardiovascular function. However, the prevalence of hypopituitarism after blast concussion/mild TBI (mTBI) has not previously been investigated. We measured twelve pituitary and target organ hormones in blood samples from Veterans of deployment to Iraq or Afghanistan with mTBI and from Veterans of deployment without blast exposure. Criteria for identifying abnormal hormone levels were derived from measurement of basal hormone concentrations in male non-Veteran control subjects. Preliminary results indicate that 42% of individuals with blast mTBI exhibited abnormal hormone levels suggestive of pituitary dysfunction, with the most prevalent deficiencies being consistent with hypogonadism and growth hormone deficiency. These findings of a high frequency of hypopituitarism after blast concussion similar to that found in other forms of TBI provide support for the value of routine hormonal screening in facilitating the recovery and rehabilitation of blast-exposed Veterans. Supported by DoD PT0753 and the Dept. of Veterans Affairs.

INTRODUCTION

Pituitary Dysfunction After Traumatic Brain Injury (TBI)

- Recent studies have reported the prevalence of hypopituitarism after TBI to be in the range of 25-50%, whereas the estimated prevalence of hypopituitarism from all causes in the general population is 300 cases per million, or 0.03%.
- The most common anterior pituitary dysfunctions post-TBI are growth hormone deficiency (GHD) and hypogonadism.
- Hypopituitarism is associated with non-specific psychological and physical symptoms that overlap considerably with those of PTSD.
- These symptoms include fatigue, anxiety, depression, irritability, insomnia, sexual dysfunction, poor concentration and memory, deleterious effects on body composition, increased risk for hypertension and cardiovascular mortality, and decreased quality of life.

Sources of Pituitary Damage in TBI

- Linear and rotational forces on the pituitary stalk resulting from brain movement
- Compression due to the pituitary's confinement in the sella turcica
- Vascular pressure surges
- Disruption of hypothalamic function and its vascular and neural input to the pituitary

Study Rationale

- Although blast concussion is the single most common injury seen in modern military combat operations and the frequency of hypopituitarism after other forms of TBI has been found to be high, the prevalence of hypopituitarism after blast mTBI has not been determined.

Mild TBI/Concussion

Mild TBI (mTBI), or concussion, is defined as traumatically induced disruption of brain function manifested by

- Brief (< 30 min) loss of consciousness, **OR**
- Amnesia for events surrounding the trauma, **OR**
- Altered mental state (confusion, disorientation, etc.) for up to 24 hr.

EXPERIMENTAL DESIGN

- Two groups of male US veterans of deployment to Iraq and/or Afghanistan:
- 1. **T** group -- diagnosed with blast-induced mTBI
- 2. **DC** (deployment control) group -- not blast-exposed and without history of head injury
- Basal morning concentrations of 12 pituitary and target-organ hormones were measured in serum/plasma
- Abnormal hormone levels were defined in relation to the distributions of hormone concentrations in a reference group of healthy community control subjects.



Fig. 1. IGF-I concentrations in serum from deployment control (DC) participants (▲) and participants with mTBI (T, ●). The screening criterion for growth hormone deficiency was an IGF-I level below the age-adjusted 10th percentile of IGF-I concentration (diagonal red line) in the community control reference group. Measures of IGF-I provide low diagnostic sensitivity for identifying GHD but are highly specific indicators. The presence of normal or elevated IGF-I levels cannot exclude GHD. Serum IGF-I values of five Veterans with mTBI fell below this cutoff line. None of the DC group met this criterion.



Fig. 2. Serum LH (left) and testosterone (right) in the deployment control (DC, ▲) and mTBI (T, ●) groups. The dual criteria for hypogonadism were a testosterone concentration below the 5th percentile of the reference group together with an LH or FSH level below the 10th percentile of each of those distributions. Only the three subjects in the T group whose data are represented by ● met both conditions and were considered to be hypogonadal. None of the DC group met both criteria.

RESULTS

RESULTS, PART 1: First Round of Preliminary Data (Table 1)

Participants with blast mTBI (T group, N=26)

Sub-threshold age-adjusted IGF-I levels indicative of GHD (Fig. 1):	N=5	(19.2%)
LH and testosterone concentrations meeting criteria for hypogonadism (Fig. 2):	N=3	(11.5%)
Abnormal prolactin levels: 1 > 95th and 1 < 5th percentile of reference range:	N=2	(7.7%)
Pituitary-adrenal or pituitary-thyroid axis deficiencies:	N=0	(0.0%)
Multiple anterior pituitary hormonal abnormalities:	N=3	(11.5%)
Extreme vasopressin concentrations: 2 elevated; 2 low with USG < 1.003:	N=4	(15.4%)
Oxytocin levels < 5th percentile of reference range:	N=4	(15.4%)
Multiple anterior and/or posterior pituitary hormone deficiencies:	N=5	(19.2%)
Abnormal basal levels in one or more pituitary hormone axes	N=11	(42.3%)

Deployment control participants (DC group, N=7)

Abnormal basal levels in one or more pituitary hormone axes	N=0	(0.0%)

	Blast Concussion/mTBI (T)																											Deployment Control (DC)						
Participant Number	T-1	T-2	T-3	T-4	T-5	T-6	T-7	T-8	T-9	T-10	T-11	T-12	T-13	T-14	T-15	T-16	T-17	T-18	T-19	T-20	T-22	T-23	T-25	T-26	T-27	T-28	DC-1	DC-2	DC-3	DC-4	DC-5	DC-6	DC-7
Age	24	26	27	33	38	46	26	25	24	26	28	27	31	30	27	28	25	24	30	28	25	29	25	26	43	41	26	29	47	24	23	38	31
Number of Blast Concussions	11	6	10	15	102	5	20	21	102	20	9	15	7	6	11	66	18	7	1	3	4	52	12	11	5	12	0	0	0	0	0	0	0
Secondary Adrenal Insufficiency																																	
Hypothyroidism																																	
Hypogonadism				★									★													★							
Prolactin Excess/Deficiency				★									★																				
Growth Hormone Deficiency				★				★								★							★			★							
Vasopressin Excess/Deficiency		★								★		★	★								★												
Oxytocin Deficiency										★				★							★					★							

Table. 1. Occurrence of pituitary dysfunction by hormone axis and individual participant. Highlighting indicates individuals with one or more pituitary axis dysfunction determined by screening criteria. Stars represent occurrence of hormonal abnormalities.

RESULTS, PART 2: Updated Screening Data for Hypogonadism and GHD Only (Fig. 3)

T group, N=35:

- 7 met screening criterion for GHD
- 5 met screening criteria for hypogonadism
- 2 of above met criteria for both deficiencies

DC group, N=15:

- 1 met screening criteria for both GHD and hypogonadism



Fig. 3. Percentages to date of veterans in each group meeting screening criteria for hypogonadism and GHD. T group (Blast Concussion) N=35; DC group (Deployment Control) N=15.

SUMMARY

- Over 40% of veterans with blast-induced mTBI met screening criteria for pituitary dysfunction in at least one hormonal axis.
- Only one (6.7%) of the deployment control veterans were found to have pituitary hormone deficiencies.
- The most frequent hormone abnormalities were those associated with GHD and hypogonadism.

CONCLUSIONS

- Blast-induced mTBI carries a high risk for pituitary dysfunction.
- Post-traumatic hypopituitarism (PTHP) is associated with a constellation of symptoms and diminished quality of life similar to PTSD.
- Therefore, routine screening for pituitary dysfunction after blast concussion shows promise for:
  - Identifying those individuals whose symptoms are of neuroendocrine origin,
  - Directing diagnostic and therapeutic strategies that might otherwise remain unconsidered, and
  - Markedly facilitating recovery and rehabilitation after blast concussion.

Acknowledgments: This work was supported by U.S. Department of Defense Congressionally Directed Medical Research Program Concept Award PT090753; the Geriatric Research, Education and Clinical Center and the Research and Development Service of the VA Puget Sound Health Care System; the VA Northwest Network Mental Illness Research, Education and Clinical Center; the Seattle Institute for Biomedical and Clinical Research; the University of Washington Alzheimer's Disease Research Center NIA AG05136; and an anonymous foundation. Graphic Design by Natalia Czajkiewicz.

https://endo.confex.com/endo/2013endo/webprogram/Paper7712.html

Pituitary Dysfunction After Blast Concussion: Imaging and Psychological Correlates

Program: Abstracts - Orals, Featured Poster Presentations, and Posters
Session: SUN 130-162-Neuroendocrinology
Clinical

Sunday, June 16, 2013: 1:45 PM-3:45 PM

Expo Halls ABC (Moscone Center)

Poster Board SUN-148

Charles W. Wilkinson[*1], Eric C. Petrie[1], Satoshi Minoshima[2], Donna J. Cross[2], Todd L. Richards[2], Kathleen F. Pagulayan[1] and Elaine R. Peskind[1]
[1]VA Puget Sound Health Care System, Seattle, WA, [2]University of Washington, Seattle, WA

Studies of traumatic brain injury (TBI) from all causes have reported a prevalence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones measured at least one year after injury, of 25-50%. Chronic hypopituitarism is associated with a constellation of symptoms that overlaps considerably with PTSD including fatigue, anxiety, depression, sleep disorders, social isolation, aggression, sexual dysfunction, cognitive deficits, and deleterious changes in body composition and cardiovascular function. However, the prevalence of hypopituitarism after blast concussion/mild TBI (mTBI) has not previously been investigated. We measured twelve pituitary and target organ hormones in blood samples from male Veterans of deployment to Iraq or Afghanistan with mTBI (n = 36) and from male Veterans of deployment without blast exposure (n = 14). Criteria for identifying abnormal hormone levels were derived from measurement of basal hormone concentrations in healthy male non-Veteran control subjects. Subjects also underwent magnetic resonance imaging of fractional anisotropy and macromolecular proton fraction to assess brain white matter integrity; [18F]-fluorodeoxyglucose positron emission tomography imaging of cerebral glucose metabolism; structured clinical assessments of blast exposure, psychiatric diagnoses, and PTSD symptoms; neurologic evaluations; and self-report scales of postconcussive symptoms, combat exposure, depression, sleep quality, and alcohol use. Six of the initial 26 subjects with a history of blast concussion enrolled in the study were found to have hormone levels consistent with hypogonadism and/or growth hormone deficiency. Basal circulating hormone concentrations, voxelwise analyses for each of the three imaging modalities, and demographic, blast exposure, psychiatric and self-report data are presented for these six subjects and for six age-matched deployed controls. We previously found a significantly greater prevalence of anterior pituitary hormone abnormalities in the blast mTBI group than in the deployment control group and now report the imaging, neuropsychological, and behavioral characteristics of the two groups. Our findings provide support for the value of routine hormonal screening in directing diagnostic and treatment decisions that might otherwise remain unconsidered and for markedly facilitating the recovery and rehabilitation of blast-exposed Veterans.

Nothing to Disclose: CWW, ECP, SM, DJC, TLR, KFP, ERP

Sources of Research Support: U.S. Department of Defense Congressionally Directed Medical Research Program Concept Award PT090753; Department of Veterans Affairs (VA) Rehabilitation Research and Development Service Merit Review Award; Geriatric Research, Education and Clinical Center, and Research and Development Service of the VA Puget Sound Health Care System; VA Northwest Network Mental Illness Research, Education and Clinical Center; Seattle Institute for Biomedical and Clinical Research; University of Washington Alzheimer's Disease Research Center NIA AG05136; and an anonymous foundation.



Abstract ACCEPTED to be presented in a poster session during the 1st PanAmerican Congress of Physiological Sciences (PanAm-2014) Physiology without borders, to be held in the Rafain Palace Hotel & Convention Center, Iguassu Falls, Brazil, in August 2-6, 2014.

[Abstract ID: 566]

PÔSTER

HIGH FREQUENCY OF PITUITARY DYSFUNCTION AND ASSOCIATED COGNITIVE AND BEHAVIORAL DEFICITS AFTER BLAST CONCUSSION

CHARLES W WILKINSON[1]; KATHLEEN F PAGULAYAN[1]; ELIZABETH A COLASURDO[1]; JANE B SHOFER[1]; MADELEINE L WERHANE[1]; ELAINE R. PESKIND[1].
1.VA PUGET SOUND HEALTH CARE SYSTEM, SEATTLE - ESTADOS UNIDOS.

Abstract

Studies of traumatic brain injury from all causes have reported a prevalence of chronic hypopituitarism, defined by deficient production of one or more pituitary hormones measured at least one year after injury, of 25-50%.To determine if a similar frequency of hypopituitarism occurs after blast concussion, we measured 12 pituitary and target organ hormones in two groups of U.S. Veterans of combat in Iraq or Afghanistan: (1) individuals with blast-induced concussions (TBI), and (2) individuals without blast exposure. Early preliminary data indicated significant hormonal abnormalities in over 40% of the TBI group and 7% of the control group. Analyses of additional data have confirmed highly significant differences between the prevalence of pituitary dysfunction in the two groups. The most frequent abnormalities observed were those related to growth hormone deficiency and hypogonadism. Hypopituitarism was found to be associated with specific cognitive deficits and altered prevalence of fatigue, sleep disorders, and depression. Blast concussions, just as TBI induced by other mechanisms, result in a high frequency of pituitary dysfunction associated with multiple negative consequences for physical and mental health.

May 9, 2014

CURRICULUM VITAE

CHARLES WILLIAM WILKINSON

EDUCATION:

University of Michigan
B.S. - Zoology, Psychology 1969
University of California, Santa Barbara
Ph.D. - Psychology (Physiological) 1977

POSTGRADUATE TRAINING:

Postdoctoral Fellow 1977-1980
Department of Physiology
University of California, San Francisco

Postdoctoral Fellow 1981
Division of Endocrinology
Department of Medicine
Mount Sinai School of Medicine of the City University of New York

UNIVERSITY POSITIONS:

Lecturer 1980
Division of Natural Sciences
University of California, Santa Cruz

Instructor 1982
Department of Pharmacology
Mount Sinai School of Medicine of the City University of New York

Research Assistant Professor 1984-1991
Research Associate Professor 1991-2014
Research Professor 2014-
Department of Psychiatry and Behavioral Sciences
University of Washington

VA POSITIONS:

Research Physiologist 1982-1984
Geriatric Research, Education and Clinical Center
VA Medical Center
Seattle, Washington

Research Physiologist 1984-2002
Geriatric Research, Education and Clinical Center
VA Puget Sound Health Care System, American Lake Division
Tacoma, Washington

VA POSITIONS Cont'd:

Research Physiologist 2002-
Geriatric Research, Education and Clinical Center
VA Puget Sound Health Care System, Seattle Division
Seattle, Washington

HONORS:

National Merit Scholarship Finalist 1962
University of Michigan Regents Alumni Scholarship 1962-1963
Midland-Ross Corporation Scholarship 1962-1963
University of Michigan Unified Science Honors Program 1962-1964
University of Michigan Senior Honors in Psychology 1968
Veterans Administration Outstanding Performance Award 1986, 1990, 1992, 1999, 2011, 2012, 2013

EDITORIAL BOARDS:

American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 1992-1995

Frontiers in Behavioral Neurosciences 2010-

Frontiers in Neurotrauma 2012-

GRANT REVIEW BOARDS:

Department of Veterans Affairs Mental Health and Behavioral Sciences Merit Review Subcommittee 2001-2003

Chair, Department of Veterans Affairs Neurobiology A Merit Review Subcommittee 2003-2004

Department of Veterans Affairs Rehabilitation Research and Development Service Scientific Merit Review Board for Brain Injury: TBI & Stroke 2012

Department of Veterans Affairs Rehabilitation Research and Development Service Special Emphasis Review Panel RRD1 Brain Injury: TBI & Stroke 2014

Department of Veterans Affairs Rehabilitation Research and Development Service Scientific Review Group RRDB 1 Chronic Brain Injury 2014

Department of Veterans Affairs Rehabilitation Research and Development Service Centralized Promotion Review Panel 2014

UNIVERSITY COMMITTEES:

Faculty Council on University Libraries 2002-2009
University of Washington

Chair, Faculty Council on University Libraries 2006-2009
University of Washington

Faculty Senate Executive Committee 2006-2009
University of Washington

Faculty Senate
University of Washington 2006-2009

Advisory Review Committee on the Dean of University Libraries 2008
University of Washington

Chair, Scholarly Communication Committee 2008-2009
University of Washington Faculty Senate

VA ADMINISTRATION:

Acting Associate Director
Seattle/American Lake Geriatric Research, Education and Clinical Center 1986

Acting Deputy Associate Director
Seattle/American Lake Geriatric Research, Education and Clinical Center 1992

VA COMMITTEES:

Research and Development Committee 1985-1988
Subcommittee on Equipment 1985-1988
Animal Studies Committee 1985-1988, 1989-1995
Chairman, Animal Studies Committee 1987-1988, 1991-1992
Radiation Safety Committee 1990-1995
American Lake VA Medical Center

Animal Studies Committee 1996-1998
Research and Development Bridging Funds Subcommittee 2001-2004
Research and Development Safety Subcommittee 2010-2011
Research and Development Research Safety Subcommittee 2011-
VA Puget Sound Health Care System

SCIENTIFIC ORGANIZATIONS:

The Endocrine Society
American Physiological Society
European Society of Endocrinology

BIBLIOGRAPHY:

Refereed Papers:

1. Dallman MF, Engeland WC, Rose JC, Wilkinson CW, Shinsako J, Siedenburg F: Nycthemeral rhythm in adrenal responsiveness to ACTH. *Am J Physiol* 235:R210-R218, 1978.

2. Wilkinson CW, Shinsako J, Dallman MF: Daily rhythms in adrenal responsiveness to adrenocorticotropin are determined primarily by the time of feeding in the rat. *Endocrinology* 104:350-359, 1979.

3. Carlisle HJ, Wilkinson CW, Laudenslager ML, Keith LD: Diurnal variation of heat intake in ovariectomized, steroid-treated rats. *Horm Behav* 12:232-242:1979.

4. Wilkinson CW, Carlisle HJ, Reynolds RW: Estrogenic effects on behavioral thermoregulation and body temperature of rats. *Physiol Behav* 24:337-340, 1980.

5. Engeland WC, Siedenburg F, Wilkinson CW, Shinsako J, Dallman MR: Stimulus-induced corticotropin-releasing factor content and adrenocorticotropin release are augmented after a unilateral adrenalectomy, independently of circulating corticosteroid levels. *Endocrinology* 106:1410-1415, 1980.

6. Laudenslager ML, Wilkinson CW, Carlisle HJ, Hammel HT: Energy balance in ovariectomized rats with and without estrogen replacement. *Am J Physiol* 238:R400-R405, 1980.

7. Holzwarth MA, Wilkinson CW, Dallman MF: Compensatory adrenal growth in immature and mature male rats. *Neuroendocrinology* 31:34-38, 1980.

8. Wilkinson CW, Engeland WC, Shinsako J, Dallman MF: Nonsteroidal adrenal feedback demarcates two types of pathways to CRF-ACTH release. *Am J Physiol* 240:E136-E145, 1981.

9. Wilkinson CW, Shinsako J, Dallman MF: Return of pituitary-adrenal function after adrenal enucleation or transplantation: diurnal rhythms and responses to ether. *Endocrinology* 109:162-169, 1981.

10. Van de Kar LD, Wilkinson CW, Ganong WF: Pharmacological evidence for a role of brain serotonin in the maintenance of plasma renin activity in unanesthetized rats. *J Pharmacol Exp Ther* 219:85-90, 1981.

11. Van de Kar LD, Wilkinson CW, Skrobik Y, Brownfield MS, Ganong WF: Evidence that serotonergic neurons in the dorsal raphe nucleus exert a stimulatory effect on the secretion of renin but not of corticosterone. *Brain Res* 235:233-243, 1982.

12. Wilkinson CW, Shinsako J, Dallman MF: Rapid decreases in adrenal and plasma corticosterone concentrations after drinking are not mediated by changes in plasma adrenocorticotropin concentration. *Endocrinology* 110:1599-1606, 1982.

13. Maayani S, Wilkinson CW, Stollak JS: 5-Hydroxytryptamine receptor in rabbit aorta: characterization by butyrophenone analogs. *J Pharmacol Exp Ther* 229:346-350, 1984.

Refereed Papers Cont'd:

14. Wilkinson CW, Dorsa DM: The effects of aging on molecular forms of beta- and gamma-endorphins in rat hypothalamus. *Neuroendocrinology* 43:124-131, 1986.

15. Peskind ER, Raskind MA, Wilkinson CW, Flatness DE, Halter JB: Peripheral sympathectomy and adrenal medullectomy do not alter cerebrospinal fluid norepinephrine. *Brain Res* 367:258-264, 1986.

16. Wilkinson CW, Crabbe JC, Keith LD, Kendall JW, Dorsa DM: Influence of ethanol dependence on regional brain content of □-endorphin in the mouse. *Brain Res* 378:107-114, 1986.

17. Murburg MM, Paly D, Wilkinson CW, Veith RC, Malas KL, Dorsa DM: Haloperidol increases plasma beta endorphin-like immunoreactivity and cortisol in normal human males. *Life Sci* 39:373-381, 1986.

18. Villacres EC, Hollifield M, Katon WJ, Wilkinson CW, Veith RC: Sympathetic nervous system activity in panic disorder. *Psychiatry Res* 21:313-321, 1987.

19. Raskind MA, Peskind ER, Veith RC, Wilkinson CW, Federighi D, Dorsa DM: Differential effects of aging on neuroendocrine responses to physostigmine in normal men. *J Clin Endocrinol Metab* 70:1420-1425, 1990.

20. Green PK, Wilkinson CW, Woods SC: Intraventricular corticosterone increases the rate of body weight gain in underweight adrenalectomized rats. *Endocrinology* 130:269-275, 1992.

21. Radant A, Peskind ER, Wilkinson CW, Veith RC, Dorsa DM, Leake RD, Ervin MG, Raskind MA: Neurohypophyseal and pituitary-adrenocortical responses to the alpha$_1$ agonist methoxamine in humans. *Neuroendocrinology* 55:361-366, 1992.

22. Gruenewald DA, Hess DL, Wilkinson CW, Matsumoto AM: Excessive testicular progesterone secretion in aged male Fischer 344 rats: a potential cause of age-related gonadotropin suppression and confounding variable in aging studies. *J Gerontol* 47:B164-B170, 1992.

23. Peskind ER, Radant A, Dobie DJ, Hughes J, Wilkinson CW, Sikkema C, Veith RC, Dorsa DM, Raskind MA: Hypertonic saline infusion increases plasma norepinephrine concentrations in normal men. *Psychoneuroendocrinology* 18:103-113, 1993.

24. Murburg MM, Wilkinson CW, Raskind MA, Veith RC, Dorsa DM: Evidence for two differentially regulated populations of peripheral □-endorphin-releasing cells in humans. *J Clin Endocrinol Metab* 77:1033-1040, 1993.

25. McCann BS, Carter J, Vaughan M, Raskind M, Wilkinson CW, Veith RC: Cardiovascular and neuroendocrine responses to extended laboratory challenge. *Psychosom Med* 55:497-504, 1993.

26. Raskind MA, Peskind ER, Wilkinson CW: Hypothalamic-pituitary-adrenal axis regulation and human aging. *Ann NY Acad Sci* 746:327-335, 1994.

27. Raskind MA, Peskind ER, Pascualy M, Edland SD, Dobie DJ, Murray S, Sikkema C, Wilkinson CW: The effects of normal aging on cortisol and adrenocorticotropin responses to hypertonic saline infusion. *Psychoneuroendocrinology* 20:637-644, 1995.

Refereed Papers Cont'd:

28. Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ, Veith RC, Dorsa DM, Murray S, Sikkema C, Galt SA, Wilkinson CW: Enhanced hypothalamic pituitary adrenocortical axis responses to physostigmine in normal aging. *J Gerontol A Biol Sci Med Sci* 50:M114-M120, 1995.

29. Watters JJ, Swank MW, Wilkinson CW, Dorsa DM: Evidence for glucocorticoid regulation of the rat vasopressin V1a receptor gene. *Peptides* 17:67-73, 1996.

30. Park CR, Benthem L, Seeley RJ, Friedman MI, Wilkinson CW, Woods SC: A comparison of the effects of food deprivation and 2,5-anhydro-D-mannitol on metabolism and ingestion. *Am J Physiol* 270:R1250-R1256, 1996.

31. Watters JJ, Wilkinson CW, Dorsa DM: Glucocorticoid regulation of vasopressin V1a receptors in rat forebrain. *Brain Res Mol Brain Res* 38:276-284, 1996.

32. Peskind ER, Raskind MA, Wingerson D, Pascualy M, Thal LJ, Dobie DJ, Wilkinson CW: Hypothalamic pituitary adrenocortical axis responses to physostigmine: effects of Alzheimer's disease and gender. *Biol Psychiatry* 40:61-68, 1996.

33. Seeley RJ, Hawkins MH, Ramsay DS, Wilkinson CW, Woods SC: Learned tolerance to the corticosterone-increasing action of ethanol in rats. *Pharmacol Biochem Behav* 55:268-273, 1996.

34. Wilkinson CW, Peskind ER, Raskind MA: Decreased hypothalamic-pituitary-adrenal axis sensitivity to cortisol feedback inhibition in human aging. *Neuroendocrinology* 65:79-90, 1997.

35. Jensen CF, Keller TW, Peskind ER, McFall ME, Veith RC, Martin D, Wilkinson CW, Raskind MA: Behavioral and neuroendocrine responses to sodium lactate infusion in subjects with posttraumatic stress disorder. *Am J Psychiatry* 154:266-268, 1997.

36. Matsushima H, Peskind ER, Clark JM, Leverenz JB, Wilkinson CW, Clark JI: Protein changes during aging and the effects of long-term cortisol treatment in macaque monkey lens. *Optom Vis Sci* 74:190-197, 1997.

37. Vitiello MV, Wilkinson CW, Merriam GR, Moe KE, Prinz PN, Ralph DD, Colasurdo EA, Schwartz RS: Successful 6-month endurance training does not alter insulin-like growth factor-I in healthy older men and women. *J Gerontol A Biol Sci Med Sci* 52:M149-M154, 1997.

38. Jensen CF, Keller TW, Peskind ER, McFall ME, Veith RC, Martin D, Wilkinson CW, Raskind MA: Behavioral and plasma cortisol responses to sodium lactate infusion in posttraumatic stress disorder. *Ann NY Acad Sci* 821:444-448, 1997.

39. Chavez M, Seeley RJ, Green PK, Wilkinson CW, Schwartz MW, Woods SC: Adrenalectomy increases sensitivity to central insulin. *Physiol Behav* 62:631-634, 1997.

40. van Dijk G, Donahey JCK, Thiele TE, Scheruink AJW, Steffens AB, Wilkinson CW, Tenenbaum R, Campfield LA, Burn P, Seeley RJ, Woods SC: Central leptin stimulates corticosterone secretion at the onset of the dark phase. *Diabetes* 46:1911-1914, 1997.

41. Rasmussen DD, Bryant CA, Boldt BM, Colasurdo EA, Levin N, Wilkinson CW: Acute alcohol effects on opiomelanocortinergic regulation. *Alcohol Clin Exp Res* 22:789-801, 1998.

Refereed Papers Cont'd:

42. McMinn JE, Seeley RJ, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW: NPY-induced overfeeding suppresses hypothalamic NPY mRNA expression: potential roles of plasma insulin and leptin. *Regul Pept* 75-76:425-431, 1998.

43. Peskind ER, Jensen CF, Pascualy M, Tsuang D, Cowley D, Martin DC, Wilkinson CW, Raskind MA: Sodium lactate and hypertonic sodium choride induce equivalent panic incidence, panic symptoms, and hypernatremia in panic disorder. *Biol Psychiatry* 44:1007-1016, 1998.

44. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM: Daily melatonin administration at middle age suppresses male rat visceral fat, plasma leptin, and plasma insulin to youthful levels. *Endocrinology* 140:1009-1012, 1999.

45. Leverenz JB, Wilkinson CW, Wamble M, Corbin S, Grabber JE, Raskind MA, Peskind ER: Effect of chronic high-dose exogenous cortisol on hippocampal neuronal number in aged nonhuman primates. *J Neurosci* 19:2356-2361, 1999.

46. van Dijk G, Seeley RJ, Thiele TE, Friedman MI, Ji H, Wilkinson CW, Burn P, Campfield LA, Tenenbaum R, Baskin DG, Woods SC, Schwartz MW: Metabolic, gastrointestinal, and CNS neuropeptide effects of brain leptin administration in the rat. *Am J Physiol* 276:R1425-R1433, 1999.

47. Petrie EC, Wilkinson CW, Murray S, Jensen C, Peskind ER, Raskind MA: Effects of Alzheimer's disease and gender on the hypothalamic-pituitary-adrenal axis response to lumbar puncture stress. *Psychoneuroendocrinology* 24:385-395, 1999.

48. Sindelar DK, Havel PJ, Seeley RJ, Wilkinson CW, Woods SC, Schwartz MW: Low plasma leptin levels contribute to diabetic hyperphagia in rats. *Diabetes* 48:1275-1280, 1999.

49. Dukoff R, Wilkinson CW, Lasser R, Friz J, Conway A, Bahro M, Peskind ER, Sunderland T: Physostigmine challenge before and after chronic cholinergic blockade in elderly volunteers. *Biol Psychiatry* 46:189-195, 1999.

50. McCann BS, Benjamin GA, Wilkinson CW, Retzlaff BM, Russo J, Knopp RH: Plasma lipid concentrations during episodic occupational stress. *Ann Behav Med* 21:103-110, 1999.

51. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C, Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC: Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. *Arch Gen Psychiatry* 56:1135-1140, 1999.

52. Wolden-Hanson T, Mitton DR, McCants RL, Yellon SM, Wilkinson CW, Matsumoto AM, Rasmussen DD: Daily melatonin administration to middle-aged male rats suppresses body weight, intraabdominal adiposity, and plasma leptin and insulin independent of food intake and total body fat. *Endocrinology* 141:487-497, 2000.

53. Pascualy M, Petrie EC, Brodkin K, Peskind ER, Wilkinson CW, Raskind MA: Hypothalamic pituitary adrenocortical and sympathetic nervous system responses to the cold pressor test in Alzheimer's disease. *Biol Psychiatry* 48:247-254, 2000.

Refereed Papers Cont'd:

54. McMinn JE, Wilkinson CW, Havel PJ, Woods SC, Schwartz MW: Effect of intracerebroventricular alpha-MSH on food intake, adiposity, c-Fos induction, and neuropeptide expression. *Am J Physiol Regul Integr Comp Physiol* 279:R695-R703, 2000.

55. Mystkowski P, Seeley RJ, Hahn TM, Baskin DG, Havel PJ, Matsumoto AM, Wilkinson CW, Peacock-Kinzig K, Blake KA, Schwartz MW: Hypothalamic melanin-concentrating hormone and estrogen-induced weight loss. *J Neurosci* 20:8637-8642, 2000.

56. Rasmussen DD, Boldt BM, Bryant CA, Mitton DR, Larsen SA, Wilkinson CW: Chronic daily ethanol and withdrawal: 1. long-term changes in the hypothalamo-pituitary-adrenal axis. *Alcohol Clin Exp Res* 24:1836-1849, 2000.

57. Wilkinson CW, Petrie EC, Murray SR, Colasurdo EA, Raskind MA, Peskind ER: Human glucocorticoid feedback inhibition is reduced in older individuals: evening study. *J Clin Endocrinol Metab* 86:545-550, 2001.

58. Seeman TE, Singer B, Wilkinson CW, McEwen B: Gender differences in age-related changes in HPA axis reactivity. *Psychoneuroendocrinology* 26:225-240, 2001.

59. Prinz P, Bailey S, Moe K, Wilkinson C, Scanlan J: Urinary free cortisol and sleep under baseline and stressed conditions in healthy senior women: effects of estrogen replacement therapy. *J Sleep Res* 10:19-26, 2001.

60. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA: Increased CSF cortisol in AD is a function of APOE genotype. *Neurology* 56:1094-1098, 2001.

61. Clark AF, Steely HT, Dickerson JE Jr, English-Wright S, Stropki K, McCartney MD, Jacobson N, Shepard AR, Clark JI, Matsushima H, Peskind ER, Leverenz JB, Wilkinson CW, Swiderski RE, Fingert JH, Sheffield VC, Stone EM: Glucocorticoid induction of the glaucoma gene MYOC in human and monkey trabecular meshwork cells and tissues. *Invest Ophthalmol Vis Sci* 42:1769-1780, 2001.

62. Kanter ED, Wilkinson CW, Radant AD, Petrie EC, Dobie DJ, McFall ME, Peskind ER, Raskind MA: Glucocorticoid feedback sensitivity and adrenocortical responsiveness in posttraumatic stress disorder. *Biol Psychiatry* 50:238-245, 2001.

63. Evans SB, Wilkinson CW, Bentson K, Gronbeck P, Zavosh A, Figlewicz DP: PVN activation is suppressed by repeated hypoglycemia but not antecedent corticosterone in the rat. *Am J Physiol Regul Integr Comp Physiol* 281:R1426-R1436, 2001.

64. Lupien SJ, Wilkinson CW, Briere S, Menard C, Ng Ying Kin NM, Nair NP: The modulatory effects of corticosteroids on cognition: studies in young human populations. *Psychoneuroendocrinology* 27:401-416, 2002.

65. Rasmussen DD, Boldt BM, Wilkinson CW, Mitton DR: Chronic daily ethanol and withdrawal: 3. Forebrain pro-opiomelanocortin gene expression and implications for dependence, relapse, and depression effect. *Alcohol Clin Exp Res* 26:535-546, 2002.

Refereed Papers Cont'd:

66. Ashman SB, Dawson G, Panagiotides H, Yamade E, Wilkinson CW: Stress hormone levels of children of depressed mothers. *Dev Psychopathol* 14:333-349, 2002.

67. Lupien SJ, Wilkinson CW, Briere S, Ng Ying Kin NM, Meaney MJ, Nair NP: Acute modulation of aged human memory by pharmacological manipulation of glucocorticoids. *J Clin Endocrinol Metab* 87:3798-3807, 2002.

68. Figlewicz DP, Van Dijk G, Wilkinson CW, Gronbeck P, Higgins M, Zavosh A: Effects of repetitive hypoglycemia on neuroendocrine response and brain tyrosine hydroxylase activity in the rat. *Stress* 5:217-226, 2002.

69. Evans SB, Wilkinson CW, Gronbeck P, Bennett JL, Taborsky GJ Jr, Figlewicz DP: Inactivation of the PVN during hypoglycemia partially simulates hypoglycemia-associate autonomic failure. *Am J Physiol Regul Integr Comp Physiol* 284:R57-R65, 2003.

70. Evans SB, Wilkinson CW, Gronbeck P, Bennett JL, Zavosh A, Taborsky GJ Jr, Figlewicz DP: Inactivation of the DMH selectively inhibits the ACTH and corticosterone responses to hypoglycemia. *Am J Physiol Regul Integr Comp Physiol* 286:R123-R128, 2004.

71. Szot P, Wilkinson CW, White SS, Leverenz JB, Greenup JL, Colasurdo EA, Peskind ER, Raskind MA: Chronic cortisol suppresses pituitary and hypothalamic peptide message expression in pigtailed macaques. *Neuroscience* 126:241-246, 2004.

72. Wisse BE, Ogimoto K, Morton GJ, Wilkinson CW, Frayo RS, Cummings DE, Schwartz MW: Physiological regulation of hypothalamic IL-1□ gene expression by leptin and glucocorticoids: implications for energy homeostasis. *Am J Physiol Endocrinol Metab* 287:E1107-E1113, 2004.

73. McMillan PJ, Wilkinson CW, Greenup L, Raskind MA, Peskind ER, Leverenz JB: Chronic cortisol exposure promotes the development of a GABAergic phenotype in the primate hippocampus. *J Neurochem* 91:843-851, 2004.

74. Kulstad JJ, McMillan PJ, Leverenz JB, Cook DG, Green PS, Peskind ER, Wilkinson CW, Farris W, Mehta PD, Craft S: Effects of chronic glucocorticoid administration on insulin-degrading enzyme and amyloid-beta peptide in the aged macaque. *J Neuropathol Exp Neurol* 64:139-146, 2005.

75. Huehnergarth KV, Mozaffarian D, Sullivan MD, Crane BA, Wilkinson CW, Lawler RL, McDonald GB, Fishbein DP, Levy WC: Usefulness of relative lymphocyte count as an independent predictor of death/urgent transplant in heart failure. *Am J Cardiol* 95:1492-1495, 2005.

76. van Dijk G, de Vries K, Nyakas C, Buwalda B, Adage T, Kuipers F, Kas M, Adan RA, Wilkinson CW, Thiele TE, Scheurink AJ: Reduced anorexigenic efficacy of leptin, but not of the melanocortin receptor agonist melanotan-II, predicts diet-induced obesity in rats. *Endocrinology* 146:5247-5256, 2005.

77. Wilkinson CW: Roles of acetylation and other post-translational modifications in melanocortin function and interactions with endorphins. *Peptides* 27:453-471, 2006.

Refereed Papers Cont'd:

78. Li G, Cherrier MM, Tsuang DW, Petrie EC, Colasurdo EA, Craft S, Schellenberg GD, Peskind ER, Raskind MA, Wilkinson CW: Salivary cortisol and memory function in human aging. *Neurobiol Aging* 27:1705-1714, 2006.

79. Sanders NM, Figlewicz DP, Taborsky GJ Jr, Wilkinson CW, Daumen W, Levin BE: Feeding and neuroendocrine responses after recurrent insulin-induced hypoglycemia. *Physiol Behav* 87:700-706, 2006.

80. Wilkinson CW, Raff H: Comparative evaluation of a new immunoradiometric assay for corticotropin. *Clin Chem Lab Med* 44:669-671, 2006.

81. Rasmussen DD, Wilkinson CW, Raskind MA: Chronic daily ethanol and withdrawal: 6. Effects on rat sympathoadrenal activity during "abstinence". *Alcohol* 38:173-177, 2006.

82. Sanders NM, Taborsky GJ Jr, Wilkinson CW, Daumen W, Figlewicz DP: Antecedent hindbrain glucoprivation does not impair the counterregulatory response to hypoglycemia. *Diabetes* 56:217-223, 2007.

83. Tyrka AR, Wier LM, Anderson GM, Wilkinson CW, Price LH, Carpenter LL: Temperament and response to the Trier Social Stress Test. *Acta Psychiatr Scand* 115:395-402, 2007.

84. Carpenter LL, Carvalho JP, Tyrka AR, Wier LM, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH: Decreased adrenocorticotropic hormone and cortisol responses to stress in healthy adults reporting significant childhood maltreatment. *Biol Psychiatry* 62:1080-1087, 2007.

85. Moorman AJ, Mozaffarian D, Wilkinson CW, Lawler RL, McDonald GB, Crane BA, Spertus JA, Russo JE, Stempien-Otero AS, Sullivan MD, Levy WC: In patients with heart failure elevated soluble TNF-receptor 1 is associated with higher risk of depression. *J Card Fail* 13:738-743, 2007.

86. Reger MA, Watson GS, Green PS, Wilkinson CW, Baker LD, Cholerton B, Fishel MA, Plymate SR, Breitner JC, DeGroodt W, Mehta P, Craft S: Intranasal insulin improves cognition and modulates beta-amyloid in early AD. *Neurology* 70:440-448, 2008.

87. Al-Noori S, Sanders NM, Taborsky GJ Jr, Wilkinson CW, Figlewicz DP: Acute THPVP inactivation decreases the glucagon and sympathoadrenal responses to recurrent hypoglycemia. *Brain Res* 1194:65-72, 2008.

88. Tyrka AR, Wier LM, Price LH, Rikhye K, Ross NS, Anderson GM, Wilkinson CW, Carpenter LL: Cortisol and ACTH responses to the Dex/CRH test: influence of temperament. *Horm Behav* 53:518-25, 2008.

89. Sanders NM, Wilkinson CW, Taborsky GJ Jr, Al-Noori S, Daumen W, Zavosh A, Figlewicz DP: The selective serotonin reuptake inhibitor sertraline enhances counterregulatory responses to hypoglycemia. *Am J Physiol Endocrinol Metab* 294:E853-E860, 2008.

90. Tyrka AR, Wier L, Price LH, Ross N, Anderson GM, Wilkinson CW, Carpenter LL: Childhood parental loss and adult hypothalamic-pituitary-adrenal function. *Biol Psychiatry* 63:1147-1154, 2008.

Refereed Papers Cont'd:

91. Peretz A, Sullivan JH, Leotta DF, Trenga CA, Sands FN, Allen J, Carlsten C, Wilkinson CW, Gill EA, Kaufman JD: Diesel exhaust inhalation elicits acute vasoconstriction in vivo. *Environ Health Perspect* 116:937-942, 2008.

92. Al-Noori S, Sanders NM, Taborsky GJ Jr, Wilkinson CW, Zavosh A, West C, Sanders CM, Figlewicz DP: Recurrent hypoglycemia alters hypothalamic expression of the regulatory proteins FosB and synaptophysin. *Am J Physiol Regul Integr Comp Physiol* 295: R1446-R1454, 2008.

93. Radant AD, Dobie DJ, Peskind ER, Murburg MM, Petrie EC, Kanter ED, Raskind MA, Wilkinson CW: Adrenocortical responsiveness to infusions of physiological doses of ACTH is not altered in posttraumatic stress disorder. *Front Behav Neurosci* 3:40, 2009. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773172/

94. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Plymate SR, Fishel MA, Watson GS, Cholerton BA, Duncan GE, Mehta PD, Craft S: Effects of aerobic exercise on mild cognitive impairment: a controlled trial. *Arch Neurol* 67:71-79, 2010.

95. Szot P, Miguelez C, White SS, Franklin A, Sikkema C, Wilkinson CW, Ugedo L, Raskind MA: A comprehensive analysis of the effect of DSP4 on the locus coeruleus noradrenergic system in the rat. *Neuroscience* 166:279-291, 2010.

96. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Cholerton BA, Plymate SR, Fishel MA, Watson GS, Duncan GE, Mehta PD, Craft S: Aerobic exercise improves cognition for older adults with glucose intolerance: a risk factor for Alzheimer's disease. *J Alzheimers Dis* 22:569-579, 2010.

97. Kohen R, Shofer JB, Korvatska O, Petrie EC, Wang LY, Schellenberg GD, Peskind ER, Wilkinson CW: ABCB1 genotype and CSF ☐-amyloid in Alzheimer disease. *J Geriatr Psychiatry Neurol* 24:63-66, 2011.

98. Carpenter LL, Tyrka AR, Lee JK, Tracy AP, Wilkinson CW, Price LH: A placebo-controlled study of sertraline's effect on cortisol response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. *Psychopharmacology (Berl)* 218:371-379, 2011. Nov;218(2):371-9.

99. Bayer-Carter JL, Green PS, Montine TJ, VanFossen B, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Walter BK, Tsai E, Plymate SR, Postupna N, Wilkinson CW, Zhang J, Lampe J, Kahn SE, Craft S: Diet intervention and cerebrospinal fluid biomarkers in amnestic mild cognitive impairment. *Arch Neurol* 68:743-752, 2011.

100. Baker LD, Asthana S, Cholerton BA, Wilkinson CW, Plymate SR, Green PS, Merriam GR, Fishel MA, Watson GS, Cherrier MM, Kletke ML, Mehta PD, Craft S: Cognitive response to estradiol in postmenopausal women is modified by high cortisol. *Neurobiol Aging* 33:829.e9-e20, 2012.

101. Wilkinson CW, Pagulayan KF, Petrie EC, Mayer CL, Colasurdo EA, Shofer JB, Hart KL, Hoff D, Tarabochia MA, Peskind ER: High prevalence of chronic pituitary and target-organ hormone abnormalities after blast-related mild traumatic brain injury. *Front Neurol* 3:11, 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273706/

Refereed Papers Cont'd:

102. Szot P, Knight L, Franklin A, Sikkema C, Foster S, Wilkinson CW, White SS, Raskind MA: Lesioning noradrenergic neurons of the locus coeruleus in C57Bl/6 mice with unilateral 6-hydroxydopamine injection, to assess molecular, electrophysiological and biochemical changes in noradrenergic signaling. *Neuroscience* 216:143-157, 2012.

103. Szot P, Franklin A, Sikkema C, Wilkinson CW, Raskind MA: Sequential loss of LC noradrenergic and dopaminergic neurons results in a correlation of dopaminergic neuronal number to striatal dopamine concentration. *Front Pharmacol* 3:184, 2012. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487487/

104. Claxton A, Baker LD, Wilkinson CW, Trittschuh EH, Chapman D, Watson GS, Cholerton B, Plymate SR, Arbuckle M, Craft S: Sex differences in treatment response to intranasal insulin for memory loss. *J Alzheimer Dis* 35:789-797, 2013.

105. Wang LY, Murphy RR, Hanscom B, Li G, Millard SP, Petrie EC, Galasko DR, Sikkema C, Raskind MA, Wilkinson CW, Peskind ER: Cerebrospinal fluid norepinephrine and cognition in subjects across the adult age span. *Neurobiol Aging* 34:2287-2292, 2013.

106. Hanson AJ, Bayer-Carter JL, Green PS, Montine TJ, Wilkinson CW, Baker LD, Watson GS, Bonner LM, Callaghan M, Leverenz JB, Tsai E, Postupna N, Zhang J, Lampe J, Craft S: APOE genotype and diet effects on apolipoprotein E lipidation and amyloid peptides. *JAMA Neurol* 70:972-980, 2013.

Book Chapters:

1. Dallman MF, Wilkinson CW: Feedback and facilitation in the adrenocortical system and the endocrine responses to repeated stimuli. In: *Environmental Endocrinology*. Assenmacher I, Farner DS (eds), Springer-Verlag, Berlin, pp. 252-259, 1978.

2. Dorsa DM, Wilkinson CW: Regulation of neuropeptides in aging. In: *Peptide Hormones: Effects and Mechanism of Action*. Negro-Vilar A, Conn PM (eds), CRC Press, Boca Raton, pp. 69-94, 1988.

3. Wilkinson CW: The adrenal cortex. In: *Textbook of Physiology, 21st Edition, Vol. 2*. Patton HD, Fuchs AF, Hille B, Scher AM, Steiner RA (eds), W.B. Saunders, Philadelphia, pp. 1501-1521, 1989.

4. Wilkinson CW: Endocrine rhythms and the pineal gland. In: *Textbook of Physiology, 21st Edition, Vol. 2*. Patton HD, Fuchs AF, Hille B, Scher AM, Steiner RA (eds), W.B. Saunders, Philadelphia, pp. 1239-1261, 1989.

5. Raskind MA, Wilkinson CW, Peskind ER: Aging and Alzheimer's disease. In: *Hormones, Brain and Behavior, Vol. 5*. Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds), Academic Press, Amsterdam, pp. 637-664, 2002.

6. Lupien SJ, Lord C, Sindi S, Wilkinson CW and Fiocco AJ: Aging and Alzheimer's Disease. In: *Hormones, Brain and Behavior, 2nd edition, Vol. 5*. Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT (eds), Academic Press, San Diego, pp. 3049-3080, 2009.

Other Publications (Invited Editorials):

1. Wilkinson CW: Circadian clocks: showtime for the adrenal cortex. *Endocrinology* 149:1451-1453, 2008.

2. Wilkinson CW: Adrenocortical responsiveness to adrenocorticotropin: StAR is ascendant. *Endocrinology* 150:2509-2511, 2009.

Abstracts and Presentations:

1. Wilkinson CW, Carlisle HJ, Reynolds RW: The effects of estradiol benzoate and gonadectomy on behavioral thermoregulation of rats. *Fed Proc* 35:481, 1976.

2. Wilkinson CW: Endocrine influences on thermoregulatory behavior in rats. *Diss Abstr Int* 38:2917B-2918B, 1977.

3. Wilkinson CW, Shinsako J, Dallman MF: Insulin, corticosterone and ACTH rhythms in rats fed 2 hr/day. *Physiologist* 20:102, 1977.

4. Dallman MF, Wilkinson CW, Engeland WC, Shinsako J: Adrenal size increases in atrophied glands after unilateral adrenalectomy. *Fed Proc* 37:811, 1978.

5. Willkinson CW, Shinsako J, Dallman MF: Rapid reduction in adrenocortical responsiveness to ACTH following restricted access to water. *Physiologist* 21:128, 1978.

6. Dallman MF, Wilkinson CW: Interactions among corticosterone (B), adrenal number and stimuli to ACTH secretion: evidence for steroid-sensitive and steroid-insensitive afferent pathways. *Fed Proc* 38:1053, 1979.

7. Laudenslager ML, Wilkinson CW, Carlisle HJ, Hammel HT: Increased heat production and dry heat loss in estradiol-treated ovariectomized rats. *Fed Proc* 38:1053, 1979.

8. Wilkinson CW, Shinsako J: Rhythms in adrenocortical responsiveness to ACTH are not mediated by direct neural connections to the adrenal. *Abstr 61st Ann Mtg Endocrine Soc*, p. 229, 1979.

9. Wilkinson CW, Wing N, Shinsako J, Dallman MF: Effects of vagotomy on rat adrenal responsiveness to ACTH. *Fed Proc* 39:1073, 1980.

10. Wilkinson CW, Shinsako J, Dallman MF: Nycthemeral rhythms, stress responsiveness and feedback on rats with regenerating adrenals. *Abstr 62nd Ann Mtg Endocrine Soc*, p. 229, 1980.

11. Van de Kar LD, Wilkinson CW, Ganong WF: Pharmacological evidence for a stimulatory effect of serotonin on renin secretion in rats. *Soc Neurosci Abstr* 6:323, 1980.

12. Van de Kar LD, Wilkinson CW, Brownfield MS, Skrobik Y, Ganong WF: Serotonergic neurons stimulate renin and corticosterone secretion via the pituitary gland. *Soc Neurosci Abstr* 7:135, 1981.

Abstracts and Presentations Cont'd:

13. Wilkinson CW, Crabbe JC, Keith LD, Dwoskin L, Robertson LM, Kendall JW, Dorsa DM: Regional changes in brain □-endorphin concentration in ethanol-dependent mice. *Alcohol Clin Exp Res* 8:127, 1984.

14. Wilkinson CW, Dorsa DM: Age-related changes in the distribution of forms of □- and □-endorphins in the brains of rats. *Abstr 7th Int Congress Endocrinology*, p. 1372, 1984.

15. Peskind ER, Raskind MA, Wilkinson CW, Halter JB: Cerebrospinal fluid norepinephrine is unaffected by peripheral sympathectomy. *Soc Neurosci Abstr* 10:65, 1984.

16. Wilkinson CW, Dorsa DM: Age-related changes in regional concentrations and structural forms of neuropeptides in the rat brain. *Soc Neurosci Abstr* 10:596, 1984.

17. Wilkinson CW, Dorsa DM: Age-related changes in molecular forms of POMC-derived peptides in the brain of rats. *Abstr 1st Int Congress Neuroendocrinology*, p. 103, 1986.

18. Wilkinson CW, Galt SA, Roberts TS, Plymate SR: Characterization of peptides derived from pro-opiomelanocortin (POMC) in a Nelson's syndrome pituitary tumor. *Soc Neurosci Abstr* 13:21, 1987.

19. Villacres EC, Hollifield M, Katon WJ, Wilkinson CW, Veith RC: Arterial epinephrine levels in panic disorder: in reply. *Psychiat Res* 25:113-114, 1988.

20. Wilkinson CW, Brownfield MS: Selective decreases in acetylated forms of beta-endorphin and alpha-MSH in the basal telencephalon of rats following stress. *Abstr 71st Ann Mtg Endocrine Soc*, p. 140, 1989.

21. Green PK, Wilkinson CW, Woods SC: Body weight gain in rats after food restriction and adrenalectomy (ADX) is increased by intraventricular (IVT) corticosterone (CORT). *Soc Neurosci Abstr* 16:1251, 1990.

22. Wilkinson CW, Carey HV, Galt SA, Brownfield MS: Seasonal variation in pro-opiomelanocortin-derived peptides in specific brain regions of the thirteen-lined ground squirrel. *3rd IBRO World Congress Neuroscience*, p. 378, 1991.

23. Wilkinson CW, Colasurdo EA, Galt SA, Jorgensen DD: Pro-opiomelanocortin-derived peptides and feeding behavior of Dungeness crabs. *Soc Neurosci Abstr* 17:395, 1991.

24. Green PK, Wilkinson CW, Woods SC: Activation of central type II adrenal steroid receptors enhances rate of weight gain in underweight adrenalectomized rats. *Soc Neurosci Abstr* 17:495, 1991.

25. Colasurdo EA, Jorgensen DD, Galt SA, Wilkinson CW: Feeding behavior and pro-opiomelanocortin-derived peptides in Dungeness crabs. *Amer Zool* 31:19A, 1991.

26. Wilkinson CW, Carey HV, Galt SA, Brownfield MS: Seasonal fluctuations of pro-opiomelanocortin-derived peptides in the brain of the thirteen-lined ground squirrel. *Abstr 13 th Ann Winter Neuropeptide Conf*, 1992.

Abstracts and Presentations Cont'd:

27. Gosink PD, Chauvez M, Green PK, Woods SC, Figlewicz DP, Wilkinson CW, Baskin DG, Schwartz MW: Central insulin administration lowers body weight via a glucocorticoid-sensitive mechanism. *Clin Res* 40:105A, 1992.

28. Gruenewald DA, Hess DL, Wilkinson CW, Matsumoto AM: Altered testicular steroidogenesis in aged male F344 rats: a potential confounding pathological variable in aging studies. *Abstr 74th Ann Mtg Endocrine Soc*, p. 369, 1992.

29. Green PK, Moore T, Wilkinson CW, Bernstein IL, Woods SC: Adrenalectomy does not produce conditioned food aversions in rats. *Soc Neurosci Abstr* 18:1067, 1992.

30. Peskind ER, Raskind MA, Wingerson D, Pascualy M, Dobie DJ, Veith RC, Dorsa DM, Wilkinson CW: Enhanced cortisol and ACTH responses to hypertonic saline infusion in older humans. *Soc Neurosci Abstr* 18:1244, 1992.

31. Raskind MA, Peskind ER, Wingerson D, Pascualy M, Dobie DJ, Veith RC, Dorsa DM, Wilkinson CW: Enhanced hypothalamic-pituitary-adrenal axis response to physostigmine in aging and Alzheimer's disease. *Soc Neurosci Abstr* 18:1436, 1992.

32. Vitiello MV, Wilkinson CW, Prinz PN, Schwartz RS: Successful endurance training does not increase plasma IGF-1 levels in healthy older men and women. *Clin Res* 42:A12, 1994.

33. Vitiello MV, Wilkinson CW, Prinz PN, Schwartz RS: Plasma IGF-1 levels in healthy older men and women are not increased by a six month endurance training program. *Gerontologist* 34, Special Issue 1:265-266, 1994.

34. Raskind MA, Peskind ER, Wilkinson CW: Effects of human aging on HPA axis sensitivity to glucocorticoid feedback inhibition. *Soc Neurosci Abstr* 20:646, 1994.

35. Raskind MA, Peskind ER, Wilkinson CW: Decreased HPA axis sensitivity to glucocorticoid feedback inhibition in human aging. *33rd Ann Mtg Am Coll Neuropsychopharmacol Abstr,* p. 79, 1994.

36. Lovallo WR, al'Absi M, McCann BS, Wilkinson CW: Cortisol: its measurement and uses in behavioral medicine research. *Ann Behav Med* 17:S33, 1995.

37. McCann BS, Benjamin GAH, Wilkinson CW, Carter J, Retzlaff BM, Knopp RH: Examination stress and plasma lipids in law students. *Ann Behav Med* 17:S37, 1995.

38. Seeley RJ, Hawkins MH, Ramsay DS, Wilkinson CW, Woods SC: Behavioral tolerance to the effects of ethanol on corticosterone secretion. *Soc Neurosci Abstr* 21:500, 1995.

39. Rasmussen DD, Levin N, Lawson PT, Wilkinson CW: Induction and maintenance of moderate blood alcohol levels by atraumatic pulsatile gastric infusions in "experienced" rats: transient effects on hypothalamo-pituitary-adrenal (HPA) activation. *Soc Neurosci Abstr* 21:1241, 1995.

40. Watters JJ, Wilkinson CW, Ferris CF, Dorsa DM: Glucocorticoid regulation of the vasopressin V1a receptor in the septum of rat brain. *Soc Neurosci Abstr* 21:2052, 1995.

Abstracts and Presentations Cont'd:

41. Rasmussen DD, Bryant CA, Boldt BM, Colasurdo EA, Wilkinson CW: Induction and maintenance of moderate blood ethanol levels by atraumatic pulsatile gastric infusions in "experienced" rats: effects on brain opiomelanocortinergic activity. *Soc Neurosci Abstr* 22:700, 1996.

42. Lawson PT, Wilkinson CW: Exposure of rats to carbon dioxide or halothane prior to sacrifice increases plasma ACTH and beta-endorphin concentrations. *Soc Neurosci Abstr* 22:2014, 1996.

43. Wilkinson CW, Sarkar DK, Peskind ER, Rasmussen DD: Dissociation between behavioral activation and neuroendocrine stress responses to cocaine. *Soc Neurosci Abstr* 22:923, 1996.

44. Asthana S, Craft S, Baker LD, Raskind MA, Avery E, Lofgreen C, Wilkinson CW, Falzgraf S, Veith RC, Plymate SR: Transdermal estrogen improves memory in women with Alzheimer's disease. *Soc Neurosci Abstr* 22:200, 1996.

45. Craft S, Asthana S, Newcomer J, Tio-Matos I, Hunter E, Lofgreen C, Raskind M, Wilkinson CW, Veith R, Plymate S, Brodkin K, Gibson L, Latendresse S: Insulin-induced enhancement of memory in Alzheimer's disease is independent of glucose. *Soc Neurosci Abstr* 22:1177, 1996.

46. Jensen CF, Keller TW, Peskind ER, McFall ME, Veith RC, Martin D, Wilkinson CW, Raskind MA: Behavioral and neuroendocrine responses to sodium lactate infusion in posttraumatic stress disorder. *35th Ann Mtg Am Coll Neuropsychopharmacol Abstr*, p. 176, 1996.

47. Wilkinson CW, Peskind ER, Colasurdo EA, Murray S, Wamble M, Raskind MA: Human age-related impairment of feedback inhibition of adrenocorticotropin secretion. *Abstr Int Congress Stress, Budapest*, p. 140, 1997.

48. Bell SM, Wilkinson CW, Thiele TE, Woods SC, Seeley RJ: Corticosterone profiles of Long Evans rats selected for high vs. low alcohol preference: diurnal cycles and reactivity to restraint-stress. *Alcohol Clin Exp Res* 21, Suppl.:78A, 1997.

49. Wilkinson CW, Peskind ER, Colasurdo EA, Murray S, Wamble M, Raskind MA: Human age- and gender-related impairment of feedback inhibition of adrenocorticotropin secretion. *Psychoneuroendocrinology* 22, Suppl. 2:S154, 1997.

50. Peskind E, Leverenz J, Wilkinson C, Wamble M, Raskind M: Glucocorticoids and hippocampal neurotoxicity in the aged nonhuman primate. *Psychoneuroendocrinology* 22, Suppl. 2:S155, 1997.

51. Leverenz JB, Wilkinson CW, Raskind MA, Peskind ER: Effects of age and chronic glucocorticoid administration on iodoclonidine binding in non-human primate hippocampus. *Soc Neurosci Abstr* 23:1849, 1997.

52. Peskind ER, Leverenz JB, Wilkinson CW, Wamble M, Raskind MA: Glucocorticoids and hippocampal neurotoxicity in the aged nonhuman primate. *Soc Neurosci Abstr* 23:1850, 1997.

53. Wilkinson CW, Peskind ER, Colasurdo EA, Murray S, Wamble M, Raskind MA: Human glucocorticoid feedback inhibition exhibits aging-related impairment in the evening as well as the morning. *Soc Neurosci Abstr* 23:2048, 1997.

Abstracts and Presentations Cont'd:

54. Rasmussen DD, Boldt BM, Bryant CA, Colasurdo EA, Wilkinson CW: Chronic alcohol, withdrawal, and pair-feeding effects on opiomelanocortinergic regulation. *Soc Neurosci Abstr* 23:1861, 1997.

55. Bell SM, Wilkinson CW, Seeley RL, Woods SC, Lattemann DF: Corticosterone profiles of outbred rats selected for high versus low alcohol preference. *Soc Neurosci Abstr* 23:2389, 1997.

56. Peskind ER, Leverenz JB, Wilkinson CW, Wamble M, Raskind MA: Effects of chronic high dose cortisol on hippocampal neuronal number in nonhuman primates. *36th Ann Mtg Am Coll Neuropsychopharmacol Abstr*, p. 322, 1997.

57. Rasmussen DD, Boldt BM, Wilkinson CW, Yellon SM, Matsumoto AM: Daily melatonin administration at middle age suppresses male rat intra-abdominal fat, plasma leptin, and plasma insulin to youthful levels. *Abstr 80th Ann Mtg Endocrine Soc*, p. 380, 1998.

58. Schwartz MW, Peacock KA, Wilkinson C, Baskin DG, Havel PJ, Seeley RJ: Evidence that pathways downstream of hypothalamic peptides mediate tumor anorexia. *Diabetes* 47, Suppl 1:A13, 1998.

59. Peskind ER, Leverenz JB, Wilkinson CW, Wamble M, Corbin S, Raskind M: Effects of chronic high dose cortisol on hippocampal neuronal number in nonhuman primates. *Neurobiol Aging* 19, Suppl 4S:S116, 1998.

60. Kanter ED, Peskind ER, Dobie DJ, Wilkinson CW, Raskind MA: Glucocorticoid feedback inhibition of the HPA axis in PTSD. *Biol Psychiatry* 43, Suppl:53S, 1998.

61. Wilkinson CW, Peskind ER, Murray S, Colasurdo EA, Sikkema C, Rein RJ, Hoff DJ, Wamble MM, Petrie EC, Raskind MA: Age-related deficits in human glucocorticoid feedback inhibition: evening study. *Psychoneuroendocrinology* 23, Suppl 1:S71, 1998.

62. Firestone JA, Raskind MA, Wilkinson CW, Peskind ER, Leverenz JB: Autoradiographic study of sauvagine slice binding distribution in the medial temporal lobe of the non-human primate. *Soc Neurosci Abstr* 24:615, 1998.

63. Wilkinson CW, Colasurdo EA, Reed SO, Beckham RW III, Rasmussen DD, Seeley RJ: Effects of food deprivation on concentration and molecular forms of ☐-melanotropin in rat hypothalamic nuclei. *Soc Neurosci Abstr* 24:704, 1998.

64. Leverenz JB, Wilkinson CW, Raskind MA, Peskind ER: Effect of chronic glucocorticoid treatment on calbindin-D28k immunoreactivity in the non-human primate hippocampus. *Soc Neurosci Abstr* 24:1920, 1998.

65. Wilkinson CW, Murray S, Rowny SB, Colasurdo EA, MacDonald LL, McCann BS, Craft S, Raskind MA, Peskind ER: Cortisol responses to mental stress are prolonged in older persons. *Proc 2nd World Congress Stress*, p. 98, 1998.

66. McMinn JE, Wilkinson CW, Havel PJ, Schwartz MW: Intracerebroventricular (Icv) infusion of alpha-MSH lowers food intake and body weight via central pathways associated with both energy balance and satiety. *Diabetes* 48, Suppl 1:A63, 1999.

Abstracts and Presentations Cont'd:

67. Lovallo WR, al'Absi M, Marucha P, Wilkinson C: Cortisol: its measurement and uses in behavioral medicine research. *Ann Behav Med* 21, Suppl:S1, 1999.

68. Schwartz MW, Peacock KA, Wilkinson C, Baskin DG, Havel PJ, Matsumoto A, Seeley RJ: Mechanisms underlying anorexia induced by Leydig cell tumors. *J Invest Med* 47:28A, 1999.

69. Rasmussen DD, Mitton DR, McGillivray SA, Wilkinson CW: Persistent HPA effects of chronic daily alcohol and withdrawal. *Alcohol Clin Exp Res* 23, Suppl:22A, 1999.

70. Rasmussen DD, Mitton DR, Wilkinson CW: Persistent effects of chronic daily alcohol and withdrawal on plasma testosterone. *Alcohol Clin Exp Res* 23, Suppl:23A, 1999.

71. Wolden-Hanson T, Mitton DR, Wilkinson CW, McCants RL, Matsumoto AM, Rasmussen DD: Daily melatonin administration to middle-aged male rats suppresses body weight, visceral adiposity, and plasma leptin and insulin without altering food intake or total body fat. *Abstr 81st Ann Mtg Endocrine Soc*, p. 228, 1999.

72. Leverenz JB, Wilkinson CW, Raskind MA, Peskind ER: Immunohistochemical localization of glucocorticoid and mineralocorticoid receptors in the primate hippocampus. *Soc Neurosci Abstr* 25:708, 1999.

73. Rasmussen DD, Wilkinson CW, Mitton DR: Chronic daily alcohol and withdrawal cycles: effects on forebrain proopiomelanocortin (POMC) gene expression. *Soc Neurosci Abstr* 25:1326, 1999.

74. Mystkowski P, Seeley RJ, Havel PJ, Baskin DG, Matsumoto A, Wilkinson CW, Schwartz MW: Hypothalamic melanin concentrating hormone is a target for the anorexic effect of estrogen. *J Invest Med* 48:32A, 2000.

75. Peskind ER, Wilkinson CW, Petrie EC, Schellenberg GD, Raskind MA: Increased cerebrospinal fluid cortisol in Alzheimer's disease is a function of apolipoprotein E genotype. *39th Ann Mtg Am Coll Neuropsychopharmacol Abstr*, p. 240, 2000.

76. Wilkinson CW, Peskind ER: Reply from the authors. Increased CSF cortisol in AD is a function of *APOE* genotype. *Neurology* 57:1523, 2001.

77. Ng-Evans SB, Wilkinson CW, Bentson K, Gronbeck P, Zavosh A, Figlewicz DP: Antecedent corticosterone does not produce the blunted activation of the paraventricular nucleus of the hypothalamus associated with hypoglycemia associated autonomic failure. *Abstr 83rd Ann Mtg Endocrine Soc*, # P1-335, 2001.

78. Leverenz JB, Wilkinson CW, Raskind MA, Peskind ER: Cerebrospinal fluid cortisol levels and hippocampal volume in aged non-human primates. *Soc Neurosci Abstr* # 176.11, 2001. www.sfn.org

79. Baker LD, Sambamurti K, Craft S, Cherrier M, Wilkinson CW, Astana S: Estrogen favorably affects plasma □-amyloid for postmenopausal women with AD. *Soc Neurosci Abstr* # 859.3, 2001. www.sfn.org

Abstracts and Presentations Cont'd:

80. Raskind MA, Szot P, Leverenz JB, Peskind ER, Wilkinson CW: Anterior pituitary POMC and CRF receptor type 1 mRNA expression in Alzheimer's are consistent with chronic hypercortisolemia. *Soc Neurosci Abstr* # 965.8, 2001. www.sfn.org

81. Peskind ER, Wilkinson CW, Galasko D, Kolodziej M, Petrie EC, Schellenberg GD, Raskind MA: Increased cerebrospinal fluid cortisol in Alzheimer's disease is a function of apolipoprotein E genotype. *Soc Neurosci Abstr* # 965.9, 2001. www.sfn.org

82. Kulstad JJ, Cook D, Watson GS, Asthana S, Peskind ER, Wilkinson CW, McMillan P, Craft S: Acute effects of insulin and cortisol on insulin degrading enzyme levels. *Soc Neurosci Abstr* # 965.10, 2001. www.sfn.org

83. Rasmussen DD, Wilkinson CW, Boutin NM: ACTH and corticosterone responses to acute ethanol self-administration. *Alcohol Clin Exp Res* 26, Suppl:147A, 2002.

84. Rasmussen DD, Wilkinson CW, Boutin NM, Puchalski S: Chronic daily ethanol and withdrawal: divergent HPA responses to acute emotional stress versus acute naloxone during "abstinence". *Alcohol Clin Exp Res* 26, Suppl:147A, 2002.

85. Cholerton B, Baker LD, Watson GS, Peskind ER, Wilkinson CW, Reger MA, Chapman D, Wait C, Purganon K, Hyde K, Hale C, Craft S: Plasma and CSF cortisol: evidence for sex differences in patients with Alzheimer's disease. *Neurobiol Aging* 23, Suppl 1:S530, 2002.

86. Shores MM, Peskind ER, Wilkinson CW, Raskind MA: Differential response of plasma norepinephrine to antidepressants in Alzheimer's disease and aging. *Am J Geriatr Psychiatry* 10, Suppl 1: 91-92, 2002.

87. Evans SB, Wilkinson CW, Gronbeck P, Bennett J, Figlewicz Lattemann DP: Hypothalamic paraventricular nucleus (PVN) inactivation partially simulates the impaired neuroendocrine response of Hypoglycemia-Associated Autonomic Failure (HAAF). *Diabetes* 51 (Suppl 2): A146, 2002.

88. McMillan PJ, Wilkinson CW, Raskind MA, Peskind ER, Leverenz JB: Effect of chronic glucocorticoid treatment on calbindin-D28k mRNA expression in the macaque hippocampus. *Soc Neurosci Abstr* # 470.18, 2002. www.sfn.org

89. Cholerton B, Baker LD, Watson GS, Reger MA, Wilkinson CW, Asthana S, Plymate S, Hale C, Craft S: Cognitive changes following acute cortisol infusion: evidence for sex differences in healthy older adults. *Soc Neurosci Abstr* # 777.12, 2002. www.sfn.org

90. Cholerton B, Baker L D, Watson GS, Peskind ER, Asthana S, Wilkinson CW, Reger MA, Wait C, Chapman D, Purganan K, Hyde K, Hale C, Craft S: Plasma and CSF cortisol: Evidence for sex differences in patients with Alzheimer's disease. Poster session presented at the 8th International Conference on Alzheimer's Disease and Related Disorders, 2002.

91. Rasmussen DD, Wilkinson CW, Boutin NM: Chronic daily ethanol and withdrawal : effects on sympathoadrenal activity during 'abstinence.' *Soc Neurosci Abstr* # 899.15, 2002. www.sfn.org

Abstracts and Presentations Cont'd:

92. Wilkinson C, Hammett JM, Peskind ER, Raskind MA, Belanoff JK, Schatzberg AF, Lupien SJ: Mediation of human glucocorticoid feedback inhibition by both mineralocorticoid and glucocorticoid receptors at the circadian peak. *Abstr 6th IBRO World Congress Neuroscience*, p. 318, 2003.

93. Zabetian CP, Wilkinson CW, Samii A, Schellenberg GD: DBH as a model of haplotype block utility in linkage disequilibrium mapping. *Am J Hum Genet* 73:S482, 2003.

94. McMillan PJ, Wilkinson CW, Raskind MA, Peskind ER, Greenup LL, Leverenz JB: Effects of chronic glucocorticoid exposure on GAD and BDNF expression in the primate hippocampus. *Soc Neurosci Abstr* # 614.17, 2003. www.sfn.org

95. Li G, Cherrier M, Tsuang D, Petrie E, Colasurdo E, Wilkinson CW, Peskind E, Raskind M: Salivary cortisol associated with cognitive decline in normal elderly. *Neurobiol Aging*, 25:S357, 2004.

96. Reger M, Watson GS, Cholerton B, Baker LD, Asthana S, Plymate S, Wilkinson CW, Peskind ER, Enstrom K, Hyde K, Belongia D, Craft S: Cortisol infusion attenuates insulin's facilitation of verbal memory in patients with Alzheimer's disease. *Neurobiol Aging*, 25:S168, 2004.

97. McMillan PJ, Wilkinson CW, Greenup L, Raskind MA, Peskind ER, Leverenz JB: Effect of chronic cortisol exposure on the expression of synaptic markers in the primate hippocampus. *Soc Neurosci Abstr* # 999.11, 2004. www.sfn.org

98. Wilkinson C: Aging-related changes in human glucocorticoid feedback inhibition. *Abstr Am Neuroendocrine Soc Workshop Neuroendocrinology of Stress*, p. 29, 2005.

99. Wilkinson CW, Peskind ER, Lash BC, Eliza S, Riekse RG, Raskind MA, Belanoff JK, Schatzberg AF, Lupien SJ: Aging-related deficits in glucocorticoid feedback inhibition reflect altered mineralocorticoid receptor function. *Abstr 36th Ann Intl Soc Psychoneuroendocrinol Conf*, p. 94, 2005.

100. Carpenter LL, Tyrka AR, Carvalho JP, Wier L, Gagne GG, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price, LH: Cortisol response to the Trier Social Stress Test in healthy adults with significant childhood adversity. Annual Meeting of the American College of Neuropsychopharmacology, 2005.

101. Tyrka AR, Carpenter LL, Wier LM, Wilkinson CW, Anderson GM, Price LH: Inhibited temperament and HPA axis function in healthy adults. Annual Meeting of the American College of Neuropsychopharmacology, 2005.

102. Carpenter LL, Carvalho JP, Tyrka AR, Wier LM, Gagne GG, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH: Decreased cortisol response to the Trier Social Stress Test in healthy adults with significant childhood adversity. Tenth Annual Brown University Research Symposium, 2006.

103. Tyrka AR, Carpenter LL, Wier LM, Wilkinson CW, Anderson GM, Price LH: Inhibited temperament and HPA axis function in healthy adults. Tenth Annual Brown University Research Symposium, 2006.

Abstracts and Presentations Cont'd:

104. Sanders NM, Taborsky GJ Jr, Wilkinson CW, Daumen W, Lattemann DF: Acute treatment with the antidepressant sertraline rescues the impaired epinephrine response in recurrent hypoglycemic rats. *Diabetes* 55, Suppl 1:A151, 2006.

105. Tyrka AR, Carpenter LL, Carvalho JP, Wier LM, Gagne GG, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH: Attenuated cortisol and ACTH responses to the Trier Social Stress Test in healthy adults with a history of childhood maltreatment. *Biol Psychiatry* 59, Suppl S:76S, 2006.

106. Wier W, Carpenter LL, Price LH, Ross N, Anderson GM, Wilkinson CW, Tyrka, AR: Parental loss in childhood and pituitary-adrenal response to the dexamethasone/corticotropin-releasing hormone test in healthy adults. Eleventh Annual Brown University Research Symposium, 2007.

107. Carpenter LL, Ross NS, Tyrka AR, Mello AF, Mello MF, Anderson GM, Wilkinson CW, Price LH: Childhood abuse, depression and gender are significant determinants of cortisol and ACTH response to the Dex/CRH test. Annual Meeting of the Society of Biological Psychiatry, 2007.

108. Carpenter LL, Tyrka AR, Anderson GM, Wilkinson CW, Price LH: Depression, childhood maltreatment, and gender are significant determinants of cortisol response to the Dex/CRH test. *Abstracts ACNP 46th Ann Mtg*, Poster 107, 2007.

109. Baker LD, Asthana S, Craft S, Cholerton B, Merriam G, Wilkinson CW, Plymate SR, Fishel M, Green PS, Watson GS, Reger MA: Co-administration of estradiol and cortisol modulates beta-amyloid, IGF activity, and cognitive function for older postmenopausal women. *Alzheimers Dement* 3, Suppl 1:S146-S147, 2007.

110. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Plymate SR, Fishel MA, Watson GS, Cholerton BA, Duncan GE, Mehta PD, Craft S: Cognitive effects of aerobic exercise for MCI: A controlled trial. International Conference of Alzheimer's Disease, 2008.

111. Szot P, White S, Franklin A, Sikkema C, Wilkinson C, Zekan M, Raskind M: Myth busting DSP4 as a selective noradrenergic neurotoxin. *Soc Neurosci Abstr* # 733.11/F8, 2008. www.sfn.org

112. Marsella SA, Carpenter LL, Tyrka AR, Wilkinson CW, Price LH: Eszopiclone treatment and decreased cortisol levels in adults with primary insomnia. 17th Annual Research Celebration, Rhode Island Hospital, 2009.

113. Baker LD, Craft S, Wilkinson CW, Green P, Plymate SR, Watson GS, Cholerton B, Smith L, Fisher L: Six months of controlled aerobic exercise reduces cortisol for women but not men with MCI. *Alzheimers Dement* 5, Suppl 1: P334, 2009.

114. Raskind MA, Wang L, Wilkinson CW, Li G, Sikkema C, Millard S, Hanscom B, Galasko D, Peskind ER: Cerebrospinal fluid norepinephrine is inversely related to aspects of cognition in normal aging. *Alzheimers Dement* 5, Suppl 1: P349-P350, 2009.

115. Baker LD, Frank LL, Foster-Schubert K, Green PS, Wilkinson CW, McTiernan A, Plymate SR, Fishel MA, Watson GS, Cholerton BA, Duncan GE, Mehta PD, Craft S: Aerobic exercise enhances executive function and alters plasma biomarkers in older adults at increased risk of progression to Alzheimer's disease. International Conference on Alzheimer's Disease, 2010.

Abstracts and Presentations Cont'd:

116. Carter J, Vanfossen B, Green P, Baker LD, Wilkinson C, Montine T, Watson GS, Plymate S, Tsai E, Callaghan M, Leverenz J, Gerton B, Kahn S, Craft S: Dietary modulation of insulin resistance affects AD biomarkers in adults with MCI. International Conference on Alzheimer's Disease, 2010.

117. Craft S, Baker LD, Green P, Minoshima S, Cross D, Montine T, Watson GS, Vanfossen B, Wilkinson C, Plymate S, Tsai E, Callaghan M, Trittschuh E: A randomized, placebo-controlled trial of intranasal insulin in amnestic MCI and early AD. International Conference on Alzheimer's Disease, 2010.

118. Wilkinson CW, Peskind ER, Colasurdo EA, Shofer JB: Chronic hypopituitarism after blast concussion mild traumatic brain injury in Iraq/Afghanistan combat veterans. *Endocr Rev* 32: OR16-4, 2011.

119. Wilkinson CW: Pituitary dysfunction after traumatic brain injury (TBI): relevance for psychological health and rehabilitation. Case Conference, Butler Hospital, Warren Alpert Medical School of Brown University, Providence, RI, 2011.

120. Wilkinson CW: Pituitary dysfunction in OIF/OEF veterans with repetitive blast mild traumatic brain injury. In Symposium: Structural and Functional Neuroimaging, Pituitary Dysfunction, and Animal Modeling in Blast Concussion mTBI, 3rd Federal Interagency Conference on Traumatic Brain Injury, 2011.

121. Wilkinson CW: Blast concussion mTBI, hypopituitarism, and psychological health in OIF/OEF veterans. Military Operational Medicine Research Program (MOMRP)/Joint Program Committee for Military Operational Medicine (JPC5) In Progress Review (IPR), Hilton Garden Inn, Frederick, MD, 2011.

122. Wilkinson CW: Pituitary dysfunction after blast concussion: relevance for psychological health and rehabilitation. National Intrepid Center of Excellence (NICoE) Grand Rounds, NICoE, National Naval Medical Center, Bethesda, MD, 2011.

123. Wilkinson CW, Peskind ER, Colasurdo EA, Pagulayan KF, Shofer JB: Chronic pituitary dysfunction after blast-related mild traumatic brain injury. *Neuropsychopharmacology* 36:S407–S408, 2011. http://www.nature.com/npp/journal/v36/n1s/full/npp2011293a.html

124. Wilkinson CW, Pagulayan KF, Shofer JB, Peskind ER: Chronic pituitary dysfunction associated with cognitive and neuropsychiatric deficits after blast-related concussion. 22nd Pacific Coast Brain Injury Conference, 2012.

125. Wilkinson CW, Peskind ER, Colasurdo EA, Pagulayan KF, Shofer JB: Prevalence and characteristics of chronic pituitary dysfunction after blast-related mild traumatic brain injury. *Brain Injury* 26:732, 2012. http://informahealthcare.com/doi/pdf/10.3109/02699052.2012.660091

126. Wilkinson CW: Chronic pituitary hormone abnormalities after blast-induced mild traumatic brain injury in combat Veterans: a psychiatric concern? Grand Rounds: University of Washington Department of Psychiatry and Behavioral Sciences, 2012.

127. Wilkinson CW: Hormonal abnormalities after blast concussion in Veterans: implications for quality of life. Research Seminar: Geriatric Research, Education and Clinical Center, VA Puget Sound Health Care System, 2012

128. Wilkinson C: Pituitary function after blast concussion: why it happens and why it matters. Neuroscience Research Seminar: VA Puget Sound Health Care System, 2013.

129. Wilkinson CW, Colasurdo EA, Pagulayan KF, Shofer JB, Peskind ER. Prevalence of chronic hypopituitarism after blast concussion. *FASEB J* 27:935.3, 2013. http://www.fasebj.org/cgi/content/meeting_abstract/27/1_MeetingAbstracts/935.3?sid=c78bc1bd-2e77-40db-b5d2-c95ae9e715ed

130. Wilkinson CW, Petrie EC, Minoshima S, Cross DJ, Richards TL, Pagulayan KF, Peskind ER. Pituitary dysfunction after blast concussion: imaging and psychological correlates. ENDO 2013 Abstracts: 34:SUN-148

131. Wilkinson CW, Li G, Colasurdo EA, Shofer JB, Peskind ER: Correlations among simultaneous basal measurements of human cerebrospinal fluid, saliva, and total and free plasma cortisol as a function of age and Alzheimer□s disease/mild cognitive impairment. *Gerontologist* 53(S1):639, 2013. http://gerontologist.oxfordjournals.org/content/53/S1.toc

132. Leverenz JB, Wilkinson CW, Sikkema C, Li G, Peskind ER, Bekris LM, Zabetian CP, Montine TM: Cerebrospinal Fluid Catecholamine Levels in Parkinson's Patients On and Off Medication. Abstracts: Intl Cong Parkinson's Dis & Movement Disorders, 2014

Current Research Support:

PH/TBI Concept Award Wilkinson (PI) 03/15/11-06/14/14
DOD Congressionally Directed Medical Research Programs
Blast Concussion mTBI, Hypopituitarism, and Psychological Health in OIF/OEF Veterans
Role: Principal Investigator

Career Development Award Wang (PI) 12/01/11-11/30/14
DVA
Agitation, Aggression, and Adrenergic Activity in Alzheimer's Disease
Role: Mentor

RR&D Merit Review Award Wilkinson (PI) 04/01/12-03/31/16
DVA
Pituitary Dysfunction, Behavioral Symptoms, and Quality of Life after Blast mTBI
Role: Principal Investigator

Reportage of the Study in Print and Electronic Media

The abstract presented at the Experimental Biology meeting was chosen by the American Physiological Society as a "hot topic," and the society issued a press release on April 22, 2013, describing the findings presented:
http://www.the-aps.org/mm/hp/Audiences/Public-Press/For-the-Press/releases/13/13.html

The press release was posted on the University of Washington home page and, often in a slightly modified form, on several science and medicine websites and print publications.

UW Today, University of Washington home page, April 29, 2013:
http://www.washington.edu/news/2013/04/29/blast-concussions-could-cause-pituitary-deficiencies-in-war-vets/

U.S. Medicine, June 2013:
http://www.usmedicine.com/agencies/department-of-defense-dod/veterans-with-mtbi-could-be-affected-by-hormone-deficiencies/

Neurologic Rehabilitation Institute at Brookhaven Hospital Blog, April 24, 2013:
http://www.traumaticbraininjury.net/tbi-related-hormone-deficiency-mimics-ptsd/

Veteran's View, June 2013:
http://news.veteransview.com/veteransconcussions/

Medical Xpress, April 22, 2013:
http://medicalxpress.com/news/2013-04-veterans-blast-concussions-hormone-deficiencies.html

Testosterone Medical Center, April 22, 2013:
http://lowtmedicalcenter.com/index.php/Blog/blast-concussions-causing-hormon-deficiencies-in-some-veterans.html

The Daily of the University of Washington, May 16, 2013:
http://dailyuw.com/archive/2013/05/16/news/veterans-returning-service-substantial-hormone-deficiencies#.UcN_JdjgflU

Whiteside Manor Blog, April 25, 2013:
http://blog.whitesidemanor.com/2013/04/ptsd-or-hormone-disorder.html

Medical News Today, April 24, 2013
http://www.medicalnewstoday.com/releases/259496.php

Science Daily - Featured Research, April 22, 2013
http://www.sciencedaily.com/releases/2013/04/130422102029.htm

News Medical, April 23, 2013
http://www.news-medical.net/news/20130423/Study-About-4225-of-screened-veterans-with-blast-injuries-have-irregular-hormone-levels.aspx

Swords to Plowshares Blog, April 23, 2013
http://www.swords-to-plowshares.org/2013/04/23/blast-concussions-may-cause-hormone-deficiencies-in-veterans/

Everyday Health, April 22, 2013
http://www.everydayhealth.com/healthy-living/ptsd-or-hormone-disorder-new-findings-could-mean-new-diagnosis-for-vets.aspx

New Scientist Deutschland, May 3, 2013
http://www.newscientist.de/inhalt/soldaten-traumata-hormonstoerung-nach-kampfeinsatz-a-899945.html

Live interview on Weekday on NPR Seattle affiliate KUOW, May 8:
http://www.kuow.org/post/international-intervention-syria-sexual-assault-military-and-studying-hormone-levels

Front page article in Los Angeles Times print edition and online, July 31, 2013:
http://articles.latimes.com/2013/jul/31/local/la-me-pituitary-damage-20130801

Scientific American website and September print edition of Scientific American MIND, August 8, 2013:
http://www.scientificamerican.com/article.cfm?id=concussions-lingering-effects-linked-hormone-deficiency

Feature article on Massachusetts Society for Medical Research website for students, September 1, 2013
http://whatayear.org/09_13.php

Live interview on Leonard Lopate Show, New York City NPR affiliate WNYC, September 5, 2013
http://www.wnyc.org/story/316248-new-research-traumatic-brain-injury/

VA Research Currents, July 16, 2013
http://www.research.va.gov/currents/summer2013/summer2013-1.cfm